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ABSTRACT 
 
HIV infection and disease is a multistage process that involves a variety of cell types as 
the virus spreads through the body. Initially, dendritic cells (DCs) present at the mucosal 
site of infection bind and internalise HIV for degradation and presentation to T cells. As 
the DCs migrate to lymph nodes and mature, part of the internalised virions remains 
infective inside endosomal compartments. During formation of the immunological 
synapse between CD4 T cells and DCs, infective virions from dendritic cells are 
transferred to CD4 T cells leading to a strong infection of those cells allowing rapid virus 
dissemination throughout the body and establishment of the typical HIV infection. 
Various membrane receptors are involved in this process. Initial HIV binding to DCs is 
mediated by C-type lectin receptors such as the mannose receptor or DC-SIGN (DC 
specific intracellular adhesion molecule 3 grabbing non integrin) which is followed by 
virus internalisation and lysis albeit virus induced changes in endocytic routing prevents a 
proportion from degradation. Productive infection of DCs has also been observed 
allowing trans infection of CD4 T cells through a different mechanism. HIV infection of 
CD4 T cells, DCs and other cells is a multistep process initiated by binding of HIV 
envelope gp120 to the CD4 receptor, a 55 kDa transmembrane glycoprotein. Subsequent 
conformational changes in gp120 allow binding to a chemokine receptor, either CCR5 or 
CXCR4, followed by membrane fusion and infection. 
The aim of this thesis was to investigate protein associations with the HIV 
receptors DC-SIGN and CD4 in order to elucidate the mechanism of complex formation, 
virus entry and/or defining target sites for antiretroviral drugs. This thesis used a 
proteomic approach for studying the receptors with mass spectrometry-based protein 
identification as its core technology. A range of different approaches were developed and 
compared for identification of protein interactions and characterisation of the identified 
protein associations. An affinity purification of the CD4 receptor complex from lymphoid 
cells was used as the basis for detecting novel CD4-binding proteins. For this approach a 
strategy based on mass spectrometry identification of CD4 associating proteins using 
affinity chromatography and affinity-tag mediated purification of tryptic peptides was 
developed. This method proved successful for the identification of CD4 interacting 
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proteins such as the strongly associated kinase p56lck, however a limited number of non-
specifically bound proteins were also identified along the receptor complex. Using one-
dimensional SDS-polyacrylamide gel electrophoresis followed by in-gel digests and mass 
spectrometry analysis, a large number of non-specifically binding proteins were 
identified along the CD4/lck complex. Evaluation of different lysis buffers in several 
independent experiments demonstrated that there was a large and inconsistent array of 
proteins that were obviously non-specifically bound to the receptor. No further specific 
binding partners were detected. These data suggested that protein interactions of CD4 on 
this cell type are of weak and/or transient nature. It also demonstrated a need for careful 
interpretation of proteomic data in the light of the propensity of non-specific binding 
under these conditions. 
 To overcome dissociation of weak protein interactions, a method was developed 
using chemical cross-linking to preserve weak protein interactions on lymphoid cells. 
Affinity purification was used to purify CD4 along with cross-linked associated proteins 
and mass spectrometry analysis identified an interaction with the transferrin receptor 
CD71 and the tyrosine phosphatase CD45. The CD45-CD4 interaction is well known. 
The CD4-CD71 interaction was demonstrated to be a result from colocalization of the 
two molecules during formation of endocytic vesicles. Flow cytometry-based 
fluorescence resonance energy transfer (FRET) measurements were applied to confirm 
colocalization. A similar interaction was suspected for CD4 and DC-SIGN on the plasma 
membrane of DCs as cis infection of DCs has been demonstrated i.e. initial binding to 
DC-SIGN then to CD4/CCR5 on the same cell. Therefore, protein associations of DC-
SIGN were investigated using the developed techniques. Using cross-linking, DC-SIGN 
was shown to assemble in large complexes on the surface of immature monocyte-derived 
DCs. Mass spectrometry analysis of the purified complexes identified them as homo-
oligomers of DC-SIGN. The absence of CD4 suggested that the fraction interacting with 
CD4 at any one time must be small. The complexes of DC-SIGN were further 
characterised to be tetramers and successfully co-immunoprecipitated with HIV gp120 
and mannan. DC-SIGN monomers were not evident demonstrating that the assembly of 
DC-SIGN into tetramers is required for high affinity binding of its natural and viral 
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ligands. Thus potential antiviral agents aimed at blocking the early stage of HIV binding 
to DCs must simulate tetramers in order to neutralise the virus efficiently. 
Overall the thesis provides new information on protein interactions of CD4 and 
DC-SIGN, a careful investigation of “proteomics” techniques for identifying the proteins 
in affinity-purified samples and demonstrates the need for multifaceted analytical 
approaches to probe complex cellular systems. 
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AMINO ACID ABREVIATIONS AND RESIDUE MASS 
 
Amino   Single   Three   Residue  Residue 
acid   Letter  letter  average monoisotopic 
code  code  mass  mass 
 
Glycine  G  Gly  57.052  57.021 
Alanine  A  Ala  71.079  71.037 
Serine   S  Ser  87.078  87.032 
Proline   P  Pro  97.117  97.053 
Valine   V  Val  99.133  99.068 
Threonine  T  Thr  101.105 101.048 
Cysteine  C  Cys  103.145 103.009 
Isoleucine  I  Ile  113.159 113.084 
Leucine  L  Leu  113.159 113.084 
Asparagine  N  Asn  114.104 114.043 
Aspartic acid  D  Asp  115.089 115.027 
Glutamine  Q  Gln  128.131 128.059 
Lysine   K  Lys  128.174 128.095 
Glutamic acid  E  Glu  129.116 129.043 
Methionine  M  Met  131.199 131.040 
Histidine  H  His  137.141 137.059 
Phenylalanine  F  Phe  147.177 147.068 
Arginine  R  Arg  156.188 156.101 
Tyrosine  Y  Tyr  163.176 163.063 
Tryptophan  W  Trp  186.213 186.079 
   
    
CHAPTER ONE: 
 
LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
1.1 The CD4 receptor – structure and function 
 
The CD4 molecule plays an important role in the immune response and also serves as a 
receptor for the human immunodeficiency virus (HIV). The structure and associations of 
CD4 are of crucial importance for the understanding of both CD4 functions and HIV 
entry. This review is aimed to give an overview on CD4 structure, function and its 
protein associations that have been reported so far. 
 
1.1.1 The CD4 molecule 
The CD4 protein is a 55 kDa transmembrane glycoprotein that belongs to the 
immunoglobulin superfamily (IgSF) of cell surface molecules. It is expressed on T helper 
lymphocytes, monocytes, macrophages, dendritic cells and specialised cells of the central 
nervous system (CNS) (Wood et al. 1983; Tourvieille et al. 1986). The 435 amino acid 
long CD4 polypeptide comprises of a 371 amino acid long extracellular region, a 26 
amino acid long transmembrane domain and a 38 amino acid long cytoplasmic tail 
(Maddon et al. 1987). The extracellular part is folded into four IgSF like domains named 
D1 to D4 (Maddon et al. 1985). 
The domains, one, two and four, each contain an intramolecular disulfide bond 
between C16 and C84 in domain one, C130 and C159 in domain two and C303 and C345 
in domain four (Bour and Strebel, 1995). The molecule contains two N-linked 
glycosylation sites at N271 and N300 (Carr et al. 1989) and two palmitoylation sites on 
C394 and C397 (Crise and Rose, 1992). The cytoplasmic tail is tightly associated with 
the tyrosine kinase p56lck through a CQC motif (Veillette et al. 1988). Figure 1.1 
schematically illustrates the structure of CD4 and the location of its protein 
modifications. 
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1.1.2 Crystal structure of the CD4 molecule 
Initial studies investigating the crystal structure of the whole extracellular fragment of 
CD4 were hindered by the low diffraction owing to the large size of the unit cells in 
crystals of those fragments (Brady et al. 1993). Nevertheless, Kwong et al. (1990) 
deduced some structural information from the obtained crystals (Kwong et al. 1990). 
They reported that CD4 was an elongated flexible molecule that crystallises as a dimer or 
as a tetramer. Proteolytic cleavage showed a flexible hinge between the D1/D2 and 
D3/D4 fragments. 
 
1.1.2.1 Structure of the extracellular D1/D2 fragment 
In 1990, two independent publications in Nature reported the resolution of the X-ray 
crystal structure from a fragment comprising of domains D1 and D2 of the extracellular 
part of CD4 (Ryu et al. 1990; Wang, J. H. et al. 1990). Wang and co-workers studied 
recombinant CD4 D1/D2 fragments produced in CHO cells. The overall structure of this 
fragment was described as rod-like, consisting of two adjacent domains each of which 
has an IgSF-like fold. Whereas D1 is homologous to the IgSF variable domains, D2 
shows similarity to the constant domains. The entire fragment is characterised by little 
flexibility between the domains D1 and D2 with the last β-strand of D1 running directly 
into the first strand of D2. Figure 1.2 is an illustration of the CD4 domain D1/D2 
Figure 1.1: 
Schematic illustration of CD4. Shown is the 
extracellular part consisting of four 
immunoglobulin superfamily like domains, the 
transmembrane domain and the cytoplasmic 
tail. N-linked glycosylation sites and 
palmitoylation sites are indicated. 
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fragment from a crystal structure analysis performed in the context of its function in T 
cell activation. 
IgSF-like molecules have a structure consisting of two antiparallel β-sheets made 
up from nine strands labelled ABCC’C”DEFG. ABDE form one sheet and CC’C”FG the 
other sheet. According to the crystal structure analysis the CD4 domain D1 is similarly 
built except that one sheet is made up of strands BDE and the other of strands 
ACC’C”FG (Wang, J. H. et al. 1990). Despite the overall similarity between CD4 domain 
D1 and IgSF variable domain structure, several differences can be distinguished. These 
include that the CC’ loop is shortened by 4 residues and the FG loop is shortened by 4 to 
6 residues. In immunoglobulin molecules those loops mediate the association between the 
VH and VL chain. CD4 is not involved in such an association explaining the reduction of 
the CC’ and the FG loop (Ryu et al. 1990). The C’C” loop, however, is 3 residues longer 
than in normal IgSF molecules. 
Domain D2 contains only seven β-strands and also forms an IgSF like fold with 
one sheet consisting of strands ABD and the other of CC’FG. Although the 
immunoglobulin-typical hydrophobic core is preserved in domain D2, the overall size of 
only 75 amino acids (compared to 100 for an IgSF constant domain) is relatively small. 
The disulfide bridge is also differentially located bridging two cysteine residues on one 
single β–strand rather than connecting two β–strands from the two different β-sheets as 
in other IgSF-like molecules (Ryu et al. 1990). The detailed structure of Domain D1 is 
also characterised by a typical IgSF hydrophobic core made up of the disulfide bridge and 
several hydrophobic residues. A salt bridge between an arginine and an aspartic acid 
further enhances the fold. Domain D2 contains a modification in the salt bridge (Wang, J. 
H. et al. 1990). 
A refined X-ray diffraction analysis of a D1/D2 fragment later confirmed that 
domains D1/D2 form a rather rigid unit with flexibility left at the D2/D3 interface (Ryu et 
al. 1994). The data presented are consistent with the earlier reports, describing the folding 
pattern of both domains as IgSF-like. The residues forming the hydrophobic core of IgSF 
domains, one disulfide bridge, a tryptophan and a tyrosine are present in D1 and modified 
in D2. A prominent feature is the phenylalanine at position 47, that is highly solvent 
exposed, which is rather unusual for such a hydrophobic residue. 
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1.1.2.2 Structure of the extracellular D3/D4 fragment. 
Whereas the D3/D4 fragment of the extracellular part of human CD4 has not yet been 
crystallised, 1993 the resolution of the crystal structure of recombinant rat CD4 D3/D4 
was reported (Brady et al. 1993). This is representative for the human D3/D4 fragment as 
rat CD4 shares a significant homology to human CD4). Analogous to the structure of the 
D1/D2 fragment, the D3/D4 fragment also forms a compact rod shaped unit and D3 and 
D4 both form IgSF-like domains (Brady et al. 1993). This supports the initial description 
of the structure of CD4 as a linear array of four IgSF like domains (Clark et al. 1987). 
Figure 1.3 shows the crystal structure of the D3/D4 fragment as described by Brady and 
co-workers. 
The same report demonstrated that the domain D3 is similar to domain D1 (and 
other IgSF variable domains), comprising nine β-Strands forming two antiparallel β-
sheets. However, the segments involved in the gp120 binding site (discussed later) in 
domain D1 have a different conformation in D3 and the disulfide bridge is not present in 
D3. Together with the increased presence of bulky leucine residues, this leads to an 
increased separation of the two β-sheets in D3 compared with domain D1 (Brady et al. 
1993). These alterations are not uncommon for IgSF-like domains. CD4 domain D2 is 
also characterised by an uncommon disulfide bridge (Ryu et al. 1990) and an IgSF like 
domain of CD2 that also lacks a disulfide bridge is not characterised by an expanded 
structure (Driscoll et al. 1991). 
Figure 1.2: 
The structure of the extracellular 
D1D2 fragment of CD4: 
The two domains D1 and D2 can 
be clearly distinguished with D1 
made up of 9 and D2 of 7 beta 
strands. Some residues critical for 
interactions are also shown. 
Taken from Wang et al. (2001). 
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Similar to domain D2, D4 only has seven β-strands that make up the IgSF like 
structure. Both domains can be superimposed easily even though there are differences in 
the structure between D2 and D4. Both key hydrophobic residues and the location of the 
disulfide bridge are altered and the structure is characterised by the two prominent loops, 
CD and FG, that protrude to the side (Brady et al. 1993). 
 
 
 
1.1.2.3 Crystal structure of the whole extracellular region 
The attempts to define the structure of the whole extracellular region of CD4 finally lead 
to the successful determination of the crystal structure of soluble CD4 (Wu, H. et al. 
1997). The crystal structure confirms the previous findings that each the D1/D2 domains 
and the D3/D4 domains form an entity that is connected through a flexible hinge at the 
residues L177 and A178. The transmembrane proximal region of amino acids 364 to 369 
was also shown to be unordered conferring more mobility to the molecule on the cell 
surface (Wu, H. et al. 1997). 
Besides defining the crystal structure of CD4, the authors also observed formation 
of CD4 dimers that are butterfly shaped with Domains D1 to D3 as “the wings” and D4 
as “the torso”. The interaction between the two monomers is reportedly weak with a KD 
of about 1 mM but could be confirmed in experiments with soluble CD4 (Wu, H. et al. 
1997). The dimer interface is exclusively located at domain D4 with rather small surface 
areas involved. Neither the glycosylation sites, nor the protruding loops CC’ and FG, 
interfere with the dimerisation. Absolutely conserved glutamine residues at position 344, 
which are separated by a hydrogen bond distance are at the core of the dimerisation 
Figure 1.3: 
The crystal structure of the D3D4 
fragment of rat CD4. The homology 
to the structure of the human D1D2 
fragment is obvious. 
As in Figure 2, D3 consists of nine β-
strands that make up two β-sheets 
whereas D4 consists of only seven β-
strands which also align to form two 
β-sheets. 
Taken from Brady et al. (1993). 
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interface (Wu, H. et al. 1997), albeit the exact distance of the glutamine residues is not 
reported. Figure 1.4 shows the crystal structure and dimerisation of CD4 at domain D4. 
 
 
Apart from the dimerisation indicated from the CD4 crystal structure (Wu, H. et 
al. 1997), disulfide bridged CD4 dimers have also been observed (Lynch et al. 1999). The 
role of CD4 dimerisation has been controversial and it has been reported to be required 
for binding of MHC class II molecules (Sakihama et al. 1995; Li et al. 1998) but not for 
binding of HIV gp120 (Sakihama et al. 1995). Recent studies have shown that the domain 
D2 disulfide bond is redox active and thus free thiols can be detected on the extracellular 
part of CD4 (Matthias et al. 2002). Those free thiols may be involved in the formation of 
disulfide bridged dimers (Lynch et al. 1999). These authors also reported evidence that 
disulfide exchange involving the domain D2 cysteines is required for HIV-1 entry 
(Matthias et al. 2002), but no further data are currently available supporting this, neither 
does the report on the crystal structure of the whole extracellular region of CD4 
characterise the CD4 D2 disulfide bridge. 
 
1.1.2.4 Structure of the cytoplasmic tail 
With the main focus regarding the CD4 structure being on the extracellular part, 
relatively little attention has been paid to the cytoplasmic domain. Though the 
intracellular part of CD4 is rather small, it is absolutely required for function, for 
example, it mediates the association with the protein kinase lck (Veillette et al. 1988). 
Wray et al. (1998) performed NMR and CD spectroscopic investigations with a synthetic 
peptide comprising the whole intracellular domain of CD4. Chemical shift data on the 
Figure 1.4: 
Crystal structure of the 
extracellular part of CD4. 
Front view showing the 
butterfly shape of two CD4 
molecules forming a dimer. 
The two D4 domains are 
superimposed in this view. 
Taken from Wu et al. (1997). 
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Cα-hydrogen atoms indicate an α-helical structure between residues 399 to 419 with the 
centre of the helix stretching from Q403 to S415. This helix is flanked by a short mobile 
linker adjacent to the transmembrane region and the unstructured C-terminal part starting 
with the CQC motif required for interaction with lck. Figure 1.5 illustrates the structure 
of the cytoplasmic tail. The five cysteine residues of the cytoplasmic tail are not involved 
in disulfide bonds but are susceptible to oxidation. Thus the experiments had to be carried 
out in an oxygen-free environment and in presence of a reducing agent, (i.e. DTT). It was 
also shown that the cytoplasmic tail has an intrinsic tendency to associate with 
membranes. About 70% of the PKC phosphorylated peptides were shown to be 
associated with microsomal membranes which demonstrates that the CD4 intracellular 
domain has some common features of membrane-associated proteins (Wray et al. 1998). 
 
 
 
1.1.3 CD4 trafficking 
The CD4 gene is made up of nine exons. The first exon codes for the leader sequence, 
followed by five exons coding for the extracellular part, one exon coding for the 
transmembrane domain and two exons encoding the cytoplasmic tail (Maddon et al. 
1987). During the synthesis, the leader sequence directs the nascent polypeptide into the 
endoplasmatic reticulum where the leader is cleaved away. CD4 is then transported 
rapidly and efficiently from the ER through the Golgi apparatus (where it is glycosylated) 
and then to the cell surface (Crise et al. 1990). 
 
 
Figure 1.5:  
Structure of the CD4 cytoplasmic tail. 
Superimposition of the 20 best final 
restrained structures of the whole 
cytoplasmic peptide of CD4. The proposed 
α-Helical structure can be clearly 
distinguished whereas the adjoining 
regions at the N-terminus and C-terminus 
are highly unstructured. Taken from Wray 
et al. (1998). 
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1.1.3.1 CD4 endocytosis 
Cell surface proteins are normally internalised through endocytosis, which allows 
degradation of the protein (Pearse and Robinson, 1990) or mediates dissociation of 
ligands bound to a membrane protein (Gruenberg and Maxfield, 1995). Endocytosis of a 
receptor can occur passively via “bulk flow” (e.g. macrophages are known to internalise 
200 % of their surface area every hour (Mellman 1996; Steinman et al. 1983)) or actively 
if the protein carries an endocytosis signal on its cytoplasmic tail. Signal sequences for 
endocytosis that have been described are tyrosine-based motifs eg in the mannose 
receptor (MR) (East and Isacke, 2002) or dihydrophobic sequences e.g. in CD4 or DC-
SIGN (Pitcher et al. 1999; Engering et al. 2002). They function via binding of the clathrin 
adaptor proteins AP-1 and AP-2, which then target the receptor for endocytosis (Mellman 
1996; Rodionov and Bakke, 1998). After internalisation, the proteins first reside in 
vesicular compartments named early endosomes. The early endosomes form part of a 
complicated vesicular network responsible for endocytosis, recycling and degradation of 
membrane proteins (Mellman 1996). From early endosomes, proteins can be targeted 
back to recycling vesicles that mediate their transport back to the cell surface. Some 
proteins carry a signal on their cytoplasmic tail that promotes the return to the cell surface 
via the recycling pathway. For example, the mannose receptor possesses a diaromatic 
motif (Schweizer et al. 2000). If not recycled, receptor molecules are targeted from early 
endosomes to late endosomes and then lysosomes. The lysosomes are characterised by a 
low pH and aid proteolytic activity. In this acidic environment, ligands can be dissociated 
from their receptor as, for example, transferrin dissociates from the transferrin receptor 
(TFR) (Baker and Morgan, 1994). The ligands then can be degraded and their cargo 
utilised and the receptor return to the cell surface. Alternatively, the receptor can also be 
degraded. The signals which govern sorting towards the lytic pathway are not clear, 
however it is thought that a triacidic motif found in some receptors (Dendritic cell 
specific intracellular adhesion molecule 3 grabbing non-integrin, DC-SIGN/CD209) 
promotes sorting to more acidic vesicles (Engering et al. 2002). 
CD4 contains a dileucine motif that mediates its endocytosis via clathrin-coated 
pits (Pitcher et al. 1999), however, the mechanism of CD4 endocytosis is more 
complicated and dependent on other proteins as well. Studies on the endocytosis of cell 
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surface CD4 have shown that CD4 transfected into non-lymphoid cells such as HeLa 
cells is rapidly internalised and subsequently recycled to the cell surface. About 30 % to 
40 % of the total CD4 was internalised at any time (Pelchen-Matthews et al. 1989). 
However, a fundamental difference between the CD4 internalisation on lymphocytic and 
non-lymphocytic cells was observed later (Pelchen-Matthews et al. 1991). Whereas CD4 
endocytosis through coated pits in non-lymphoid cells such as the promyelocytic HL-60 
cell line resembled the dynamics observed in HeLa cells, the lymphocytic cells showed 
little internalisation of CD4. The authors suggested a role for the lymphocyte specific 
kinase p56lck ie cell surface retention could be mediated through lck binding to the CD4 
cytoplasmic tail (Pelchen-Matthews et al. 1991). This suggestion was confirmed one year 
later when the same research group reported that p56lck inhibits CD4 internalisation by 
preventing its entry into coated pits. The expression of an intact cytoplasmic tail of CD4 
was reported necessary for endocytosis and this was not prevented when a chimera of lck 
is expressed that lacks the CD4 binding domain (Pelchen-Matthews et al. 1992). The 
differential internalisation of CD4 in lymphocytic and myelocytic cell lines could be 
confirmed for primary lymphoid and myeloid cells. P56lck-positive primary lymphocytes 
showed little endocytosis whereas monocytes and macrophages rapidly internalised CD4 
(Pelchen-Matthews et al. 1998). 
 
1.1.3.2 The effect of PMA on CD4 endocytosis 
Phorbol esters such as Phorbol 12-myristate 13-acetate (PMA) are known to activate 
cellular mechanisms associated with cell growth through their ability to activate protein 
kinase C (Smith, A. D. 2000). Stimulation of lymphocytes with PMA has been shown to 
lead to the downregulation of cell surface CD4 (Acres et al. 1986), phosphorylation of 
serine residues in the CD4 cytoplasmic tail (Acres et al. 1986) and dissociation of CD4-
p56lck (Hurley et al. 1989). The phorbol ester-induced downregulation of CD4 was later 
described to be a multistep process, which is attributed to several effects of PMA 
(Pelchen-Matthews et al. 1993). In lymphocytes, PMA leads to the phosphorylation by 
protein kinase C of the key serine residues S408 and S415 flanking the dileucine motif 
mediating endocytosis. This was proposed to lead to the dissociation of p56lck (Pelchen-
Matthews et al. 1993) and enhanced the affinity of CD4 for the clathrin adaptor proteins 
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AP-1 and AP-2 up to 700 fold (Pitcher et al. 1999). PMA also directs the sorting of 
endocytosed receptor molecules towards late endosomal compartments instead of the 
recycling pathway (Pelchen-Matthews et al. 1993). 
 
1.1.4 CD4 associating molecules 
Before proceeding to the discussion of the various functions which the CD4 molecule 
plays in immunology, it is necessary to know and understand the different molecules that 
can associate with CD4. The following part of this review will discuss the molecules that 
naturally associate with CD4 in lymphoid cells starting with the molecules associating 
with the CD4 cytoplasmic tail, then the extracellular ligands MHC class II molecules and 
the soluble ligands IL-16 and gp17. It will finish with an overview of the molecules 
associating with CD4 in non-lymphoid cells. The HIV proteins gp120, vpu and nef, 
which can also associate with CD4, are discussed later in this review, in the section on 
the human immunodeficiency virus (sections 1.2.3.2 and 1.2.5.3). 
 
1.1.4.1 Proto-oncogene protein tyrosine kinase lck (p56lck) 
The expression of p56lck was first reported in 1986 in the human T-cell leukemia Jurkat 
cell line and the gene was described as homologous but distinct from the src, yes and fgr 
oncogenes (Trevillyan et al. 1986). Similar cDNA could not be isolated from B cell 
lymphoma lines or myeloid cell lines, showing the expression of the protein was T cell 
specific (Trevillyan et al. 1986). The homology of 70 % to 80 % between a putative 
protein tyrosine kinase catalytic domain of the deduced protein sequence and sequences 
of catalytic domains of other protein kinases suggested kinase activity of the protein 
(Koga et al. 1986). Later the association of lck with the cytoplasmic tail of the CD4 and 
CD8 molecules in T-lymphocytes was described (Veillette et al. 1988). The gene 
organisation reflects the homology of lck with other protein kinases of the src family. 
Except for the unique N-terminal sequence, the organisation of the exons is the same as 
in other protein tyrosine kinases of the src family (Rouer et al. 1989). 
Protein tyrosine kinases of the src family were first discovered in the “rous 
sarcoma virus” and comprise of a family of tyrosine kinases that are characterised by not 
only a protein kinase domain but also a src homology 2 domain (SH 2) and src homology 
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3 domain (SH 3) following a unique N-terminal domain. Prominent members apart from 
lck are src, yes, fyn, lyn, blk, hck, fgr and yrk (Smith, A. D. 2000). The SH 2 domain 
binds phosphorylated tyrosine residues in peptides/proteins and also mediates 
autoinactivation of the kinase (Smith A. D. 2000). The SH 3 domain mediates protein-
protein interactions with specific protein sequences containing hydrophobic and proline 
residues (Smith, A. D. 2000). In lck, as in most other src-family kinases, the unique N-
terminal domain is followed by the SH 3 and then SH 2 homology domain. The protein 
kinase domain is located at the C-terminus followed by a short regulatory domain (Eck et 
al. 1994). A residue important in lck function is Y394, the phosphorylation of which is 
required for activation of kinase function (Veillette and Farnel, 1990). Lck can 
phosphorylate its own Y394 residue leading to lck autoactivation (Caron et al. 1992). It 
also possesses an inhibitory residue, Y505. Phosphorylation of this residue leads to a 
change in lck structure via binding of the Y505 containing regulatory stretch to the SH2 
homology domain. This structural change inactivates the kinase domain (Yamaguchi and 
Hendrickson, 1996). The phosphorylation states of both Y394 and Y505 thus control lck 
kinase activity.  
Crystal structure analyses on individual parts of lck have been reported, focussing 
on the SH2 homology domain, which binds to tyrosine, phosphorylated molecules. The 
resolution of the crystal structure of the lck SH 2 homology domain complexed with an 
11 residue phosphopeptide revealed involvement of R134 in the recognition of the 
phosphotyrosine. On the phosphopeptide, the isoleucine residue at the +3 position with 
respect to the phosphotyrosine (Tong et al. 1996) was also shown to be involved in the 
binding. Lck possesses an intrinsic ability to localise with the plasma membrane, which is 
mediated through its unique N-terminal domain (Bijlmakers et al. 1997). 
 
Association between CD4 and lck and the cytoskeleton 
The connection between CD4 and lck was first discovered via co-immunoprecipitation of 
both molecules from a lymphoid CD4+CD8_ cell line (Veillette et al. 1988). The 
association was soon mapped to the CD4 cytoplasmic tail where the CQC motif was 
shown to be critical for the interaction (Shaw et al. 1990; Turner et al. 1990). The 
interaction is mediated via a Zn2+ ion between the two “CQC”-cysteines of CD4 and 
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another pair of cysteines in the amino terminal domain of lck (Huse et al. 1998). Studies 
using lymphoid cell lines as well as fibroblasts transfected with lck have shown 
association of lck with the detergent insoluble matrix (Louie et al. 1988). Further studies 
observed that lck expression can also render CD4 resistant to detergent solubilisation and 
that lck can mediate reorganisation of the cell surface into structures resembling adhesion 
junctions upon CD4 activation (Kinch et al. 1994). The authors conclude that there is a 
linkage between lck and the cytoskeleton that is involved in the modelling of cell 
adhesion but the nature of which remains elusive. It was reported that the cytoskeletal 
protein ezrin is phosphorylated upon stimulation of T lymphocytes with CD3 antigen in a 
manner suggesting the involvement of lck (Thuillier et al. 1994). Further evidence arised 
from colocalization studies between CD4 and ezrin (T. Hope, unpublished data). Analysis 
of the partitioning of CD4 and lck between the detergent-soluble and insoluble fractions 
(containing the cytoskeleton) after CD4 cross-linking with antibodies was shown to 
increase insolubility of those two proteins in nonionic detergent, which was interpreted as 
an association with the cytoskeleton (Ha-Lee et al. 2000). Another study investigated 
location and movement of CD4 on lymphoid and myeloid cells. The authors reported that 
lck binds CD4 and targets it to microvilli independent of kinase activity. They also 
observed reduced mobility of CD4 on the cell surface and interpreted it as an association 
of CD4 with the cytoskeleton (Foti et al. 2002). However, those observations have to be 
interpreted in the context of lipid rafts (discussed later in section 1.1.6), which can also 
render proteins insoluble in non-ionic detergents. Taken together, those findings suggest 
that there is a possible connection between CD4/lck and the cytoskeleton which might be 
mediated via adaptor proteins or via phosphorylation of proteins through lck which then 
bind to either CD4 or lck (Kinch et al. 1994). Direct evidence for binding of CD4 and/or 
lck to a cytoskeletal protein has yet to be reported. However, the recent finding that β-
adducin, an actin filament associated protein, can interact with the SH2-homology 
domain of the src kinase fyn after phosphorylation suggests the possibility of such a link 
(Shima et al. 2001). 
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1.1.4.2 Other proteins associating with the CD4 cytoplasmic tail 
The following proteins have been described to associate with CD4 but will only be 
discussed briefly as either the association is controversial or has not been confirmed by 
independent experiments. 
In 2001 the identification of a novel intracellular CD4 binding protein was 
reported and named ACP33 (Zeitlmann et al. 2001). The protein was identified in an 
attempt to screen for interactors of the cytoplasmic tail using the yeast two-hybrid 
system. The interaction was confirmed with co-immunoprecipitation and could be 
mapped to the hydrophobic C-terminal part of the cytoplasmic tail. The authors suggested 
a role of this molecule in the transduction of “negative signals” through the CD4 receptor 
in contrast to the activating signals transmitted by p56lck (Zeitlmann et al. 2001). 
The linker for activation of T cells (LAT) is a protein involved in the signalling 
pathway triggered upon TCR stimulation (Zhang, W. et al. 1998a). In 1999, Bosselut and 
co-workers reported that it can associate with CD4 providing a mechanism through which 
it is recruited to the TCR signalling machinery. The association was detected via 
immunoprecipitations and was said to be dependent on the same cysteine motif required 
for the CD4-lck association even though the interaction mechanism is different (Bosselut 
et al. 1999). The authors suggest that LAT-1 phosphorylation participates in the signal 
transduction event during T cell activation (Bosselut et al. 1999). 
The association of the CD4/lck complex with both a GTP binding protein p32 and 
a raf related p110 polypeptide was reported in 1992 (Prasad and Rudd, 1992). The p110 
protein bound preferentially to the assembled CD4/lck complex and was shown to be 
serine-phosphorylated upon treatment of cells with phorbol esters (Prasad and Rudd, 
1992). The protein was thought to act as a bridge between the CD4/lck receptor complex 
and serine/threonine kinase pathways during T cell activation (Prasad and Rudd, 1992). 
 
1.1.4.3 Laterally associated membrane proteins 
Being a membrane protein, CD4 can not only bind intracellular and extracellular proteins, 
but also engage in lateral associations with other membrane proteins. Proteins residing in 
proximity of CD4 can highly influence its function and the two lateral associations, the T 
cell receptor (TCR) and CD45 will be discussed here. 
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CD45 and its association with the CD4 receptor complex: 
CD45 is a transmembrane glycoprotein of a mass ranging from 180 kDa to 220 kDa 
(Trowbridge and Thomas, 1994; Thomas 1995). Alternative splicing of exons 4, 5 and 6 
creates up to 8 different isoforms of the CD45 molecule depending on whether those 
exons are included or not. The shortest isoform, termed CD45R0, consists of 1143 amino 
acids whereas the longest isoform, CD45RABC, is 1304 amino acids long (Streuli et al. 
1987; Hall et al. 1988). CD45 is expressed on all nucleated haematopoietic cells 
(Trowbridge and Thomas, 1994; Thomas 1995) and constitutes 10 % of all cell surface 
glycoproteins on T cells (Veillette et al. 1999). Of the 8 different isoforms of CD45, five 
are expressed at significant levels in T cells (Rogers et al. 1992). All T cells express more 
than one CD45 isoform and the expression of the different isoforms is tightly regulated 
during T cell development and activation (Alexander 1997). Though CD45 is expressed 
at very high levels on the cell surface, it is not incorporated into HIV virions (Esser et al., 
2001). 
CD45 is thought to exert its function through its tyrosine phosphatase activity, 
targeting the CD4 associated kinase lck (Koretzky et al. 1990). To exert its effect on lck, 
CD45 needs to interact with the CD4/lck complex. Investigating noncovalent associations 
of cell surface molecules using a mild detergent (Brij-58), two large complexes of 
membrane proteins one of which contained CD45 along with the TCR proteins and CD4 
were found (Cerny et al. 1996). A different study, using co-capping and fluorescent 
microscopy reported high association of CD4 with CD45RC, CD3 and other molecules 
but only weak association with CD45RB and no association with CD45R0 and CD45RA 
(Dianzani et al. 1995). However, a report in 2002 employing FRET technology showed 
that the CD45R0 isoform preferentially associated with CD4 (Dornan et al. 2002). The 
authors also provide evidence for homodimers of CD45, which have a potentially 
inhibitory function on T cell receptor activation. Besides the abovementioned, other 
reports have also demonstrated an association of CD4 and CD45 so that it is now a 
generally accepted concept (Leitenberg et al. 1996; Bonnard et al. 1997). 
CD45 can act on lck by dephosphorylating either the activating tyrosine Y394 
(Yamaguchi and Hendrickson, 1996) or the inhibitory tyrosine Y505 (Ostergaard et al. 
1989). Thus it can either increase or decrease lck activity. It is now thought to maintain 
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lck in a partially activated stage preventing autoactivation but facilitating full activation 
after stimulation of the T cell with antigens (Holdorf et al. 2002). 
 
The T cell receptor complex (TCR) 
Given the fact that during recognition of a MHC class II molecule carrying an antigenic 
peptide both CD4 and the T cell receptor make contact with the MHC molecule, it has 
been suggested that there is a preformed association between the TCR and CD4 before 
antigen recognition in order to facilitate the complex formation. This suggestion, 
however, has been subject to long and rather controversial research. Already during the 
discovery of the CD4-lck association, Vieillette and co-workers found a protein co-
precipitating with the CD4-lck complex that they described as “TCR-like” but the authors 
failed to precipitate CD4 and/or lck together with the TCR (Veillette et al. 1988). In the 
following years, several publications have described an association between CD4 and 
some or all of the TCR components. Using fluorescence resonance energy transfer 
(FRET) technology, the CD3 complex was found to associate with the CD4 molecule 
dependent on the interaction of CD4 with lck (Mittler et al. 1989). This study, however, 
was conducted on T cells that were treated via CD3 receptor ligation and thus is not 
representative for resting T cells. In 1991, the successful co-immunoprecipitation (CoIP) 
of the CD3 ε- and ζ-chain with the CD4/lck complex was reported (Burgess et al. 1991). 
The authors, however, could only identify those complexes using a T lymphoblastoid line 
but could not detect any CD4-TCR association in resting peripheral blood lymphocytes 
(Burgess et al. 1991). Similar results were obtained by Beyers et al., who conducted 
immunoprecipitation studies to detect associations between CD4/CD8, the TCR, the CD2 
and CD5 marker as well as the kinases lck and fyn. The authors report association of all 
those molecules in a loose complex and explain different results obtained by other groups 
with the loose nature of the association and the use of different detergents (Beyers et al. 
1992). A paper on CD45 and the CD45 associating protein (CD45AP) also reported 
successful CiP of CD4 and the TCR complex. CD4, the TCR and CD45 and CD45AP 
were found to be associated in a membrane complex with the TCR providing the binding 
of CD45 and CD45AP (Veillette et al. 1999). Using mutational analysis creating 61 
different mutants of CD4, the research group of Vignali and co-workers aimed to identify 
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epitopes in CD4 that bind to the TCR complex. Studying T cell function in dependence of 
CD4 structure, the authors identified several residues on CD4, the mutation of which, 
reduced or abrogated the T cell response that was investigated. Given the location of 
those mutations on the CD4 domains D3 and D4, this part of the molecule was suggested 
to be involved in a CD4/TCR association (Vignali et al. 1996; Vignali and Vignali, 
1999). 
Recent kinetic and structural studies, however, have questioned the proposed 
association of CD4 and the TCR. Using BIAcore™ technology, the affinity constants for 
CD4/MHC class II/TCR associations were determined to be 6-8 µM for the TCR-MHC 
class II association. The MHC class II-CD4 association was reported to be 200 µM but a 
TCR-CD4 association could not be detected (Xiong et al. 2001). This is in accordance 
with the structural investigations of the MHC class II-CD4 interaction, which provides a 
ternary model of the MHC class II complex with CD4 and the T cell receptor. The 
structure of this complex describes CD4 and the TCR as rather distant from each other 
and makes an association of both molecules during MHC recognition unlikely (Wang, J. 
H. et al. 2001). However, this is contradictory to the model that CD4 functions to bring 
lck in proximity to the TCR cytoplasmic domains (Konig et al. 1995). These different 
views of the CD4-TCR associations have yet to be reconciled, leading to definitive 
conclusions about the CD4-TCR interaction. 
 
1.1.4.4 Class II major histocompatibility complex 
The human major histocompatibility complex (MHC) was identified as the genes that are 
responsible for tissue rejection reactions in humans (Bouvier, M. 2003). The reason for 
this is the polymorphism among the MHC genes among humans, which lead to the 
recognition of graft MHC molecules as “foreign”, thus inducing an immune response. 
The function of MHC molecules is to present peptides derived from foreign organisms to 
T lymphocytes to stimulate an immune response (Abbas et al. 2000). The MHC 
molecules are distinguished into two different classes: Class I molecules present peptides 
derived from cytoplasmic proteins to CD8+ cytolytic T-lymphocytes (CTLs), assisting in 
the destruction of intracellular microbes like viruses. Class II molecules present peptides 
derived from endocytosed extracellular proteins to CD4+ helper T-lymphocytes assisting 
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in the eradication of extracellular organisms such as bacteria. For details on antigen 
processing see reviews (Germain 1994) or standard books on immunology (Abbas et al. 
2000). 
Cells presenting MHC class II-peptide complexes to T cells are mainly dendritic 
cells, macrophages and B cells. Dendritic cells function as professional antigen 
presenting cells (APCs) sampling antigen from all areas of the body and after a process of 
maturation and migration to lymph nodes there they present MHC-peptide complexes to 
naïve T cells. T cells specific for the antigen are then activated and after clonal expansion 
form a large number of effector T cells which migrate to the sites of inflammation. If the 
T cells then encounter macrophages or B cells, presenting peptides specific for the TCR, 
they activate those macrophages to increase their lytic activity or they stimulate the B 
cells towards antibody secretion (Abbas et al. 2000). 
The first step of T cell activation is the interaction of peptide-MHC class II 
complexes with the T cell receptor complex, which accounts for the specificity of the 
peptide. The MHC class II molecule also binds to CD4 which increases the binding 
affinity and accounts for the MHC class II restriction of CD4+ T cells (Marrack and 
Kappler, 1986; Gay et al. 1987). The structure of class II molecules is perfectly refined to 
its function in binding and presenting peptides. Each MHC class II molecule is a 
heterodimer of an α- and a β- chain which are non-covalently associated. Each chain 
consists of a membrane proximal domain, (α2 and β2) which has an IgSF-like fold and a 
membrane distal domain (α1 and β1). The membrane distal domains form a flat surface 
consisting of eight β-strands (four from each polypeptide) on top of which are 2 α-helices 
(one from each polypeptide) forming a peptide binding cleft occupied by the antigenic 
peptide (Brown, J. H. et al. 1993). During the antigen recognition, CD4 binds to 
nonpolymorphic regions located on the membrane proximal domains of the MHC 
molecule (Gay et al. 1987). The interaction between CD4 and MHC class II molecules is 
rather weak, a KD of 200 µM has been reported (Xiong et al. 2001), which is still stronger 
than the KD determined for the CD4 self association of 1 mM (Wu, H. et al. 1997). 
Attempts to define the segments that are involved in the binding of MHC class II 
molecules on CD4 first described the area of MHC binding as a rather broad area 
involving residues from both domain D1 and D2 (Clayton et al. 1989). Key residues for 
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the interaction were found to be K35, K46, R59 and especially the exposed hydrophobic 
residue F43. These residues are all located in the C’C” ridge suggesting the importance of 
this stretch for the binding which is further confirmed by the involvement of the buried 
residues W62 and S49 that support the top and the bottom of the C’C” loop (Moebius et 
al. 1992). Further studies have shown the area on CD4 involved in MHC class II 
recognition extends to residues on all lateral surfaces of D1 and neighbouring parts of 
domain D2 (Moebius et al. 1993). The size of the CD4 surface involved requires that 
there is more than one MHC class II molecule involved in binding. Thus the authors 
hypothesised that CD4 can bind more than one MHC class II molecule or that part of 
CD4 domain D1 is involved in a CD4-CD4 association which is necessary for the MHC 
class II recognition (Moebius et al. 1993). 
A more detailed view of the CD4-MHC class II interaction arose from the 
resolution of the crystal structure of a MHC class II-peptide complex with the D1/D2 
fragment of CD4 (Wang, J. H. et al. 2001). In contrast to the previous reports of an 
extended binding area containing CD4 domains D1 and D2, the authors found only D1 
involved in MHC II binding, occupying a groove between the two membrane proximal 
domains of the two MHC II chains. The main binding interaction is mediated through the 
hydrophobic residue F43 on the CD4 C” strand, which is surrounded by a pocket of five 
hydrophobic amino acids from the α2 and β2 domain. A second contact site is formed by 
the CD4 C” strand and the β2 D strand which supposedly supports the F43 mediated 
interaction. Furthermore, a third association site is made up of salt bridges between the 
DE loop α-helical segment and residues of the MHC α2 domain. The majority of the 
strength for the interaction is, however, derived from the binding through F43. Regarding 
the extensive contact area reported via mutagenesis studies, the authors conclude that 
their results are in accordance with the majority of the residues reported to be important 
through mutagenesis. However, the residues that lie outside the interaction site 
determined via X-ray diffraction are supposedly involved in a hydrogen-bonding pattern, 
the abrogation of which, interferes with MHC class II binding (Wang, J. H. et al. 2001). 
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1.1.4.5 Extracellular soluble ligands 
 
Lymphocyte chemoattractant factor IL-16 
The discovery that the effect of a lymphocyte chemoattractant factor (now interleukin-16) 
is dependent on surface expression of CD4, showed that there is a different role for CD4 
as a receptor for IL-16 (Cruikshank, W. W. et al. 1994). IL-16 was first discovered in 
1982 as a lymphocyte attractant factor, which is secreted from stimulated PBMCs 
(Cruikshank and Center, 1982). Interestingly, IL-16 has also been found to inhibit HIV 
mRNA synthesis (Baier et al. 1995) underlining its importance. This will be discussed in 
section 1.2.5.4. 
IL-16 is synthesised in the form of a 631 amino acid precursor (Baier et al. 1997) 
that is cleaved by caspase-3 to form the 121 amino acid bioactive molecule which is 
secreted (Zhang, Y. et al. 1998c). The level of IL-16 production upon stimulation is not 
regulated on the level of transcription or translation (Laberge et al. 1995) but through 
activation of caspase-3 followed by processing of the constitutively expressed precursor 
(Wu, D. M. et al. 1999). After release, IL-16 assembles into tetramers (Cruikshank, W. 
W. et al. 1994), but the importance of IL-16-oligomerisation has been subject to some 
controversy. While one study reported that all the constructs they investigated showed 
bioactivity in the monomeric state (Muhlhahn et al. 1998), other papers report that its 
bioactivity is dependent on formation of tetramers (Cruikshank, W. W. et al. 1994; Amiel 
et al. 1999). 
The amino acid sequence of the secreted part of IL-16 does not share any 
significant similarity with known cytokines and chemokines but primary structure 
analysis as well as comparison of NMR and X-Ray crystal structure data predicted the 
presence of a PDZ domain (Muhlhahn et al. 1998). PDZ domains are usually found 
intracellularly where they mediate the protein associations required for the formation of 
large protein complexes such as ion channels or for signal transduction (Ponting and 
Phillips, 1995). IL-16 might therefore be the first secreted protein containing such a 
domain. NMR structural analysis of the PDZ domain of IL-16 together with sequence 
comparison to other PDZ proteins showed only low homology between the PDZ domain 
of IL-16 and that of other proteins (Center et al. 2000). Additionally, it has been found 
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that the IL-16 PDZ domain does not posses the usual peptide binding properties of a PDZ 
domain which is partly due to a bulky tryptophan residue located at the centre of the 
peptide binding cleft (Muhlhahn et al. 1998). These findings suggest that the bioactivity 
of the molecule is not mediated via the PDZ domain. 
The sequence homology between the IL-16 molecules of different species 
suggests that the CD4 binding site is also conserved. Peptide inhibitory studies together 
with mutational analysis have revealed two short sequence stretches on CD4 domain D4 
as critical with the residues V334 and V336 (murine counting) being most important (Liu 
et al. 1999). The proposed IL-16 contact site lies in close proximity to the CD4 dimer 
interface reported by Wu et al. (1997) and this might have physiological consequences. 
The concept that CD4 is the receptor for IL-16 has been challenged by one study 
where PBMCs from CD4 knockout mice where shown to be similarly responsive to IL-
16 as PBMCs from CD4 positive mice (Mathy et al. 2000). This, however, leaves the 
possibility that IL-16 is recognised by receptors other than CD4, especially in the absence 
of the receptor, a feature that is common among cytokines and called redundancy (Abbas 
et al. 2000). IL-16 is synthesised upon stimulation by an array of cells. Among the cells 
that have been found to secrete IL-16 are epithelial cells, mast cells, eosinophils, 
fibroblasts, neuronal cells and CD4+ and CD8+ T cells. Similarly striking is the list of 
target cells for IL-16, which includes T cells, eosinophils, monocytes, dendritic cells, 
neuronal cells and pro B cells (Center et al. 2000; Cruikshank, W. W. et al. 2000). The 
function of CD4 as a chemotactic receptor for IL-16 provides an explanation for its 
presence on a large number of cells where it does not function as a co-receptor for MHC 
class II molecules. CD4 has been shown to mediate IL-16-induced migration of 
eosinophils (Bandeira-Melo et al. 2002), activated CD8+ T cells expressing CD4 (Kitchen 
et al. 2002) and, at least in part, Langerhans cells (Stoitzner et al. 2001). The mechanism 
of IL-16 induced signalling through CD4 will be addressed later. For more detailed 
information on IL-16 see the recent reviews cited (Center et al. 2000; Cruikshank, W. W. 
et al. 2000). 
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Gp17 
In 1991, the identification of a CD4 binding glycoprotein in human seminal plasma 
named gp120, was reported which was found to bind CD4 in Domains D1 and D2 
(Autiero et al. 1991). Two gp17 regions involved in CD4-binding are located at the 
amino- and carboxyterminal part of gp17 with amino acids D87, R90 and E91 most likely 
representing contact residues (Basmaciogullari et al. 2000). The affinity of the gp17-CD4 
interaction is high with a KD of 9.1 and 38 nM (Autiero et al. 1997). Gp17 was shown to 
inhibit T cell apoptosis induced by CD4 cross linking and TCR/CD3 activation in 
monocyte-depleted PBMCs (Gaubin et al. 1999) further confirming an 
immunomodulatory role of CD4 distant from its role in MHC class II recognition. 
 
1.1.4.6 CD4 associating proteins in non-lymphoid cells 
Despite evidence that CD4 functions as a signalling molecule on cells other than CD4+ T 
cells (Parada et al. 1996; Krautwald 1998), no CD4 associating proteins that could initiate 
signalling events have been identified yet. However, on monocytoid Thp-1 cells, CD4 
was also shown to be active as a signalling molecule, and two proteins of 45 and 55 kDa 
were reported to bind to the CD4 cytoplasmic tail. Mass spectrometry analysis indicated 
that both proteins exhibit novel sequences (Graziani-Bowering et al. 2002).  
 
1.1.5 CD4 function 
 
1.1.5.1 T Cell activation through MHC class II molecules. 
Binding of MHC class II molecules presenting non-self peptides located on the surface of 
antigen presenting cells (APCs) leads to full T cell activation, as reviewed by (Germain 
and Stefanova, 1999). T cell activation is initiated by a low-affinity binding of the antigen 
specific TCR to the MHC class II molecule presenting the antigenic peptide (Germain 
1994). Subsequent binding of CD4 to nonpolymorphic regions on the MHC class II 
molecule (Doyle and Strominger, 1987) stabilises the TCR-MHC association but also 
recruits the src homology kinase p56lck to the intracellular part of the TCR complex 
through the association of CD4 with lck (Konig et al. 1995). Before T cell activation, lck 
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is being kept in a semi-activated stage through association of the CD4/lck complex with 
the tyrosine phosphatase CD45 (Holdorf et al. 2002). 
Activated lck then phosphorylates immune receptor tyrosine-based activation 
motifs (ITAMs) located on the cytoplasmic site of the TCR complex CD3 and ζ-chains. 
Subsequently, the ζ-associated protein (ZAP-70) is recruited to the phosphorylated 
ITAMs and activated by lck which leads to the assembly and activation of further 
molecules like p36, vav and SLP-76 (Kane et al. 2000). Those activated molecules 
initiate signalling cascades such as the phospholipase C-γ1 (PLC-γ1)-dependent cascade 
(Noh et al. 1995). Other signalling pathways activated are the p21ras triggered MAPK 
pathway and PI-3K pathway (Franklin et al. 1994; Rudd et al. 1994). These signalling 
processes finally result in a change of gene expression characteristic for T cell activation 
(Kane et al. 2000). 
Whereas this view might indicate that the signalling entities consist of one MHC 
class II heterodimer, one TCR heterodimer associated with the CD3 and ζ-chains and one 
CD4 molecule, recent reports suggested that dimerisation or oligomerization of some or 
all of the components is required for efficient signalling. Sakihama et al. (1995) report 
that dimerisation of CD4 is required for MHC class II binding by investigating the effects 
of a dominant negative mutation of CD4 that inhibits binding of CD4 to the MHC class II 
molecule. Introduction of this mutation into CD4+ cells led to inhibition of MHC class II 
molecule binding even though wt CD4 is still present on the cell surface. Furthermore, 
studies with CD4 chimeras where domains 3 and 4 were replaced by different domains 
that were unable to dimerise indicated that CD4 molecules lacking this part were not able 
to bind MHC class II molecules presented by B cells (Sakihama et al. 1995). These 
findings are consistent with the later resolution of the CD4 crystal structure (Wu, H. et al. 
1997) which suggests a formation of CD4 dimers through domain D4. Li et al. (1998) 
discuss the recent evidence for a CD4 dimerisation site in domain D4 and follow up with 
the discussion of a putative second dimerisation site in domain D1. This site was 
investigated by molecular modelling studies, which showed a possible D1-D1 interaction 
through positively and negatively charged patches on the domain. The authors suggest 
that the CD4 dimerisation through domain D1 is much weaker than the one mediated 
through domain D4 and thus cannot be seen in the crystal structure or in solution. 
 24
According to the authors the function of this interaction might be in the formation of a 
network of signalling molecules on the cell surface (Li et al. 1998). A model proposed is 
that initial binding of 2 TCR molecules to a proposed MHC class II “dimer of dimers” 
leads to the binding of 2 CD4 molecules. The dimerisation of the MHC class II complex, 
which is a heterodimer of an α and a β chain was first described with the resolution of the 
crystal structure of the HLA-DR1 molecule (Brown, J. H. et al. 1993). The CD4 
molecules then dimerise through their D4 domain and further oligomerise through their 
D1 domains leading to a “supercluster” of signalling molecules on the cell surface. This 
is supported by a study which conducted mutational analysis on both the MHC class II α 
and β chain and reported that, in addition to the CD4 binding site on the β chain, another 
binding site exists on the α chain (Konig et al. 1995). The possible formation of a MHC 
class II molecule “dimer of dimers” is further supported by a study employing double 
amino acid mutations in the putative dimerisation site on MHC class II molecules. Those 
mutations lead to a reduced T cell response.  Single amino acid substitutions, however, 
did not affect T cell activation (Lindstedt et al. 2001). 
Those findings have to be seen in the context of the formation of the 
immunological synapse, that is the area of close contact between the APC and the T-cell 
which is characterised by a very tight association through a very ordered pattern of the 
molecules involved in MHC class II recognition, signal transduction and adhesion. 
Formation of the immunological synapse is a prerequisite for successful T cell activation 
(Dustin et al. 2000). The process of synapse formation starts with a ring of TCR-pMHC 
II interactions surrounding a central region of integrin-mediated adhesion termed the 
“nascent immunological synapse” (Lee, S. J. et al. 2002b). Within five minutes, the 
nascent synapse develops into a “mature synapse” with an inverted pattern of TCR-
pMHC II interactions in the centre surrounded by a ring of integrin-mediated adhesion 
(Lee, S. J. et al. 2002b). Research on the immunological synapse is moving rapidly and 
the interested reader is referred to recent reviews (Dustin et al. 2000; Lee, S. J. et al. 
2002b; Sumen et al. 2002). 
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1.1.5.2 Partial T cell activation 
As described above the full activation of T cells, as seen in peripheral T cell activation 
and thymic selection, requires the involvement of the T cell receptor and CD4 for 
efficient signalling. However, activation of a T cell is not an on-off response as partial T 
cell activation has been described. Full T cell activation requires a sustained signal over 
an extended period of time (>2 h) eventually leading to IL-2 synthesis, which serves as a 
marker for full T cell activation (Iwashima 2003). Ligands that lead to partial activation 
of a T cell are divided into partial agonists if they lead to incomplete activation of T-cells 
and partial antagonist ligands if they inhibit agonist-induced activation. There are several 
reviews on partial T cell activation through the T cell receptor (Kersh and Allen, 1996; 
Madrenas and Germain, 1996; Iwashima 2003). 
The early events of partial activation are similar among different partial agonists 
and are mainly characterised by phosphorylation patterns that are suboptimal compared 
to those in full T-cell activation, especially if the partial T cell activation is independent 
of CD4 (Chau et al. 1998). To explain those findings a model was proposed suggesting a 
threshold of signals that are required to accumulate during T cell activation to finally 
trigger full activation and IL-2 production (Iwashima 2003). Failure to accumulate the 
required quantity of signals does not result in IL-2 production, however, some changes in 
the T cell phenotype have been observed. An increase in cell size, together with a 
decrease in IL-2 secretion after subsequent activation of the T cell receptor with 
manipulated ligands has been reported (Racioppi et al. 1993). Other responses that have 
been observed are acidification of the extracellular environment (Beeson et al. 1996), 
transient and/or partial calcium signals (Wulfing et al. 1997), modulation of TCR 
expression (Valitutti et al. 1995) and the upregulation of certain cell surface molecules 
like the IL-2 receptor or LFA-1 (Kersh and Allen, 1996; Madrenas and Germain, 1996). 
The downstream responses after these effects are inhibition of agonist induced cell 
proliferation and/or cytokine production, split cytokine production and induction of T cell 
anergy (Racioppi et al. 1993) that are described as partial T cell activation. 
Taken together, these findings suggest that activation of T-lymphocytes is more 
than just a single mechanism operating in an on-off matter, but rather a delicately 
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balanced response to various different stimuli that can trigger signals through some or all 
of the components of the T cell receptor and/or CD4. 
 
1.1.5.3 CD4 mediated signalling 
CD4 has been described to function as a chemotactic receptor for IL-16 on T cells and 
other cells (Cruikshank, W. W. et al. 1987) but little was known about the mechanism of 
chemotaxis induced through CD4 engagement. Signals that were observed after CD4 
stimulation with IL-16 are an increase in intracellular Ca2+, IP3 and CD4 phosphorylation 
(Cruikshank, W. W. et al. 1991). Additionally, in lymphocytes, autophosphorylation of 
lck occurs (Ryan et al. 1995) as well as desensitisation of the CXCR4 receptor (Van 
Drenth et al. 2000). In eosinophils, IL-16 treatment induced release of IL-4 but not IL-12 
and primed cells for enhanced calcium ionophore induced secretion of leukotriene (C4) in 
a manner that was dose dependent and also dependent on the chemokine receptor CCR-3 
(Bandeira-Melo et al. 2002). Signalling events such as PKC translocation and pathway 
activation have also been observed in monocytes/macrophages (Parada et al. 1996; 
Krautwald 1998) or on the monocytoid cell line Thp-1 (Graziani-Bowering et al. 2002).  
The phenotypic changes in T cells upon IL-16 activation are described as an 
“inflammatory phenotype” (Center et al. 2000) to discriminate them from the T cell 
response that is triggered upon MHC class II interaction with the T cell receptor and 
CD4. The suggested physiological role of this T cell phenotype is to increase CD4+ T cell 
accumulation while preserving future antigen responsiveness which is in accordance with 
the transient nature of the “inflammatory phenotype” (Center et al. 2000). 
Interestingly, CD4 ligands other than IL-16, such as anti CD4 antibodies, also 
trigger a cellular response as CD4 signalling induced by antibody-mediated ligation 
modulates subsequent TCR signals (Newell et al. 1990). Because this antibody 
stimulation of CD4 altered the TCR induced signalling similar to the effects of IL-16 but 
fails to switch on the “inflammatory phenotype” (Center et al. 2000) it was suggested that 
the CD4 receptor can discriminate between different ligands. Taken together, those 
findings show a different, but yet ill-defined role of CD4 as a chemotactic receptor on T 
lymphocytes as well as other CD4 expression cells. 
 
 27
1.1.6 Lipid rafts 
The fluid mosaic model described by Singer and Nicholson in 1972 has been the standard 
model for the description of cellular membranes for decades (Singer and Nicholson, 
1972). However, in the last ten years, more and more evidence has demonstrated that 
there are different compartments in membranes distinct from the fluid phase that are 
enriched in special lipids which are called lipid rafts. “Lipid rafts” is being used 
according to the nomenclature proposed earlier (Simons and Toomre, 2000) for all liquid-
ordered membrane microdomains. 
Lipid rafts were first discovered during investigations of vesicle trafficking in 
epithelial cells (Simons and van Meer, 1988). Epithelial cells have two distinct 
membranous compartments, with different lipid constitutions. These are the apical 
membrane facing the lumen and the basolateral membrane facing the connective tissue. 
Vesicles budding from the trans Golgi network (TGN) trafficking towards the membrane 
have been found to be organised into two different circuits. One pathway is targeted to 
the basolateral membrane whereas other vesicles traffic towards the apical membrane. 
Different lipids are sorted into lipid rafts before budding from the TGN along these two 
pathways, resulting in different sets of lipids being transported to the apical and 
basolateral membranes (van Meer and Simons, 1988). 
The concept of lipid rafts was initially attacked as detergent-induced artefacts 
(Mayor and Maxfield, 1995). Later studies however have shown that artefactual creation 
of protein-enriched microdomains does not occur (Ostermeyer et al. 1999). Recent 
technological advances also overcame the initial difficulties in observing of such 
dynamic structures on the cell membrane. Techniques like photonic force microscopy 
(Pralle et al. 2000) have made the observation of those structures possible and led to the 
acceptance of the raft hypothesis by the scientific community. Lipid rafts are covered in 
this review because lck and possibly CD4 are raft associated (Ilangumaran et al. 1999; 
Percherancier et al. 2003). T cell receptor mediated signalling has also been shown to 
occur in rafts (Xavier et al. 1998). Moreover, the human immunodeficiency virus, which 
is the subject of the second part of this review, buds from lipid rafts in the cell membrane 
of T cells and probably also enters these cells similarly (Manes et al. 2000; Campbell et 
al. 2001). 
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1.1.6.1 Structure and investigation of lipid rafts 
Lipid rafts are dynamic regions on the plasma membrane that are rich in cholesterol and 
sphingolipids. They are less fluid than the surrounding membrane owing to the different 
composition in fatty acids and cholesterol (Schroeder et al. 1994). Rafts are found in all 
types of mammalian cells and even in yeast. Estimates of the percentage of cell-surface 
area occupied by rafts range from 5 % to 50 % (Horejsi 2003). They are characterised by 
insolubility in non-ionic detergents like Triton X-100 (but soluble in other detergents like 
n-octylglucosid or SDS (Horejsi 2003)) leading to the description of rafts as “detergent 
insoluble glycolipid-enriched complexes” (DIG). However, when investigating rafts, care 
has to be taken as, depending on the type of detergent and the extraction conditions, 
varying results can be obtained towards association of compounds with DIGs (Simons 
and Toomre, 2000). 
Caveolae are a different type of raft that is characterised by the incorporation of 
caveolin. They are morphologically characterised as deep invaginations in the plasma 
membrane. As T lymphocytes do not contain Caveolae (Simons and Toomre, 2000), they 
will not be reviewed here. 
As mentioned above, the existence of rafts has been controversial for a rather long 
time until defined by recent technological advances such as fluorescence resonance 
energy transfer (FRET) (Varma and Mayor, 1998), Chemical cross-linking (Friedrichson 
and Kurzchalia, 1998), immunofluorescence microscopy (Harder et al. 1998), photonic 
force microscopy (Pralle et al. 2000), single dye tracking (Schutz et al. 2000) and 
electron microscopy (Wilson et al. 2000). Further, studies of rafts included extraction 
with different detergents  (Hooper 1999), gradient centrifugation (Brown and Rose, 1992) 
or altering the lipid composition of membranes (Liao et al. 2001). For example, 
incubation with beta-cyclodextrin depleted membranes of cholesterol and renders the 
raft-associated proteins detergent soluble. However, care must be taken when using such 
compounds as they might have other effects on the cellular metabolism than mere 
cholesterol depletion (Ikonen 2001; Horejsi 2003). 
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1.1.6.2 Raft associated proteins 
The most important property of rafts is that they can specially include or exclude proteins 
and thus lead to enrichment of proteins in special domains. Proteins can reside in rafts 
transiently, for up to several minutes (Pralle et al. 2000) and clusters of up to 15 identical 
proteins have been observed in the same raft (Friedrichson and Kurzchalia, 1998; Varma 
and Mayor, 1998). Classes of proteins that are targeted to lipid rafts include GPI-
anchored proteins (Hooper 1999), N-terminally myristoylated and palmitoylated proteins 
like src family kinases (Wolven et al. 1997; Webb et al. 2000) or α-subunits of 
hetertotrimeric G-proteins (Moffett et al. 2000). 
Whereas the GPI-anchor seems to function as a raft-targeting signal for 
extracellular proteins (Sharom and Lehto, 2002) and myristoylation for intracellular 
proteins, no direct raft-targeting signal has been identified for transmembrane proteins. 
Some proteins like CD45 are known to be non-raft resident (Horejsi 2003) whereas 
others like CD44 were described as raft associated (Neame et al. 1995). It has been 
suggested that transmembrane proteins are packed into lipid rafts owing to the interaction 
of their hydrophobic membrane anchor and adjacent lipid modifications with the raft 
lipids. Nevertheless, several transmembrane proteins that do not contain lipid 
modifications can partition in lipid rafts. This has been attributed to amino acids at the 
exoplasmic part of their transmembrane domain (Scheiffele et al. 1997; Simons and 
Toomre, 2000). Marker proteins for rafts are mainly GPI-anchored proteins and caveolin 
for Caveolae. Other raft markers reported are flotillins and ganglioside GM1 and GM3 
(Zajchowski and Robbins, 2002). 
For further reading on lipid rafts see reviews on rafts and signal transduction 
(Simons and Toomre, 2000), rafts and membrane transport (Ikonen 2001), general 
concept of rafts (Simons and Ikonen, 1997; Zajchowski and Robbins, 2002), rafts and T 
cell activation (Horejsi 2003) or lipid modifications of proteins (Casey 1995). 
 
1.1.6.3 CD4 partitioning in lipid rafts 
Several findings support the notion that CD4 resides inside lipid rafts. First, it contains 
two palmitoylation sites which can increase the affinity of proteins to lipid rafts (Crise 
and Rose, 1992; Melkonian et al. 1999). Second, CD4 functions in T cell activation and T 
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cell signalling has been reported to originate from rafts (Janes and Peterlin, 2000). Third, 
it associates with p56lck, a kinase that has been shown to be located in lipid rafts as a 
result of its lipid modifications (Ilangumaran et al. 1999) and the CD4-lck interaction has 
been shown to be responsible for targeting of CD4 into lipid rafts (Foti et al. 2002).  
Lipid rafts can also mediate a connection between the cellular membrane and the 
cytoskeleton (Babiychuk and Draeger, 2000; Rozelle et al. 2000). The reported 
associations between CD4/lck and the cytoskeleton, as discussed in part 1.1.4.1, could be 
a result of the location of CD4 in the lipid raft microdomains and the partitioning of CD4 
in detergent-insoluble compartments. It could well be that CD4 residing in rafts is 
connected to the cytoskeleton via lck and adaptor molecules. However no such molecules 
have been identified yet. It is also worth noting that the controversial results obtained in 
experiments aimed at co-immunoprecipitating TCR components with CD4 (part 1.1.4.3) 
could be a product of the colocation of these proteins and CD4 in the same raft, although 
not physically associated with the TCR components. 
 
1.1.6.4 Functions of lipid rafts 
The two main roles that have been assigned to lipid rafts are signal transduction and 
transport. The role of rafts in transport led to their initial discovery when they were found 
to support a distinct traffic pathway from the TGN to special membrane compartments 
(van Meer and Simons, 1988). Moreover, rafts have been shown to be involved in 
secretion as cholesterol depletion blocked the formation of regulated, constitutive 
secretory vesicles in neuroendocrine ArT-20 cells (Wang, Y. et al. 2000b). The described 
link between rafts and the actin cytoskeleton (Babiychuk and Draeger, 2000; Rozelle et 
al. 2000) could provide the mechanism for raft-mediated transport. 
Rafts can also play a role in endocytosis and could provide an alternative 
mechanism for protein endocytosis in comparison to clathrin-coated pits (Deckert et al. 
1996).  The most important role that rafts play on the cell surface is in signal 
transduction. Rafts provide platforms for signalling by specifically recruiting the requisite 
molecules and by excluding molecules that could inhibit signalling, such as phosphatases. 
Therefore, these lipid domains create a new microenvironment for the signalling 
molecules leading to an amplification of the signalling (Simons and Toomre, 2000). 
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Signalling processes that have been shown mediated by lipid rafts are immunoglobulin E 
signalling (Sheets et al. 1999), GDNF (glial cell line-derived neurotropic factor) 
signalling (Tansey et al. 2000), ras signalling (Roy et al. 1999), hedgehog signalling 
(Incardona et al. 2000), other growth factor signalling processes and GPI-protein 
signalling (Zajchowski and Robbins, 2002) and TCR signalling (Janes and Peterlin, 
2000). The latter is of particular interest here. For a detailed review on the role of rafts in 
signalling see recent publications (Simons and Toomre, 2000; Zajchowski and Robbins, 
2002). 
Most of the molecules that are involved in TCR signalling are initially associated 
with lipid rafts or become associated during TCR activation. The molecules involved in 
TCR signalling that are constitutively associated with rafts include LAT, lck, fyn, PIP2 
and ras (Liu et al. 1998; Ilangumaran et al. 1999; Roy et al. 1999). The association of the 
TCR complex with lipid rafts itself has been more controversial. The components of the 
complex have been found to be detergent soluble as well as detergent insoluble, as 
reviewed by Janes et al. (2000). Those discrepancies are likely to originate in differential 
detergents and differential methods when the extraction was performed and the TCR in 
the non-activated stage is likely to have only a moderate affinity for lipid rafts (Janes and 
Peterlin, 2000). Upon activation, however, the amount of TCR associated with lipid rafts 
increases (Montixi et al. 1998; Xavier et al. 1998) and other proteins are also recruited to 
lipid rafts, including PLC-γ1, Sos and Grb2 (Zhang, W. et al. 1998a; Zhang, W. et al. 
1998b). Indeed treatment of cells with agents that disrupt lipid rafts inhibits signalling 
through the TCR complex (Xavier et al. 1998). This supports the model of the role of 
lipid rafts in TCR signalling described by Janes et al. (2000) i.e. the cell surface contains 
small isolated patches of lipid microdomains each containing only a few molecules 
involved in the TCR response. Upon TCR activation, those patches cluster together to 
form a large signalling platform, which specially includes the molecules, involved in 
signalling and excludes inhibitory molecules. This model is also consistent with the 
concept of the immunological synapse (see 1.1.5.1) where the interface between the APC 
and the T cell has a very ordered structure of molecules involved in signal transduction 
and adhesion. The clustering of lipid rafts could therefore be the key step for the 
formation of the immunological synapse (Janes and Peterlin, 2000). This model has been 
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subsequently refined. The first steps in TCR signalling seem to occur independently of 
lipid rafts but rafts are required for later stages of signalling (Horejsi 2003). This is 
consistent with the recent finding that the early TCR signalling events are also 
independent of immunological synapse formation (Lee, K. H. et al. 2002a). 
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1.2 The Human Immunodeficiency Virus 
 
 
 
Figure 1.6 Worldwide prevalence of HIV. Adults and children to be living with HIV/AIDS as of end of 
2003. Figure and number obtained from UNAIDS. 
 
1.2.1 Introduction to HIV 
The Human Immunodeficiency Virus HIV-1 is the etiologic agent of AIDS, the “acquired 
immunodeficiency syndrome”, a disease to which more than 20 million people have 
succumbed by the year 2001. Alone in 2001, three million people died of AIDS, there are 
14 million orphans because of it and another 40 million infected people (Stover et al. 
2002). Predictions estimate another 45 million infections between 2002 and 2010 if 
adequate prevention mechanisms are not developed and/or implemented (Stover et al. 
2002). Figure 1.6 shows the worldwide prevalence of HIV as estimated for the end of 
2003. So far no vaccine is available to prevent HIV infection and no cure has been found 
to eradicate the virus from body tissue. The ongoing spread of HIV in the world therefore 
highly requires effective and cheap ways to prevent and treat HIV infection (See (Weiss 
2001) or (Stover et al. 2002) for more information). This review aims to give an overview 
over the structure and pathogenesis of HIV with the ultimate aim of identifying possible 
research targets for the improvement of our understanding of HIV. 
 
 
 
North America: 
790 000-1 mio 
Carribbean: 
350 000 - 590 000 
Latin America: 
1.3 mio - 1.9 mio 
Western Europe: 
520 000 - 690 000
Eastern Europe 
and Central Asia: 
1.2 mio - 1.8 mio 
North Africa and Middle East:
470 000 - 730 000 
Sub-Saharan Africa: 
25.0 mio - 28.1 mio 
East Asia and Pacific: 
700 000 - 1.3 mio 
Southeast Asia: 
4.6 mio - 8.2 mio 
Australia and New Zealand: 
12 000 - 18 000 
Total: 34 - 46 mio 
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1.2.1.1 History and global impact of HIV/AIDS 
AIDS was first discovered in 1981 (Centres of Disease Control and Prevention, 1981) 
and HIV was identified as its etiological agent in 1983 (Barre-Sinoussi et al. 1983). The 
virus is transmitted through sexual contact (sexual transmission), from mother to child 
(vertical transmission) or through horizontal transmission via needles and blood 
transfusions. The latter has become very rare owing to screening of blood products for 
HIV from 1985 leaving the sharing of syringes between intravenous drug users as the 
main way for horizontal transmission (Levy 1998). HIV has spread widely throughout the 
world and the area that is worst affected by the epidemic is sub-saharan Africa. Recent 
spread of the virus in southern and south east Asia and eastern Europe/Russia is of great 
concern. In developed countries, the spread of HIV/AIDS has been reduced because of 
promotion of prevention measurements such as the use of condoms and through the 
introduction of efficient treatment for HIV-positive patients. In developing countries, the 
lack of education and funds for expensive therapies has lead to a spread of HIV that is 
threatening the stability of some countries. With up to 36 % of the population between 15 
and 49 infected with HIV in some African countries, the disease is already severely 
affecting the economic and social structure of those countries by depleting the population 
of young adults (Piot et al. 2001). A second, though less discussed danger accompanied 
by the HIV epidemic is the possibility that microbes, previously not adapted for humans, 
can adapt to the human environment in AIDS immunocompromised patients and evolve 
as pathogens that could “settle” into the healthy population (Piot et al. 2001; Weiss 
2001). In developed countries the most successful control measure for HIV has been 
education. An increased awareness for HIV together with the use of condoms and 
screening of blood products for HIV as well as syringe exchange programs have reduced 
the risk for an infection in western countries and some countries in the developing world 
(Force for Change: World AIDS campaign with young people, Joint United Nations 
Programme on HIV/AIDS 1998; Bluthenthal et al. 2000). Additionally “Highly active 
antiretroviral therapy” (HAART) has had a positive impact on HIV disease progression 
and life expectancy in western countries (Richman 2001) as well as reducing viral load in 
blood and genital secretions. However, in 2003 a rise in HIV infections was reported for 
New South Wales for the first time in eight years (Jones, Cindy 2003). Because of the 
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persistent lack of a vaccine and cure against HIV further research on this highly 
pathogenic virus is of the utmost importance. 
 
1.2.1.2 HIV and SIV 
HIV-1 and HIV-2, which causes a similar disease belong to the Retroviridae family of 
viruses and within those to the genus of lentiviruses. Lentiviruses share several 
characteristics including long incubation period, host species specificity, latent and 
persistent infections of target cells as well as having a highly polymorphic genome. Other 
lentiviruses apart from HIV-1 are Equine infectious anaemia virus, Bovine, Feline and 
Simian Immunodeficiency Virus See (Levy 1998) for more details on lentiviruses. The 
origin of HIV-1 is thought to be a cross-species transfer of Simian Immunodeficiency 
Virus (SIV) to humans probably from chimpanzees. The time when the cross-species 
transfer occurred is now estimated to be the 1930s (Korber et al. 2000). The first 
evidence for HIV-1 infection in humans came from a sample taken in 1959 (Nahmias et 
al. 1986). The virus remained silent/hidden until it began to spread around the globe 
assisted by increasing mobility of individuals some 25 years ago. 
The simian hosts of SIV do not develop AIDS indicating that their immune 
system is capable of controlling the virus. Crossing the species to humans, however, has 
enabled the virus to acquire new terrain and spread extensively. The high mutational rate 
of HIV-1 together with selective pressure allowed for the development of a high genomic 
diversity of the virus around the world and, to a lesser extent, in single infected 
individuals. HIV-1 can create more genetic diversity in one single individual than the 
influenza A virus creates worldwide during an epidemic. According to its genetic 
evolution, HIV-1 is divided into two groups main (M) or outlier (O) with group M being 
responsible for the worldwide expansion. The M group is further divided into clades, 
which differ between geographic regions. So clade B predominates in North America and 
western Europe, clade E in some Asian Countries and clade C predominates in Southern 
Africa. Recombination between different clades further complicates the genealogy of 
HIV-1 especially the definition of these clades (Weiss 2001). In newly infected regions 
often two or more clades are introduced. 
 
 36
1.2.1.3 HIV-1 Disease Progression 
The progression of HIV-1 in individual humans from infection to AIDS can be divided 
into three principal stages (see (Levy 1998) for a more detailed description). The first 
stage is the acute infection occurring in 30-50 % of infected patients and characterised by 
symptoms that are common to many viral infections like fever, headaches, a sore throat 
and rashes (Levy 1998; Anderson 2003). In this stage, the virions have travelled from the 
site of entry to the lymph nodes where they infect CD4+ cells. The host immune system 
responds to the primary infection with high levels of HIV-1 specific antibodies (mainly 
against the viral envelope or the matrix protein p24) and HIV-1 specific cytolytic T 
lymphocytes. This latter response correlates with a quick decline in the load of viral 
particles in the plasma and a recovery of the patient (Niu et al. 1993). However, the 
immune system is not able to totally eradicate the virus. Following the primary infection 
is a long asymptomatic period that is characterised by very high levels of HIV replication 
in CD4+ T cells together with the decline of those blood cells (Ho, D. D. et al. 1995). The 
level of CD4+ T cells, normally around about 1000 cells/µl ranges from around 700 
cells/µl to around 300 cells/µl in this phase (Abbas et al. 2000).  
Some infected individuals have survived for almost 20 years after being infected 
with HIV-1 but without developing AIDS (longterm non-progressors). Usually, after 
months to years the immune system is no longer able to control the HIV-1 replication, 
probably due to the reduction of CD4+ T cells and destruction of lymphoid tissue 
(McCune 2001). In this last phase of the disease, the virus increases replication, becomes 
more aggressive towards CD4+ T cells and opens the gate for opportunistic infections that 
eventually kill the host (Abbas et al. 2000). When the CD4+ T cell count falls below 200 
cells/µl, the immune system is no longer capable of controlling otherwise harmless 
pathogens. AIDS patients thus succumb to microbes that are usually not fatal such as 
Protozoa, Bacteria, Fungi or other viruses (“opportunistic infections”). Additionally, 
patients may develop tumours, encephalopathy and wasting syndromes (Levy 1998; 
Abbas et al. 2000). The use of antibiotics and antiretroviral therapy has eased the 
symptoms and reduced the disease progression, but still, HIV-1 eventually leads to death 
and especially in countries where the economic situation does not allow therapy, many 
people die in inhuman circumstances. The search for a vaccine/cure is therefore of high 
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priority and understanding of the structure and replication of the virus and its immune 
control is the key to accomplish this. 
 
1.2.2 Structure of the HIV-1 virus 
 
1.2.2.1 Structure of the virion 
 
 
 
Figure 1.7 shows the simplified structure of a typical HIV-1 virion. The cone-shaped core 
structure contains a dimer of the viral RNA with which the HIV-1 proteins reverse 
transcriptase, protease and integrase are associated. It is surrounded by a layer of the 
capsid protein p24 and also contains the nucleocapsid proteins p6 and p9. This 
nucleocapsid is surrounded by the matrix, which is made up of the matrix protein p17. 
This structure is enveloped by a cholesterol-rich host cell-derived lipid bilayer which also 
contains host cell-derived proteins (Aloia et al. 1988; Graham et al. 2003). The matrix is 
attached to the membrane through myristoylation of the p17 protein. The nucleocapsid 
also contains the accessory proteins Vpr, Vif and Nef but their location is ill defined 
(Frankel and Young, 1998; Levy 1998). On the surface of the membrane in the shape of 
72 spikes is the viral envelope protein. Each spike consists of a trimer of the 
transmembrane protein gp41 and a trimer of the surface protein gp120 (Lu et al. 1995). 
The overall shape of the submembraneous matrix is icosahedral and the size of the virion 
is about 100 to 120 nm (Collier et al. 1998). 
Figure 1.7 
 
Structure of the HIV-1 virion 
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1.2.2.2 Structure of the HIV-1 genome: 
 
 
Figure 1.8: Structure of the HIV-1 genome 
 
Figure 1.8 shows the HIV-1 genome. It has approximately 9 kb, is flanked by two long 
terminal repeats (LTR) and codes for a total of 15 proteins in nine open reading frames. 
Besides the three major viral components gag, pol and env, six accessory proteins are 
encoded (Frankel and Young, 1998). Gag, pol and env are each synthesised as large 
precursors which are then processed into smaller components. The gag precursor (p55) is 
cleaved to give rise to the matrix protein (MA, p17), the Capsid protein (CA, p24) and 
the nucleocapsid proteins NC (p7) and p6. The pol protein yields the necessary viral 
enzymes reverse transcriptase (RT), integrase (IN) and protease (PR). The env protein is 
synthesised as a 160 kDa precursor (gp160) and cleaved by cellular proteases that are 
located in the Golgi, forming the transmembrane protein (TM, gp41) and the surface 
protein (SU, gp120). The accessory proteins consist of two regulatory proteins (tat and 
rev) which are spliced from the primary transcript and four other proteins (vif, nef, vpu 
and vpr). The functions of those proteins will be discussed later. Three of them, vif, vpr 
and nef are part of the virion (Frankel and Young, 1998; Levy 1998). Apart from coding 
for the viral proteins, the viral RNA contains several regulatory elements that are required 
for virus function namely (Frankel and Young, 1998): 
(i) nucleotides 1 to 55 form the TAR loop, which is recognized by the regulatory 
protein tat; 
(ii) the primer-binding site from nucleotide 182 to 199 recruits a tRNALys from the 
host cell to become the site of initiation for the reverse transcription; 
(iii) the packing signal Ψ is required for assembly of the viral RNA into the budding 
virion. It comprises of the nucleotides 240 to 350; 
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(iv) the sequence between nucleotide 248 and 271 is called the kissing loop: it is 
involved in dimerisation of the RNA leading to the assembly of two copies of the 
viral RNA in a budding virion; 
(v) the dominant donor splice site at nucleotide 290 is required for the formation of 
the subgenomic RNAs; 
(vi) a gag-pol frameshift region is necessary for the pol proteins to be translated 
correctly. It includes nucleotides 1631 to 1673, which form a secondary structure 
that leads to the reading of eight nucleotides as three codons thus shifting the 
reading frame by –1; 
(vii) the rev response element (RRE), including nucleotides 7362 to 7596, binds the 
regulatory protein rev and increases the production of structural proteins and full 
length RNA by preventing splicing of the primary transcript; and 
(viii) many donor and acceptor splice sites are present which provide multiply spliced 
transcripts encoding various combinations of the regulatory proteins. A poly A 
signal at nucleotides 9205 to 9210 is also present. 
 
1.2.3 The HIV-1 Life Cycle 
 
1.2.3.1 Overview 
 
 
Figure 1.9 
Schematic diagram of the 
HIV-1 life cycle seen from 
within an infected cell  
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Figure 1.9 shows an overview of the HIV-1 life cycle from within an infected cell, 
starting with the entry and ending with the release and maturation of new virions. The 
HIV-1 life cycle has also been described from the perspective of the virion starting with 
the transcription of the viral RNA and finishing with the integration of the viral DNA into 
the host cell genome (Frankel and Young, 1998). The HIV-1 life cycle can be divided 
into up to 15 discrete steps (Frankel and Young, 1998), but in this review, it will be 
divided into only four major steps. The first step is the entry of the infectious virion 
starting with the virus attachment, receptor and coreceptor engagement and finally 
membrane fusion. The second step describes the post entry events including transport to 
the nucleus, reverse transcription and integration of the viral DNA into the genome, 
which in the case of infected lymphocytes can be followed by a period of cellular latency. 
The third step is the transcription of the viral genes, starting with the transcription of 
early genes and ending in the production of full-length viral RNA and structural proteins. 
The last step starts with the assembly of viral particles at the membrane, the budding of 
the virus followed by its maturation to become infectious. Each of these steps harbours 
several potential target sites for interference with HIV-1 replication.  
 
1.2.3.2 HIV-1 entry 
HIV-1 entry into its target cells is a multistep process starting with the attachment of the 
virus to the target cells via the envelope glycoprotein gp120 binding to the virus receptor 
CD4. This is followed by the exposure of a coreceptor-binding site in gp120 and binding 
of a coreceptor, usually CXCR-4 or CCR-5. Further changes in the gp120 structure 
finally lead to the fusion of the viral and cellular membrane. This has been reviewed by 
Doms and Trono (2000). Figure 1.10 illustrates the major steps of HIV entry that are 
understood so far. 
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Figure 1.10: The entry of the human immunodeficiency virus into a target cell. Taken from (Doms and 
Trono, 2000) 
 
Virus attachment 
CD4 was identified early as the receptor of HIV (Klatzmann et al. 1984; Maddon et al. 
1986) which gains entry into target cells via binding of the viral envelope protein gp120 
to CD4 (Lasky et al. 1987). Binding of gp120 to CD4 was initially thought to be the only 
mechanism for initial attachment of the virus, which was supported by the high binding 
constant of 1 to 10 nM (Moore and Binley, 1998). Recent studies, however, have shown 
that other receptors may assist initial binding, particularly in certain cell types eg. anti-
CD4 antibodies blocked HIV-1 attachment to T cells but not to HeLa cells expressing 
CD4 (Mondor et al. 1998). Interestingly, though HIV-1 does attach to HeLa cells even in 
the presence of anti-CD4 antibodies, it does not attach to CD4 negative T cells (Mondor 
et al. 1998) suggesting that HeLa cells express surface molecules capable of serving as 
HIV receptors. This suggests that CD4 is the major receptor for HIV attachment on T 
cells but that on other cells other receptors can mediate virus attachment as well (Ugolini 
et al. 1999). Those data have to be interpreted with caution, though, as virus from 
different sources may exhibit different binding characteristics. 
 It is now known that a series of other molecules serve as accessory HIV-1 
attachment receptors on cells where CD4 expression is low. Macrophages express a high 
level of heparan sulfate proteoglycans (HSPG) that have been shown to mediate initial 
binding of gp120 to the cells as well as CD4 which is still a major CD4 binding receptor 
on those cells (Saphire et al. 2001). HIV-HSPG binding is due to an interaction of basic 
residues in the gp120 V3 loop and the negatively charged HSPG proteins explaining also 
the HIV-1 attachment to CD4 negative HeLa cells which are HSPG+ cells (Saphire et al. 
2001). 
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 Macrophages and dendritic cells (DCs) express a series of C-type (Calcium 
dependent) lectin receptors (CLRs) that normally serve to trap soluble glycosylated 
antigens consistent with the function of the cells as professional antigen presenting cells 
(Figdor et al. 2002). Those CLRs are the mannose receptor (MR, expressed on 
macrophages and DCs), dendritic cell specific ICAM-3 grabbing non-integrin (DC-
SIGN, expressed on monocyte-derived DCs) and Langerin (expressed only on langerhans 
cells, a sub-set of DCs in the epidermis) (Figdor et al. 2002). Those molecules can 
efficiently bind HIV-1 and concentrate it on the cell surface (Turville et al. 2002). 
Interestingly, whereas macrophages can be easily infected with HIV-1 (Cunningham et 
al. 2000) immature DCs are infected at low levels and mature DCs hardly at all. 
Nevertheless, both can mediate the infection of CD4 lymphocytes at virus concentrations 
that are not sufficient to infect the CD4 lymphocytes in the absence of DCs (Cameron et 
al. 1992; McDonald et al. 2003), (reviewed by (Pope and Haase, 2003)). This mechanism 
of trans infection is partly mediated by DCs endocytosing HIV followed by diversion to 
the T cell contact zone, away from the normal endolysosomal degradation of the virus. 
Dendritic cells also present HIV antigens to these contacting T cells (as reviewed in the 
part on CD4). Indeed specific activation of responding CD4 lymphocytes at the same 
time as infection may lead to explosive HIV replication in DC-T cell clusters. Immature 
DCs can also be infected by HIV at low levels and this virus transferred to contacting T 
cells. Work in our institute has demonstrated that there are two sequential phases of 
transfer from DCs to CD4 lymphocytes, leading to the theory that early phase transfer 
may occur while the DC is still in the mucosa whereas later stage transfer probably 
occurs after the DC has migrated to local lymph nodes (Turville et al. 2003). 
Apart from HPSGs and CLRs, virus attachment can be increased by an array of 
host cell derived membrane proteins that become part of the viral envelope during 
budding and then recognize their ligand on the target cell. CD44 is an example for one of 
those molecules (Guo and Hildreth, 1995). See also Baribaud et al. (2001) or (Ugolini et 
al. (1999) for more details on host cell derived factors that increase virus attachment. 
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Binding to the CD4 receptor 
The CD4 receptor was established early on to be the principal receptor for HIV-1 entry 
into its target cells. This was based upon the findings that CD4 is expressed on all cells 
that are susceptible to HIV-1 and that cells can be infected with HIV-1 after transfection 
of the CD4 gene (Maddon et al. 1986). Additionally, anti CD4 antibodies blocked HIV-1 
infection of target cells (Klatzmann et al. 1984). Soon thereafter, a viral protein named 
gp110 (now gp120) was identified as responsible for binding of HIV to target cells 
(McDougal et al. 1986). Understandably, intense research was then aimed at investigating 
the epitopes involved in this binding reaction, especially with the aim to develop 
structure-based drugs. Lasky et al. (1987) reported the determination of an epitope on 
gp120 responsible for CD4 binding. This epitope comprised the amino acids 397 to 439. 
Additionally the binding constant was measured to 4 nM indicating a very strong binding 
reaction (Lasky et al. 1987). Mutational analysis carried out with the CD4 molecule 
showed that the gp120 binding is located at domain D1 with the residues 40 to 48 in the 
CDR2 loop playing the most important role. Again, the unusually protruding 
hydrophobic residue F43 was reported to be absolutely essential for binding, with other 
residues being less important (Clayton et al. 1988; Mizukami et al. 1988; Peterson and 
Seed, 1988; Arthos et al. 1989). 
 
Structure of gp120 
As gp120 is the viral protein responsible for binding and entry into the target cells, 
understandably intense research was conducted towards determining the structure of this 
molecule. Initial studies focussed on the amino acid sequence and showed that gp120 was 
characterised by five variable regions (named V1 to V5) located between more conserved 
regions (Starcich et al. 1986). The four variable regions V1 to V4 form loops protruding 
from the surface which contain a disulfide bridge at their base (Leonard et al. 1990). The 
same report also described the extensively glycosylated nature of gp120. A major 
breakthrough came in 1998, when Hendrickson and Sodroski published the resolution of 
the crystal structure of gp120 complexed with CD4 and a neutralising human antibody. 
They also reported on the antigenic structure of gp120 (Kwong et al. 1998; Wyatt et al. 
1998a). 
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In order to obtain structural information, the researchers had to extensively reduce 
the structure of the gp120 molecule. Both termini were truncated, the V1/2 and V3 loops 
were substituted by short amino acid stretches and the molecule was extensively 
deglycosylated. Still, the gp120 molecule did bind CD4 and was recognized by the 
antibody indicating that large regions of the molecule are not required for CD4 
engagement. Figure 1.11 shows the structure of gp120 determined in that study. The 
overall shape of the gp120 molecule is a heart-shaped ellipsoid with the approximate 
dimensions 50Å x 50Å x 25Å. It comprises of 25 β-sheets, 5 α-helices and 10 loop 
segments. The molecule can be divided into two major parts: an inner domain and an 
outer domain (referring to the relative location of the gp120/gp41 trimer axis) from which 
the loop segments protrude. The inner domain is a two-helix two-strand bundle with a 
five-stranded β-sandwich at its termini proximal end and a projecting V1/2 stem. The 
outer domain is a stacked double barrel that runs parallel to the inner domain. The two 
barrels form one hydrophobic core. The V1/V2 loops are located at the inner domain on 
the opposite site as the N and C termini. The V3 loop emanates from the distal end of the 
outer domain and the V4/V5 loops are located at its proximal end. 
The gp120 structure is unique sharing only some similarities with FabA 
dehydrase and dUTP pyrophosphatase. Assigning conserved and variable regions to the 
gp120 structure reveals that the inner domain is more conserved than the outer domain, 
that the most variable parts are the solvent exposed ones whereas the hydrophobic core is 
more conserved. HIV-1 gp120 shares 35 % identity with HIV-2 gp120. The identity 
between clade M and O is 51 % and between M and C is 77 % revealing a certain level of 
conservation despite the high variability in HIV (Kwong et al. 1998). 
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CD4-gp120 interaction 
The crystal structure of gp120 engaged with CD4 and an antibody showed that CD4 
occupies a cavity between the inner and outer domain of gp120. The structure of CD4 is 
not altered by binding as the structure of free and bound CD4 Domains D1/D2 do not 
show any striking changes. The binding site on gp120 is free of carbohydrate residues 
and the residues of CD4 at the binding site were similar to the residues that were 
identified by mutational analysis. The important residues are R59 and F43 with F43 alone 
accounting for about one quarter of all interatomic contacts. Interestingly, 60 % of the 
contacts to CD4 are made by main-chain atoms of gp120. This has consequences for the 
ability of antibodies to neutralise gp120. As antibodies are predominantly directed 
towards side chain atoms, a mutation in gp120 that changes the side chains will lead to 
the loss of binding ability of the antibody, however, as the contacts to CD4 are made by 
the main chain, this interaction will not be influenced. This is one example for the 
strategies of HIV-1 to escape immune surveillance (Kwong et al. 1998; Wyatt et al. 
1998a). The gp120-CD4 binding is of very high affinity compared to the majority of 
protein-protein interactions. Myszka et al. (2000) report an extremely high binding 
enthalpy (-63 kcal/mol) balanced by a substantial loss in the degrees of freedom of both 
molecules upon binding which still results in a very strong binding constant of 5 nM 
(Myszka et al. 2000). 
 
 
Figure 1.11: 
Structure of HIV-1 gp120. The division of the 
molecule into inner and outer domain can be 
seen as well as the makeup of the domains from 
the different β-sheets and α-helices. Also the 
location at the variable loops that have been cut 
are shown. Taken from (Kwong et al. 1998). 
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Structural changes triggered by the CD4-gp120 interaction 
Binding of gp120 to CD4 has been reported to cause rearrangements in the CD4 domain 
D1 (Denisova et al. 1997). This has been probed using various monoclonal antibodies 
directed against CD4. Similar to the binding of the various ligands of CD4, binding of 
gp120 also causes signalling events through CD4 that can lead to functional changes such 
as T cell apoptosis (Laurent-Crawford et al. 1993). (The role of gp120 induced signalling 
will be discussed later). Interestingly, this observed structural change is contradictory to 
the observation of Kwong et al (1998) that CD4 structure is not significantly altered upon 
gp120 binding (Kwong et al. 1998). More important in the context of HIV-1 entry is the 
conformational change in gp120 structure upon CD4 binding. One early observation 
pointing towards a structural change in gp120 taking place after CD4 binding was the 
shedding of gp120 from virions after binding of sCD4 (Moore et al. 1990). This 
rearrangement was found to be concentration, temperature and time dependent (Hart et al. 
1991) and was then (not now) thought to be an integral event in the virus entry. Further 
evidence came from the reported increased sensitivity of the gp120 V3 loop to protease 
cleavage (Sattentau and Moore, 1991) and from studies with monoclonal antibodies 
indicating the exposition of previously masked regions on gp120 upon CD4 binding 
(Sattentau and Moore, 1991; Thali et al. 1993). The main rearrangements that are thought 
to occur are a movement of the V1/V2 loop structure together with a rearrangement of 
the gp120 hydrophobic core structure bringing together previously loosely associated 
regions (Wyatt et al. 1995; Zhang, W. et al. 1999; Myszka et al. 2000). The gp120-CD4 
crystal structure suggests that the observed structure with normally hidden sites exposed, 
is unlikely to exist without CD4 bound to gp120. That is this structure developed after 
binding of CD4 through rearrangements (Kwong et al. 1998). The accompanied increase 
of order accounts for the unfavourable entropy of the reaction which is still efficiently 
driven by the high binding enthalpy (Myszka et al. 2000) (See standard textbooks on 
thermodynamics for explanations of enthalpy and entropy). After rearrangement, the 
coreceptor binding site becomes exposed on gp120. The mechanism of masking the 
coreceptor binding site is thought to contribute to HIV-1 immune evasion. The coreceptor 
binding site is conserved and also susceptible to neutralising antibodies. Therefore, 
hiding this area from immune surveillance as long as possible helps the virus to escape 
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the attack of neutralising antibodies. Thus the use of CD4 as a receptor followed by 
exposure of the coreceptor binding site is thought to be an evolution from a primordial 
system where only the coreceptor was used for binding. In such a system, the coreceptor 
binding site would be permanently exposed to the host immune system and the virus 
more likely to be eradicated by neutralising antibodies (Wyatt and Sodroski, 1998; Doms 
and Trono, 2000). 
 
Binding of the Coreceptor 
The fact that CD4 alone is not sufficient for full entry of HIV-1 into target cells 
(Chesebro et al. 1990) but triggers conformational changes (discussed above) finally led 
to the discovery of coreceptors which are bound after the CD4-induced rearrangement of 
gp120. The two major coreceptors that are used by HIV-1 are “CC”-type chemokine 
receptor 5 (CCR-5) (Trkola et al. 1996; Wu, L. et al. 1996) and “CXC-type chemokine 
receptor 4 (CXCR4) (Lapham et al. 1996). Several other potential coreceptors besides 
these have also been described (Berger et al. 1999). 
The use of different coreceptors finally elucidated the mystery of virus tropism. It 
was found that most primary HIV-1 isolates, as well as the HIV-1 strains mediating 
transmission, are M-tropic, which means that they infect only macrophages and 
monocytes (and also activated primary T cells but not T cell lines). Conversely, HIV-1 
strains that are associated with disease progression predominantly infect T-
lymphoblastoid cell lines and primary T-lymphocytes and are thus called T-tropic. The 
finding that M-tropic strains enter their target cells predominantly via CD4 and CCR5, 
whereas T-tropic strains enter T-lymphoblastoid cells and primary T-lymphocytes via 
CD4 and CXCR4 could provide an explanation for the viral tropism (Berger 1997).  
According to the coreceptor usage, strains are now termed R5 (if they use CCR5) or X4 if 
they use CXCR4. Strains responsible for transmission are usually R5 viruses whereas X4 
viruses evolve later during disease progression. The emergence of dual tropic R5X4 
strains prior to X4 strains supports the concept of virus evolution (Berson and Doms, 
1998). Mutations in coreceptors can confer high level resistance to HIV-1 infection as for 
example observed for a 32 bp deletion mutant in CCR5 that leads to a non-functional 
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receptor. Homozygous carriers of this mutation are highly resistant to HIV-1 infection 
(Samson et al. 1996).  
The coreceptor binding site on gp120 is the region exposed during the 
rearrangement of gp120 (mainly V1 & V2 loops) that follows CD4 binding as well as 
part of the V3 loop (Kwong et al. 1998). Important residues that make contact with the 
coreceptor on gp120 are the basic and polar residues K121, R419, K421 and Q422 
(Kwong et al. 1998). A later report describes the residues I420, K421, Q422, P438 and 
G441 as important (Rizzuto and Sodroski, 2000). Those basic residues are likely to 
interact with the acidic N-terminus of CCR-5 (Kwong et al. 1998). This mechanism for 
the gp120-CCR5 interaction is confirmed by the interaction of tyrosine sulfated peptides 
comprising the CCR5 N-terminus with gp120 (Cormier et al. 2000) and the inhibition of 
HIV-1 entry by a similar peptide (Farzan et al. 2000). Those findings point towards an 
importance of the tyrosine residues in the CCR5 N-terminus for HIV-1 entry. Residues 
on CXCR4 that are critical for HIV-1 entry are Y7, Y12, D193, D262 and D97. Again, 
the critical residues are either tyrosines or acidic residues pointing towards a similar 
mechanism for both CCR5 and CXCR4 binding through gp120 (Brelot et al. 2000). The 
evolution from R5 to X4 viruses is thought to be an accumulation of positively charged 
residues in the V3 loop that enable gp120 to interact with a second negatively charged 
surface of CXCR4 (Berson and Doms, 1998). 
 
Membrane fusion 
The final stage of the virus entry (and the target for the newly developed drug T20) is the 
fusion of viral and host membrane. It is not fully understood how the recruitment of the 
coreceptor finally triggers the steps leading to the membrane fusion, but several of the 
structural changes in gp41 that lead to fusion have been described (Doms and Trono, 
2000). The fusion is mediated by insertion of the fusion peptide, a trimer of helical 
bundles, into the host cell membrane (Blair et al. 2000). Conformational changes in gp41 
lead to the formation of a six-helix bundled gp41 ectodomain core structure which 
presumably occurs concomitantly with fusion (Melikyan et al. 2000). The opening of the 
fusion pore then enables the entry of the viral capsid (Melikyan et al. 2000). For more 
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information on membrane fusion see the reviews of Doms et al. (2000), Blair et al. (2000) 
and especially Gallo et al .(2003).  
 
Preformed complexes of CD4 with the chemokine receptors 
Some evidence has been reported on complexes of CD4 with the chemokine receptors in 
the absence of gp120. Though Ugolini et al. could only detect an increased colocalization 
of CD4 and CXCR4 upon incubation with gp120 (Ugolini et al. 1997), Xiao et al. (1999) 
report a constitutive cell surface association between CD4 and CCR5 even without 
treatment with gp120. Further studies have shown colocalization of CD4, CXCR4 and 
CCR5 in microvilli on macrophages and T cells facilitating interaction of HIV-1 gp120 
with the chemokine receptors upon CD4 interaction (Singer, II et al. 2001). However, 
more evidence is needed to prove whether direct protein-protein interactions between 
CD4 and the coreceptors really exist. 
 
1.2.3.3 Reverse transcription and integration 
After the naked viral nucleocapsid has entered the cell, it adheres to the internal surface 
of the cell membrane and is reorganised into a preintegration complex (PIC) (T. 
Cunningham, pers. communication). This process is facilitated by cellular kinases 
contained within the virion, assisted by cyclophilins and sensitive to cyclosporin A 
(Luban et al. 1993; Levy 1998). Subsequently, a double stranded DNA copy of the viral 
RNA is synthesised. This process is catalysed by the enzyme reverse transcriptase and 
initiated through binding of a cellular tRNALys to the primer-binding site on the viral 
RNA. The synthesis of the DNA is a complex process of RNA-dependent DNA 
synthesis, DNA-dependent DNA synthesis, degradation of viral RNA by RNAse H and 
strand transfer reactions (Hsu and Wainberg, 2000). The nucleocapsid protein p7 is 
involved in this process. Reverse transcription proceeds within the preintegration 
complex consisting of MA, vpr and integrase proteins while being transported to the 
nucleus. This transport occurs along microtubules and mediated by cytoplasmic motor 
proteins (McDonald et al. 2002) though the exact mechanism of transportation is still 
subject to research. After transport to the nucleus vpr and MA trigger the entry of the 
complex through the intact nuclear envelope. (Bukrinsky et al. 1993; Heinzinger et al. 
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1994). Then the viral DNA (provirus) is integrated into the host genome. This reaction is 
catalysed by the viral integrase enzyme (Brown, P. O. 1997). This reaction completes the 
infection of a cell with HIV-1 and can be followed by a period of cellular latency, where 
the provirus is present in the genome but no proviral RNA and viral proteins are 
synthesised (Levy 1998). 
 
1.2.3.4 Transcription of viral DNA and synthesis of viral proteins 
The first mRNA species synthesised after integration is a doubly spliced mRNA coding 
for the regulatory proteins tat, rev and nef (Frankel and Young, 1998). The promoter that 
is responsible for the transcription is located in the 5’ LTR region and susceptible to the 
cellular molecules NF-κB, SP-1 and TBP (Jones, K. A. et al. 1994). However, 
transcription is very inefficient and results in premature termination until the viral protein 
tat is synthesised. This accessory protein interacts both with RNA polymerase II and the 
TAR element of the synthesised viral RNA and other cofactors eg cyclin T1 and cdk 9 
leading to an increase in the transcription of viral RNA by about 100 fold (Brigati et al. 
2003). After establishing high level RNA transcription and the synthesis of the regulatory 
(early) proteins, full length viral RNA must be synthesised for both the production of the 
gag, pol and env proteins as well as for assembly of new virions which require full length 
RNA. This switch from production of spliced RNA to unspliced RNA is accomplished by 
the rev protein. This protein binds to the rev response element (RRE) on nascent RNA 
and leads to the export of unprocessed full length RNA into the cytosol that can then be 
translated into gag, pol or env proteins or incorporated into new virions (Fischer et al. 
1995). Gag and pol are synthesised in the cytosol whereas env is translated at the ER  
(Frankel and Young, 1998). See the review from Peterlin and Trono (2003) for more 
details on HIV-1 transcription. 
 
1.2.3.5 Virus assembly and budding 
The release of new virions from infected cells requires the assembly of all particles that 
make up the new virion in a defined order inside the cell membrane. This process is 
governed by intrinsic features of the gag and gag-pol polypeptides and assisted by some 
of the accessory proteins. Gag and gag-pol are assembled into the virion unprocessed and 
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are only cleaved into the individual components by the viral protease during or after the 
budding (Frankel and Young, 1998). Nevertheless, the individual parts of gag play 
different roles in the assembly process: 
The matrix protein MA, which forms the N-terminal part of gag is myristoylated 
and assembles into trimers. Both trimerisation and membrane location, which is mediated 
by the acyl group and a stretch of basic amino acid residues is required for formation of 
new virions. The MA trimer also contains pockets to accommodate the cytoplasmic tails 
of the env proteins  (Hill et al. 1996). The second component of gag, CA, also functions 
in viral assembly through its ability to dimerise the domain for which is located at the C 
terminus (Gamble et al. 1997). The NC protein, also part of the gag polypeptide, interacts 
with the Ψ-signal on the RNA through two zinc finger domains. Together with the ability 
of the RNA to dimerise via its kissing loop, this leads to the incorporation of exactly two 
copies of viral RNA (Schmalzbauer et al. 1996; Clever and Parslow, 1997). The C-
terminal part of gag, p6 recruits vpr to the assembling particle (Kondo and Gottlinger, 
1996). Other proteins that become incorporated into the budding virion except for vpr are 
nef (about 70 molecules) and vif, which is necessary for the production of infectious 
viruses in some cell types (non-permissive, discussed later in this review).  
The env protein, which was synthesised in the ER and cleaved into gp120 and 
gp41 by cellular proteases (Moulard et al. 2000) is transported to the surface where the 
bud forms with the aid of nef and vpu. Vpu degrades preformed CD4-gp120 complexes 
and nef assists in the downregulation of CD4 to prevent the formation of such complexes 
on the cell surface (Bour et al. 1995b; Mangasarian and Trono, 1997). Once all parts are 
assembled the capsid is completely surrounded by the host cell-derived lipid bilayer and 
is released from the cell. This virion is not yet infectious but needs to undergo a final 
maturation step. The protease enzyme, which cleaves the gag and gag-pol polypeptides 
into the individual components MA, CA, NC, p6, IN, PR and RT is responsible for this 
maturation which is completed by structural rearrangements inside the capsid leading to a 
fully infectious virus (Kaplan et al. 1994; Frankel and Young, 1998). Reports have shown 
that trafficking of HIV-1 particles is dependent on lipid rafts (see part one of this review) 
and virus budding occurs through rafts supporting the importance of those domains in 
viral pathogenesis (reviewed by (Campbell et al. 2001)). Apart from rafts, some cellular 
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proteins have also been shown to be required for correct virus assembly (Garrus et al. 
2001; Zimmerman et al. 2002). 
 
1.2.4 HIV-1 target cells and the formation of viral reservoirs 
Although CD4+ T lymphocytes are the main target for HIV-1 a broad range of other cells 
in various tissues can be productively infected with HIV-1. Many other cells have been 
shown to contain HIV-1-DNA through sensitive PCR techniques (Levy 1998). The main 
target tissue types for HIV-1 are haematopoietic cells, lymphoid tissue, the brain and the 
gastrointestinal system. Other haematopoietic cells, apart from helper and memory T 
cells, that can be infected with HIV-1 are macrophages, monocytes or dendritic cells. 
(Cameron et al. 1992; Blauvelt et al. 1997; Levy 1998). HIV-1 has been detected in other 
blood cells like CD8+ cells or NK cells but without any apparent physiological 
significance. More important is the infection of stromal fibroblasts and endothelial cells 
in the bone marrow (Scadden et al. 1990; Moses et al. 1996; Levy 1998). 
Lymphoid tissue is another prime target of HIV-1 and the destruction of this 
tissue is associated with ongoing disease progression. Besides CD4+ T cells residing in 
the lymph nodes, interdigitary dendritic cells can be infected by the virus (Levy 1998). 
The follicular dendritic cells (FDCs) of the lymphoid tissue, however are not infected by 
HIV-1, but can trap infectious viruses and present them to CD4+ cells. Through this 
mechanism, FDCs lead to an extremely long infectivity of trapped HIV-1 virions (Smith, 
B. A. et al. 2001a). The level of HIV-1 in the lymph nodes is very high but still, only a 
fraction of the cells that are infected actively produces infectious virus (Chun et al. 
1997a). Cells from the brain have also been shown to be susceptible to HIV-1. Productive 
infection occurs in resident macrophages and microglia cells and latent or nonproductive 
infection in astrocytes whereas neurons do not become infected. The exact mechanism of 
HIV-1 infection of brain cells in the cause of HIV-1 associated dementia has yet to be 
determined (Levy 1998; Kaul et al. 2001) although cellular toxins released from 
macrophages and acting on neurons appear to be important (Smith, D. G. et al. 2001b). 
Further tissues that are susceptible to HIV-1 are the gastrointestinal tract, where 
endothelial cells can be infected (Nelson et al. 1988) or the skin with a possible infection 
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of fibroblasts or langerhans cells (Kawamura et al. 2001). See (Levy 1998) for a more 
detailed overview of HIV-1 susceptible cells and tissues. 
Though the development of the highly active antiretroviral therapy (HAART) can 
efficiently control HIV-1 replication, the virus is not totally eradicated from the body 
(Furtado et al. 1999). Monitoring the viral load after the start of the therapy shows a rapid 
decline during the first day representing the block of HIV-1 replication in CD4+ T cells. 
After one day the viral load starts to fall more slowly, and the decline of this second 
phase has a half-life of about 2 weeks. This decline may be due to the eradication of HIV 
from cells more resistant to HIV cytopathic effects such as macrophages. Still the virus 
can be detected in body tissue and a third phase of decline with an extremely slow 
reduction of viral load shows that it would require more than 60 years on average of 
treatment to eradicate HIV-1.  
This behaviour is due to the ability of HIV-1 to remain quiescent in viral 
reservoirs. As mentioned above, HIV-1 can infect a broad range of cell types, and 
depending on the latency of the infection and the average life span of the infected cell, 
survive very long without signs of replication. The most important viral reservoirs 
responsible for the three-phase decline of the viral load in response to therapy are first the 
short-lived CD4+ T lymphocytes, which are replicating rapidly but are very sensitive to 
antiviral therapy. The block of HIV-1 replication in this cell type accounts for the steep 
decline of viral load during the first day of therapy (Abbas et al. 2000). HIV-1 infection 
of macrophages is probably responsible for the slower decline of HIV-1 load in the 
second phase (Abbas et al. 2000; Igarashi et al. 2001). However, drug therapy is not able 
to totally eradicate the virus from the body. This is due to the virus infecting microglial 
cells in the CNS, an immunological sanctuary where cell-mediated responses are reduced 
(Blankson et al. 2002). The third phase is provided by resting T cells where HIV remains 
for a long time in a state called proviral latency. Those cells can harbour the virus for a 
long period of time and then produce infectious viruses upon activation (Chun et al. 
1997b; Blankson et al. 2002). Other cells in which HIV-1 enters a stage of proviral 
latency might include DCs, monocytes, microglia and seminal cells (Peterlin and Trono, 
2003). 
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1.2.5 Viral and host factors in HIV-1 progression 
After discussing structure, life cycle and cellular targets for HIV-1, it is important to 
know how this virus interacts with the host system. What are the immune responses 
launched against HIV-1 by the host and how is it able to escape them? How does HIV-1 
eventually destroy the host immune system? What are the roles of the various accessory 
proteins in the interaction with the host and why is HIV-1 replication susceptible to 
interleukin-16? Those questions will be discussed in the following sections. 
 
1.2.5.1 Immune response to HIV-1 and immune evasion 
The immune system, once confronted with HIV-1, launches both a cell-mediated and a 
humoral response that are capable of controlling the acute HIV-1 infection (Abbas et al. 
2000). This first phase of control is accompanied by immune evasion of the virus. A cell-
mediated immunity is the first response that can be detected after infection and consists 
of killing of HIV-1 infected cells by natural killer cells (NK cells) and CD8+ CTLs. 
Indeed, there is a massive expansion of CD8+ CTLs in the initial response and those cells 
account for the partial control of HIV infection during the early and late stage (Levy 
1998; Abbas et al. 2000; McMichael and Rowland-Jones, 2001). Antibodies against HIV-
1 can be detected from 6 to 9 weeks post infection and are mainly directed against the 
HIV-1 env protein, but antibodies against p24, gag, pol or RT have also been found 
(Abbas et al. 2000). However, the majority of those antibodies fail to have any effect on 
HIV-1. In contrast they can lead to enhanced effectiveness of HIV-1 through Fc receptor-
mediated endocytosis of antibody coated virions (Levy 1998). A small portion of the 
antibodies, however have neutralising ability against HIV-1, those antibodies 
predominantly target epitopes on gp120 and some epitopes on gp41. The principal 
neutralising domain targeted by the antibodies is the V3 loop of gp120, a second domain 
the CD4 binding site. However, the overall role of neutralising antibodies in host defence 
is thought to be rather small. See Levy (1998) for a very detailed discussion of cellular 
and humoral immune response against HIV-1 or McMichael and Rowland-Jones (2001) 
for a review on the cellular immune response to HIV-1. 
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As mentioned above, the host immune system is not able to totally eradicate an 
HIV-1 infection. Several reasons account for this HIV-1 immune evasion. First, HIV-1 
creates proviral latency in some cells and infects cells in immunological sanctuaries 
(discussed in chapter 4). Those cells provide an ongoing source of new virions while they 
are very hard to control by the immune system (see (McMichael and Rowland-Jones, 
2001) and (Peterlin and Trono, 2003) for more details). Secondly, the high mutation rate 
during the HIV-1 reverse transcription leads to mutations in the most antigenic epitopes 
of gp120. Those mutated epitopes escape both the surveillance of neutralising antibodies 
and CD8+ CTLs. It is thought that those mutations lead to the development of highly 
resistant virus quasispecies under the selective pressure of the immune system 
(McMichael and Rowland-Jones, 2001). Additionally, like so many other viruses, HIV-1 
downregulates MHC class I molecules on the surface of infected cells. Those molecules 
normally present peptides derived from intracellular proteins (including viral proteins in 
infected cells) to CD8+ CTLs helping in the killing of infected cells. Downregulation of 
MHC I molecules helps infected cells to escape recognition by CTLs (Schwartz et al. 
1996). Interestingly, only the MHC I molecules HLA-A and HLA-B are downregulated, 
which prevents infected cells from being killed by natural killer cells that recognize cells 
that do not express any MHC I molecules (Lichtor et al. 1999). It has been found that 
HIV-1 specific CD8 CTLs have a reduced expression of perforin. That renders them less 
efficient in target cell lysis (Appay et al. 2000). 
 
1.2.5.2 HIV-1 immune suppression 
One of the main features of HIV-1 infection is the eventual destruction of the host 
immune system. Several mechanisms induced by HIV-1 directly or indirectly contribute 
to the loss of host defence. The main contribution is the destruction of the CD4+ T cell 
reservoir. Several mechanisms have been proposed for this as reviewed by McCune 
(2001). The loss of CD4+ T cell function is due to anergy early after infection with HIV 
and later because of killing of the CD4+ T cells. This increased destruction of mature 
CD4+ T cells in blood and lymphoid tissue is accompanied by an HIV-1 induced 
impaired production of those cells from the thymus. The causes for the destruction of 
mature CD4+ T cells are direct destruction of infected cells as a consequence of the 
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expression of viral gene products like env as well as indirect induction of death in 
bystander cells that are not infected. The death of peripheral CD4+ T cells can also be 
induced by HIV specific CTLs (but only 10-20 % of the CD4 death is due to CTLs), 
through autoimmune reactions and via fusion of infected cells with uninfected cells by 
gp120-CD4 reactions (syncytia formation). Death can also be induced through action of 
unbound gp120 on uninfected cells, as a consequence of contact with an HIV infected 
antigen presenting cell or as a consequence of increased Fas expression of infected cells 
induced by nef. See McCune (2001) and Peterlin and Trono (2003) for a detailed 
discussion of that matter. 
Much research has been devoted to the apoptotic properties of viral proteins 
mainly focussing on the apoptotic effects of gp120. Thus binding of gp120 to CXCR4 
has been proposed to trigger T cell apoptosis (Roggero et al. 2001). Conversely, binding 
of gp120 to CD4 has been reported to prime T cells for activation-induced apoptosis 
(Banda et al. 1992), see (Badley et al. 2000) for a review on HIV-1 associated 
lymphocyte apoptosis. A decrease in the overall T cell count could be enhanced owing to 
a different migration pattern of CD4+ T cells upon HIV-1 infection, additionally, reduced 
CD4+ T cell production contributes to the loss of those cells. The mechanisms for 
reduced production of CD4+ T cells may be direct consequences of HIV-1 infection of 
progenitor cells in the thymus or destruction of the supporting tissue needed for T cell 
maturation by the virus. Indirect mechanisms leading to decreased CD4+ T cell 
production are cytokine dysfunctions, opportunistic infections, HIV-1 induced apoptosis, 
infiltrating malignancies, effects of drug therapy or vitamin deficiency (McCune 2001). 
Another contribution may be the exhaustion of the reservoir of memory T cells during the 
infection. 
In summary, HIV-1 infection leads to a chronic infection of immune cells by virus 
mutants that escape the initial infection. This chronic infection leads to a persistently 
activated immune system through permanent exposure to the virus. HIV-1 induced T cell 
destruction together with reduced production of CD4+ T cells leads to a final exhaustion 
of the immune system and to its collapse resulting in the establishing of opportunistic 
infections (AIDS) that eventually kill the host. 
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1.2.5.3 Functions of the HIV-1 accessory proteins 
Besides gag, env and pol, the HIV-1 genome codes for the six accessory proteins tat, rev, 
vpr, vif, vpu and nef which play various roles in HIV-1 infection. This section 
summarises the function that is known of the individual proteins. 
 
Tat 
It was discovered early that the HIV-1 tat protein is required for efficient replication of 
HIV-1. This was demonstrated as tat-defective viruses fail to productively replicate 
which is compensated by introduction of the tat gene that then positively regulates the 
expression of viral proteins (Dayton et al. 1986). It is now known that tat functions both 
in transcriptional activation and elongation of viral transcripts. In the absence of tat, not 
only is the transcriptional activation of the HIV-1 promoter poor, but also the RNA 
polymerase II prematurely terminates the transcription. The transcriptional activation of 
tat is via binding to the TAR sequence on the nascent RNA and subsequent recruitment 
of numerous transcriptional enhancers such as CDK 9 or cyclin T1. Those factors not 
only bridge transcriptional activators with the basal transcription machinery, but they also 
function as histone acetyl transferases which make chromatin more accessible to 
transcription (Brigati et al. 2003). 
Interestingly, tat can be secreted from HIV-1 infected cells via a leaderless 
secretory pathway (Chang et al. 1997) reviewed by (Brigati et al. 2003). Extracellular tat 
can then bind to receptors on the cell membrane triggering signal transduction events 
(Brigati et al. 2003). Other reports on tat include the induction of apoptosis in endothelial 
cells (Park et al. 2001), cross-talk with p53 in an indirect way (Ariumi et al. 2001), 
chemotaxis (Lokensgard et al. 2001) and influence on proviral latency and MHC I gene 
expression as reviewed by (Peterlin and Trono, 2003). 
 
Rev 
As mentioned in section 1.2.3.4, the rev protein is required for the export of full length 
RNA for the production of the structural proteins or the assembly of new virions. Rev 
thereby overcomes the default splicing pathway by actively promoting RNA export rather 
than by inhibiting the splicing pathway (Fischer et al. 1995; Frankel and Young, 1998). 
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Rev is a nucleocytoplasmic shuttle protein that functions via binding to the rev response 
element (RRE) that is present on unspliced and incompletely spliced mRNAs. Upon 
multimerisation, rev binds to the export receptor CRM1/exportin1 via its nuclear export 
signal (NES) that constitutes of a short stretch of hydrophobic amino acids, mainly 
leucine (Fischer et al. 1995; Frankel and Young, 1998; Hofmann et al. 2001). Other 
factors that are required for the export process are eIF-5A and RanGTP (Elfgang et al. 
1999; Hofmann et al. 2001). However, some reports suggest that entry into the splicing 
process is required for rev function and that rev can also inhibit nuclear splicing as 
reviewed by Frankel and Young (1998). See this report also for a structural discussion of 
the association between rev and the HIV-1 mRNA. 
 
Vpr 
Vpr is a 96 amino acid highly conserved protein the structure of which is characterised by 
the formation of two alpha helical domains. Vpr is incorporated into the virus and it 
exerts several different functions: transcriptional activation; cell cycle arrest and nuclear 
localisation are the main functions that are known  (Frankel and Young, 1998; Sherman 
et al. 2002). 
The effect of HIV-1 Vpr on the cell cycle has long been known, however, the 
mechanism through which this effect is performed is not completely clear. It is assumed 
that vpr interferes with upstream phosphorylation mechanisms ultimately leading to the 
inactivation of cdc2 that then causes the cell cycle arrest in the G2 phase (Bour et al. 
2000). Interestingly, virus associated vpr is sufficient to induce cell cycle arrest so that 
unproductively infected cells are locked in the G2 phase without viral proteins being 
synthesised (Poon et al. 1998). The cell cycle arrest by itself could already contribute to 
the transcriptional activation of vpr as the G2 phase is characterised by increased 
transcriptional activity (Goh et al. 1998). However, an intrinsic transcriptional-activating 
feature of vpr has been reported and is assumed to be associated with the leucine-rich 
region and mediated via binding to the p300 transcriptional activator (Felzien et al. 
1998). 
Another important role of vpr is the promotion of nuclear import of the 
preintegration complex into the nucleus. This active transport mechanism allows 
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infection of nondividing cells like macrophages as it overcomes the need for cell division 
and concomitant dissolution of the nuclear envelope for integration of the DNA into the 
nucleus. The role of vpr in nuclear import is not precisely defined. It is supposed to 
stabilise the interaction of the preintegration complex with the importin system (Popov et 
al. 1998). A different group has found recently that vpr actually contains two different 
nuclear localisation signals that are distinct and can use different receptors for their 
function (Jenkins et al. 1998). 
Besides those functions, vpr has been shown to have apoptosis-modulating 
effects. It has the ability to induce host-cell apoptosis through direct binding to the 
mitochondrial membrane (Muthumani et al. 2003). 
 
Vif 
Vif is a 23 kDa/192 amino acid basic protein that is incorporated in the virion and the 
function of which is associated with the production of infectious virus. This has been 
shown by evidence that cells infected with vif mutants produced viruses that are not 
infectious. Interestingly, only certain cell types show this observation. Whereas 
production of viruses in “permissive” cell types does not require a functional vif protein, 
virions produced by “nonpermissive” cells infected with vif mutated viruses are generally 
not infectious (Frankel and Young, 1998; Bour et al. 2000). 
 The mechanism of this phenomenon has been elusive until recently a human gene 
was isolated which inhibited HIV infection and was suppressed by vif (Sheehy et al. 
2002). The gene was named Cem15 (now APOBEC3G) and has been shown to act as a 
cytidine deaminase inducing G to A hypermutation in newly synthesised viral DNA. This 
negative effect on the virus is counteracted by vif (Mangeat et al. 2003; Zhang, H. et al. 
2003). The remaining effect of hypermutation on viral reverse transcription, however, 
contributes to the genetic variability of the virus (Harris et al. 2003). 
Additionally, it has been shown that vif does associate with the cytoskeleton, 
precisely with the component of the intermediate filament, vimentin. However neither the 
function of this association is known, nor whether it is an independent role for vif or 
whether it is related to its role in viral infectivity (Bour et al. 2000). 
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Vpu 
Vpu is an 81 amino acid/17 kDa phosphoprotein that consists of a transmembrane helical 
domain and a cytoplasmic domain made up of two amphipathic helices that are separated 
by a linker region. It has several different functions, one of which is the formation of 
discrete ion-conducting channels in the lipid bilayer. This function is associated with the 
transmembrane domain of the protein (Marassi et al. 1999). 
More important is the role of vpu in degrading newly synthesised CD4 in the ER. 
CD4 and env often form complexes in the ER preventing env from migrating to the cell 
surface. Vpu has been shown to physically interact with CD4 in the ER and this 
interaction is necessary to promote degradation of CD4 (Bour and Strebel, 1995). This 
interaction is mediated either directly or indirectly through the cytoplasmic tails of both 
molecules and regulated by the key serine residues S52 and S56 in the vpu molecule 
(Paul and Jabber, 1997). The mechanism of this degradation is thought to be the 
interaction of vpu with components of cellular proteasomes, however the exact way of 
CD4 degradation is not clear (Bour et al. 2001). 
Additionally, vpu promotes increased particle release, which is thought to be a 
distinct function from the CD4 degradation and is dependent of the proliferation state of 
the cells. Vpu is therefore required for the efficient particle release from quiescent cells 
(Deora and Ratner, 2001). Recent data shows that vpu promotes the targeting of gag to 
the plasma membrane which is a possible way the protein exerts its function (Deora et al. 
2000). Interestingly, CD4 has been found to inhibit the efficient release of viral particles 
(Bour et al. 1999). 
 
Nef 
HIV-1 nef is a 206 amino acid protein, which is myristoylated at its N-terminus. A 
functional nef protein is essential for a productive HIV-1 infection as the absence of an 
intact nef gene was linked with long term nonprogressive HIV-1 infection (Kirchhoff et 
al. 1995). Like the other HIV-1 auxiliary proteins, nef exerts multiple functions that are 
important for HIV-1 pathogenesis. The most important roles for nef are downregulation 
of both MHC class I molecules and CD4 molecules (Mangasarian et al. 1999) but nef has 
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also been shown to increase viral infectivity (Chowers et al. 1994), to induce apoptosis in 
bystander cells but to protect the infected cell from apoptosis (Geleziunas et al. 2001). 
 The mechanism through which nef increases viral infectivity includes nef-
mediated T cell activation which is caused by the interaction of nef with parts of the T 
cell receptor complex (Fackler and Baur, 2002). Another effect of this is the upregulation 
of Fas ligand on virally infected cells leading to the death of uninfected bystander cells 
via the Fas pathway (Geleziunas et al. 2001; Fackler and Baur, 2002). Interestingly, nef 
also promotes the expression of Fas on infected cells (Debatin et al. 1994) but protects 
those cells from apoptotic death through interfering with the necessary signalling 
cascades. Nef has hereby been shown to inhibit the ASK1 molecule which plays a key 
step in both Fas and TNFα-induced apoptosis and thus confers resistance to apoptosis to 
infected cells (Geleziunas et al. 2001). 
The downmodulation of MHC class I molecules through nef protects HIV-1 
infected cells from death induced from CTLs (Collins et al. 1998). The mechanism 
through which nef downregulates the HLA-A and HLA-B molecules is not fully 
understood but it has been shown that nef induces the diverting of cell-surface MHC I 
molecules to endosomal compartments. This is supposedly done through bridging of 
MHC I molecules to complexes of the endocytosis adaptor proteins by nef but direct 
binding of nef to MHC I molecules has not yet been shown (reviewed by (Peterlin and 
Trono, 2003)). 
The way in which nef induces CD4 downregulation is better understood and is a 
sequential pathway of different events modulated by nef (Doms and Trono, 2000). Nef 
directly binds to the CD4 cytoplasmic tail (Preusser et al. 2001) as well as to the adaptor 
protein complex of clathrin coated pits leading to the formation of CD4 containing 
endocytic vesicles (Aiken et al. 1994; Mangasarian et al. 1997a). This interaction is 
probably mediated through a dileucine motif in nef. After formation of early endosomes, 
nef binds to the COP-I coatomer by a diacidic sequence triggering the sorting of the 
endosome towards the lytic pathway where CD4 is finally degraded (Piguet et al. 1999). 
Other studies report the induction of cytoskeletal changes through nef (Fackler et 
al. 1999), the association of nef with lipid rafts (Wang, J. K. et al. 2000a) and the 
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interference with other signalling pathways (Renkema and Saksela, 2000; Wolf et al. 
2001). 
 
1.2.5.4 IL-16 mediated inhibition of HIV-1 replication 
In 1995 Baier et al described that IL-16 isolated from either African green monkeys or 
humans has an inhibitory effect on HIV-1 replication in lymphocytes (Baier et al. 1995). 
Several assays designed to determine inhibiting effects of ligands of HIV-1 receptors 
ruled out any interference of IL-16 with the HIV-1 entry (Center et al. 2000). Zhou et al. 
(1997) reported that the inhibition of HIV-1 replication occurs at the level of mRNA 
synthesis and not at viral entry or reverse transcription (Zhou et al. 1997). Additionally, it 
was found that pretreatment of CD4+ lymphoid cells with rIL-16 repressed the HIV-1 
promoter activity up to 60 fold and thus prevented both tat and PMA activation 
(Maciaszek et al. 1997). Transfection of T cells with IL-16 also inhibits HIV-1 
replication and that can be enhanced by cotransfection of an anti gp41 antibody (Devadas 
et al. 2003). The mechanism by which IL-16 induces CD4 cross-linking in T cells and 
how it modulates the transcription of the HIV-1 DNA is not clear but in monocytic cells 
the repressive effect of IL-16 seems to occur at the entry stage (see (Kornfeld and 
Cruikshank, 2001) for more details). 
 
1.2.6 HIV-1 Therapy and vaccine development 
 
Drug therapy 
The first drug developed that was successful in inhibiting HIV-1 replication was AZT 
(zidovudine). This nucleoside analogue interferes with the reverse transcription of viral 
RNA probably by terminating DNA polymerisation and competing with nucleosides. The 
detailed mechanism of its action however, is not yet understood. Following that, other 
nucleoside analogues and non-nucleoside inhibitors of RT (NNRTI) have been developed 
including didanosine, zalcitabine and stavudine (NRTIs) and neveripene and efavirenz 
(NNRTIs). Apart from RT, the protease molecule is the second major target for 
antiretroviral drugs. Protease inhibitors interfere with the correct processing of the HIV-1 
polypeptides into its functional components. Effective protease inhibitors used in HIV-1 
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therapy include saquinavir, ritonavir, indinair or nelfinavir. Major problems with each of 
those drugs, apart from the side effects, are the evolution of mutated virus that are 
resistant to the drugs and the failure to eradicate viral reservoirs in macrophages or 
latently infected T lymphocytes (or more specifically in the brain). The most success has 
been achieved with a cocktail of two reverse transcriptase inhibitors in combination with 
a protease inhibitor and is termed “highly active antiretroviral therapy” (HAART). This 
therapy has led to the reduction of plasma RNA to undetectable levels in most patients 
for more than 3 years (Abbas et al. 2000). See also (Levy 1998) for a more information 
on HIV-1 drug therapy. 
The first temporal target site in HIV replication for anti HIV-1 drugs is virus 
entry. After CD4 was established to be the receptor for HIV-1 entry, studies were 
conducted using sCD4 to inhibit the entry process. However, this approach failed during 
the clinical trials as the viral strains present in vivo were far less susceptible to sCD4 than 
the ones tested in vitro (Daar and Ho, 1991). Subsequent development of compounds 
interfering with the gp120-CD4 interaction that are currently investigated are PRO542, a 
fusion of CD4 with IgG2 or small molecule inhibitors like FP21399 or PRO2000. The 
discovery of the chemokine receptors as coreceptors for HIV-1 has introduced novel 
possibilities in the development of HIV-1 coreceptors. One strategy is to use the natural 
ligands of the chemokine receptors MIP-1α, MIP-1β, RANTES (all CCR-5) and SDF-1α 
(CXCR-4) as models for the development of components that block attachment of 
gp120/CD4 to the coreceptors. This is supported by the fact that the CCR-5 ligands are 
inhibitors of HIV-1 infection in vitro (Ross et al. 1999). A different strategy aims at 
blocking the epitope on gp120 responsible for attachment to CCR-5 or CXCR-4. 
Compounds developed towards blocking HIV-1 entry via this approach include a tyrosine 
sulfated peptide which is based upon the CCR-5 N-terminus peptide (Farzan et al. 2000). 
See also (Vermeire and Schols, 2003) for antiviral agents based on CD4 down-
modulation. 
A different target for antiviral drugs based on the HIV-1 entry is gp41. Several 
inhibitors of gp41 mediated membrane fusion have been developed, one of them, T20, a 
peptide based on the gp41sequence has been approved as “Enfuvirtide” by most national 
authorities as a new antiretroviral drug and has been found to decrease viral load in 
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infected individuals (Lazzarin et al. 2003). However, treatment is very expensive and in 
the US the cost of a years supply is estimated to be just under $20,000 (Steinbrook 2003). 
Despite the high cost, introduction of this new drug can be seen as an encouraging 
example of the clinically applied results of HIV-1 entry research. For further reading see 
(Steinbrook 2003). 
 
HIV vaccine and post exposure prophylaxis (PEP) 
The development of an HIV-1 vaccine is still subject to intense research. A powerful 
vaccine probably needs to elicit both broadly neutralising antibodies and CD4+/CD8+ 
memory T cells. To achieve that, viral antigens need to be effectively administrated to 
trigger an immune response. Actual best strategies to achieve this are prime boost 
regiments, priming with DNA vaccines and boosting with recombinant vaccinia or 
recombinant pox viruses or using recombinant adenoviruses and/or recombinant 
oligomeric envelope protein. Unfortunately, there are still serious difficulties that need to 
be overcome to develop an effective HIV-1 vaccine. For example the heterogeneity of the 
virus makes it very difficult to generate broadly neutralising antibodies and effective T 
cells against all strains, clades and groups and the administration of life-attenuated 
viruses can still lead to pathogenesis induced by the defect virus. See (Tramont and 
Johnston, 2003) for more details and further reading. 
Besides HIV-1 therapy and vaccine development, the existence of a post exposure 
prophylaxis (PEP) regiment should be mentioned that has been developed for immediate 
treatment of persons who were exposed to HIV-1 through situations such as sexual, 
needle sharing or contact of a child with milk from an HIV-1 infected woman. PEP 
consists of a short (28 days) retroviral treatment that needs to be started no longer than 72 
h after exposure and consists of a combination of 2 to 3 retroviral drugs. PEP aims at 
stopping HIV-1 from disseminating through the body thus preventing the person from 
becoming HIV positive at all. See (Havens et al. 2003) for more information. 
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1.3 Summary 
The CD4 receptor is a multifunctional protein playing an essential role both in the 
immune response as in the pathogenesis of HIV-1. Additionally it may play a role in 
lymphotaxis but not much is known about that. The functions of CD4 are closely 
connected with its interactions. The interactions with CD45 and p56lck are well 
established and play a crucial role in the function of CD4 as a coreceptor in MHC class II 
recognition. However, much evidence points towards CD4 being associated with 
additional molecules. Reports have shown co-immunoprecipitations of various membrane 
proteins with CD4, novel intracellular ligands as well as the connection between CD4 and 
the cytoskeleton. Furthermore, CD4 is expressed on the surface of various cells that do 
not function in MHC class II recognition and the function of CD4 on those cells is not 
established. Those cells do not express p56lck and since CD4 itself cannot transduce 
signals, there are likely to be other associating partners in those cells. CD4-expressing 
cells are susceptible to infection with the HIV-1 virus. CD4 functions as a primary 
receptor to which the HIV-1 gp120 protein binds. Structural changes in gp120 lead to 
binding of the coreceptors and ultimately membrane fusion. Gp120 binding to CD4 and 
coreceptors is known to induce signalling and signalling through CD4 is likely to involve 
associated proteins. On lymphocytes, CD4 also functions as the receptor responsible for 
initial attachment of HIV. However, on other cell types other receptors can mediate the 
attachment of HIV. On dendritic cells, which are thought to be the first cells that HIV 
encounters after transmission, the virus attachment is mediated by a series of C-type 
lectin receptors one of which is DC-SIGN. Binding of DC-SIGN leads to internalisation 
of the virion, however, HIV induced changes in the endocytic routing of HIV prevents a 
proportion of it from degradation and allows virus transfer to T-cells. The quarternary 
structure of DC-SIGN has been suggested to be tetrameric and to mediate high affinity 
ligand binding. However, this has been done using synthetic ligands and recombinantly 
expressed extracellular DC-SIGN whereas no studies were conducted demonstrating 
quarternary structure of native DC-SIGN on dendritic cells and studying the influence of 
quarternary structure on binding affinity using its native ligands such as gp120. 
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1.4 Outline of thesis 
The work presented in this thesis bridges medical research with the relatively new 
discipline of proteomics. While this was a very difficult task, it has eventually proven to 
be extremely rewarding. Successful prosecution of this project required an understanding 
of the biology of the human immunodeficiency virus and its main receptor CD4 together 
with and evaluation and practical exposure to techniques broadly classified as 
“proteomics”. To reflect this knowledge in this thesis, the extensive literature review on 
the cell surface receptor CD4 and the human immunodeficiency virus presented above 
aims to provide a comprehensive introduction on the biology of this thesis. To address 
the knowledge required for this thesis on the use of mass spectrometry and “proteomics”, 
A brief introduction to mass spectrometry has been included into the chapter describing 
the methods that were used in this thesis. Each of the individual results chapters is 
designed to be “self-contained” with respect to the literature required for understanding 
the results and evaluation of the results within the available literature. 
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CHAPTER TWO: 
 
MATERIALS AND METHODS 
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2.1 Cells 
The human lymphoblastoid cell lines CemT4 and the CD4 negative lymphoblastoid 
derivative cell line A2.01 (both DC-SIGN negative) were obtained from the NIH AIDS 
Research and Reference Reagent Program (Rockville, MD, USA). The OKT4 hybridoma 
cell line was obtained from the American Type Culture Collection (ATCC) (Rockville, 
MD, USA). The Q4120 and the Q425 hybridoma cell lines were a generous gift from Dr 
Quentin Sattentau (Centre d’Immunologie de Marseille-Luminy, Marseille, France). 
WM82 hybridoma cells were generously donated by Dr Tony Hennicker (Westmead 
Hospital, Westmead, NSW, Australia). Monocyte-derived dendritic cells were obtained 
from Dr John Wilkinson, Dr Andrew Harman or Ms Kerrie Dunstan (all Centre for Virus 
Research, Westmead Millennium Institute, Westmead, NSW, Australia) and prepared 
from isolated blood monocytes as described elsewhere (Turville et al. 2002). Cells were 
normally maintained in RF-10 medium (CSL, Parkville, Vic, Australia) or in protein free 
hybridoma medium (CSL, Parkville, Vic, Australia) for antibody production. 
 
2.2 Equipment 
The following equipment was used for the experiments described in this thesis 
 
Table 2.1 Equipment used in this study: 
 
Equipment      Source 
Chromatography 
Biologic Low Pressure chromatography system BioRad, Regents Park, NSW, Australia 
Model 221 Fraction Collector   BioRad, Regents Park, NSW, Australia 
 
Electrophoresis and western blotting 
Mini-PROTEAN II electrophoresis system BioRad, Regents Park, NSW, Australia 
Mini Trans-Blot Transfer Cell   BioRad, Regents Park, NSW, Australia 
CP 1000 X-Ray processor    Agfa, Pymble, NSW, Australia 
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Mass spectrometry sample preparation and analysis 
Q-Tof2™      Micromass, Manchester, UK 
Speed-vac™ vacuum centifuge   Savant, Farmingdale, NY, USA 
 
Spectroscopy and imaging 
Beckman DU520 UV/Vis Spectrometer  Beckman Coulter, Fullerton, CA, USA 
Odyssey infrared imaging system   Li-Cor Biosciences, Lincoln, NE, USA 
Fluor-S Multi-imager, Gel documentation  BioRad, Regents Park, NSW, Australia 
System 
 
Flow cytometry and FRET measurements 
FACScalibur flow cytometer Becton Dickinson, San Diego, CA, 
USA 
FACSVantage SE DiVA Becton Dickinson, San Diego, CA, 
USA 
 
2.3 Buffer solutions 
The following buffers were used in the work described in this thesis 
 
Phosphate-buffered saline (PBS)  SDS-PAGE reservoir buffer 
50 mM Na2HPO4    25 mM Tris 
140 mM NaCl    192 mM Glycine 
pH 7.5      0.5 % (w/v) SDS 
      no pH adjustment required 
HEPES-buffered saline (HBS) 
10 mM HEPES    Western blot transfer buffer 
140 mM NaCl    25 mM Tris 
pH 7.5      192 mM Glycine 
      0.025 % SDS 
TRIS-buffered saline (TBS)   pH 8.3 
25 mM TRIS 
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140 mM NaCl    Western blot wash buffer 
3 mM KCl     1 x TBS, pH 8.0 
pH 8.0 or pH 7.5 as indicated  0.05 % (v/v) Triton X-100 
 
Cross-link buffer (CLB)   FACS buffer 
10 mM HEPES    1 x PBS, pH 7.5 
140 mM NaCl    0.1 % (w/v) BSA 
1 mM MgCl2     0.1 % (w/v) NaN3 
0.1 mM EGTA 
0.02 % (w/v) NaN3    Coupling buffer 
pH 8.0      0.1 M NaHCO3 
      0.5 M NaCl 
Lysis buffer1     pH 8.3 
1 x HBS, pH 7.5 
1 % (v/v) Triton X-100   Acetate buffer 
1 % (v/v) NP-40    0.1 M acetic acid 
10 mM MgCl2    0.5 M NaCl 
10 U/mL Dnase    pH 4.0 
1 mM PMSF 
10 µg/mL Aprotinin    Cy3 labelling buffer 
100 µg/mL Soybean Trypsin Inhibitor 0.1 M NaHCO3 
10 µg/mL Leupeptin    pH 9.3 
 
Lysis buffer 2     Trypsin buffer 
1 x CLB, pH  8.0    25 mM Tris 
0.5 % (w/v) Sodium deoxycholate  1 M Urea 
0.1 % (w/v) SDS    10 mM CaCl2 
1 % (v/v) NP-40    pH 8.5 
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SDS-PAGE sample buffer    Fluorescein labelling buffer 
(non-reducing)    0.1 M NaHCO3 
62.5 mM Tris     pH 8.3 
0.025 % (w/v) bromophenolblue   
2 % (w/v) SDS    Coomassie staining solution 
10 % (v/v) Glycerol    10 % (v/v) Methanol 
adjust pH to 6.8 prior to addition of  10 % (v/v) Acetic acid 
bromophenol blue, SDS and glycerol 0.1 % (w/v) Coomassie Brilliant Blue 
 
All buffers were made up with RO (reverse osmosis) water produced in-house. 
 
2.4 Chemicals 
The following chemicals were used in the experiments described in this thesis 
 
Chemical      Source   Location 
6-(fluorescein-5-carboxamido)hexanoic acid, Molecular Probes Eugene, OR, USA 
succinimidyl ester 
Acetic acid     ChemSupply  Gillman, SA, Australia 
Acetonitrile     Sigma   St Louis, MO, USA 
Ammoniumbicarbonate    Sigma   St Louis, MO, USA 
Aprotinin     Sigma   St Louis, MO, USA 
Bromophenolblue    Sigma   St Louis, MO, USA 
BSA      Sigma   St Louis, MO, USA 
Calcium chloride    ICN chemicals  Seven Hills, NSW, Australia 
Coomassie brilliant blue    Sigma   St Louis, MO, USA 
Cy3 NHS ester     Amersham-Pharmacia Uppsala, Sweden 
D-Biotin     Pierce   Rockford, IL, USA 
Dithiothreitol     Sigma   St Louis, MO, USA 
DMSO       Amresco  Solon, OH, USA 
DSS      Pierce   Rockford, IL, USA 
DSP      Pierce   Rockford, IL, USA 
EDTA      Sigma   St Louis, MO, USA 
EGTA      BDH/Merck  Kilsyth, Vic, Australia 
Ethanol      ChemSupply  Gillman, SA, Australia 
Ethanolamine     Sigma   St Louis, MO, USA 
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Formic acid     Sigma   St Louis, MO, USA 
Glycerol     Sigma   St Louis, MO, USA 
Glycine      Amresco  Solon, OH, USA 
HEPES      Amresco  Solon, OH, USA 
Hydrochloric acid    BDH/Merck  Kilsyth, Vic, Australia 
Isopropyl alcohol    ICN chemicals  Seven Hills, NSW, Australia 
Leupeptin     Sigma   St Louis, MO, USA 
Magnesium chloride    BDH/Merck  Kilsyth, Vic, Australia 
Methanol     ChemSupply  Gillman, SA, Australia 
N-(biotinoyl)-N'-(iodoacetyl)-ethylenediamine Molecular Probes Eugene, OR, USA 
NP-40      Sigma   St Louis, MO, USA 
PMA      Sigma   St Louis, MO, USA 
PMSF      Boehringer  Mannheim, Germany 
Potassium chloride    BDH/Merck  Kilsyth, Vic, Australia 
SBTI      Sigma   St Louis, MO, USA 
SDS      Sigma   St Louis, MO, USA 
Sodium azide     Sigma   St Louis, MO, USA 
Sodium bicarbonate    Sigma   St Louis, MO, USA 
Sodium chloride     BDH/Merck  Kilsyth, Vic, Australia 
Sodium deoxycholate    Sigma   St Louis, MO, USA 
Sodium hydroxide    BDH/Merck  Kilsyth, Vic, Australia 
TNBP      gift from  University of Wollongong 
     Dr Jennifer Burgess Wollongong, NSW, Australia 
TCEP      Pierce   Rockford, IL, USA 
Tris      Sigma   St Louis, MO, USA 
Triton X-100     Sigma   St Louis, MO, USA 
Urea, ultra pure     ICN Chemicals  Seven Hills, NSW, Australia  
Water, HPLC grade    Sigma   St Louis, MO, USA 
 
2.5 Immunochemicals 
The horseradish peroxidase (HRP)-labelled, secondary, anti mouse polyclonal antibody 
was raised in sheep and obtained from Silenus/Chemicon (Hawthorn, VIC, Australia). 
The HRP-labelled, secondary, anti rabbit polyclonal antibody was raised in donkey and 
obtained from Amersham-Pharmacia (Uppsala, Sweden). Fluorescein isothiocyanate 
(FITC)-labelled, secondary, anti mouse polyclonal antibody was raised in goat and 
obtained from Beckton-Dickinson (San Jose, CA, USA). The non-specific mouse 
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immunoglobulin IgG2b was obtained from ICN Biochemicals (Seven Hills, NSW, 
Australia). Mouse IgG2a and mouse IgG1 were obtained from Sigma (St. Louis, MO, 
USA). The FITC labelled mouse immunoglobulins IgG1 and IgG2a were from BD-
Pharmingen (San Diego, CA, USA). HIV-1 gp120 (Clade E, #3234) was obtained from 
the NIH AIDS Research and Reference Program. 
Table 2.2 lists all the primary antibodies employed in this study 
 
Table 2.2: Primary antibodies employed in this study: 
Antigen  Antibody name Isotype  Source 
 
CD4 Domain 1 Q4120  mouse IgG1 purified from hybridoma supernatant 
CD4 Domain 3 Q425  mouse IgG1 purified from hybridoma supernatant 
CD4 Domain 4 OKT4  mouse IgG2b purified from hybridoma supernatant 
CD71  WM82  mouse IgG2b purified from hybridoma supernatant 
CD45  HI30  mouse IgG1 BD Pharmingen1, Cat# 555480 
CD98  UM7F8  mouse IgG1 BD Pharmingen, Cat# 556074 
DC-SIGN  120507  mouse IgG2b R & D Systems2, Cat# MAB161 
CD4  PolyT4-5 rabbit IgG generous gift from Dr Ray Sweet3 
CD71  polyclonal rabbit IgG Santa Cruz Biotechnology4, Cat# sc-9099 
DC-SIGN polyclonal rabbit IgG Santa Cruz Biotechnology, Cat# sc-20081 
gp120  polyclonal sheep IgG Centres for Biologicals Eval. and Res.5 Lot DV-012 
 
1San Diego, CA, USA 
2Minneapolis, MN, USA 
3Smith Kline Beecham, King of Prussia, PA, USA 
4Santa Cruz, CA, USA 
5Centres for Biologicals Evaluation and Research, FDA, Bethesda, MD, USA 
 
2.6 Cell lysate preparation 
Cells were grown to the required number and lysed in either lysis buffer 1 or 2. For lysis 
in buffer 1, the cells were washed twice with ice cold PBS and resuspended in lysis 
buffer 1 at a concentration of 107 cells/mL. For lysis in buffer 2, cells washed twice with 
ice cold CLB and then lysed in lysis buffer 2 at a concentration of 107 cells/mL. After a 1 
h incubation at 4 0C, insoluble material was pelleted at 10 000 x g and the supernatant 
was passed through a 0.22 µm sterile filter (Millipore, Bedford, MA, USA). 
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2.7 Affinity purification of CD4 complexes 
Affinity purification of CD4 complexes was performed as previously described (Lynch et 
al. 1999). Briefly this involved preparing lysate from around 109 cells. The affinity 
chromatography was carried out using approximately 1 mL Q425 sepharose in an Econo-
Column Chromatography Column (BioRad, Regents Park, NSW, Australia). A separate 
column was used for different preparations employing different lysis buffers or cells 
treated with a cross-linker. If indicated, a column containing 1 mL IgG1 sepharose 
preceded the Q425 column. Both columns were connected to a BioLogic™ liquid 
purification system and followed by a model 2110 fraction collector (both BioRad, 
Regents Park, NSW, Australia). The columns were equilibrated with 20 mL HBS 
containing 1 % (v/v) Triton X-100, 1 % (v/v) NP-40 and 10 mM CaCl2. The lysate was 
supplemented with 10 mM CaCl2 and then applied to the columns at a flow rate of around 
1 mL/min. If more than one column were used they were disconnected and each one 
washed and eluted separately. Each column was washed with 50 mL TBS, pH 8.0, 1 % 
(v/v) Triton X-100, 1 % (v/v) NP-40 and 10 mM CaCl2 followed by 20 mL of TBS, pH 
8.0, 1 % (v/v) Triton X-100, 1 % (v/v) NP-40. Proteins were then eluted with TBS, pH 
8.0, containing 10 mM EDTA and 0.1 % (v/v) Triton X-100 and 0.1 % (v/v) NP-40. 
Alternatively, they were eluted with 0.2 M Glycine, pH 2.5 – 2.8. Then, acidic fractions 
were immediately supplemented with 40 µL of a 1 M Tris pH 9.0 solution per 1 mL 
fraction. Elution fractions were tested for CD4 using poly T4-5 antibody and Donkey anti 
rabbit antibody coupled to HRP (Amersham-Pharmacia, Uppsala, Sweden). 
 
2.8 Biotin labelling of cysteines and tryptic digest:  
Proteins were labelled with N-(biotinoyl)-N'-(iodoacetyl)-ethylenediamine (BIAM, 
Molecular Probes, Eugene, OR, USA) as previously described (Gygi et al. 1999). This 
involved first denaturing of the proteins by adding 0.36 g urea per 750 µL of the CD4-
containing elution fractions and control fractions. This yields 1 mL of a 6 M urea solution 
containing the proteins. Proteins were then reduced by adding tributylphosphine (TNBP) 
to a final concentration of 5 mM and incubating for 1 h at 37 ºC. Free sulfhydryls were 
labelled with biotin by addition of 1 % of a 10 mM solution of BIAM in DMSO. The 
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reaction was incubated for 1 h in the dark at 37 ºC. Proteins were then purified by gel 
filtration into Trypsin buffer using NAP-10 columns (Amersham-Pharmacia, Uppsala, 
Sweden). Columns were first equilibrated with 3 x 5 mL Trypsin buffer followed by 
application of 1 mL of the protein solution whilst the flow-through was discarded. 
Another 1.5 mL Trypsin buffer were added and the flow through containing the proteins 
was collected. Modified, sequencing grade trypsin (Promega, Madison, WI, USA) was 
added to a concentration of 1 µg/mL and the protein digestion was performed over night 
at 37 ºC. 
 
2.9 Avidin chromatography of biotin-containing peptides 
Approximately 200 µL of a 50 % slurry of immobilised monomeric avidin (Pierce, 
Rockford, IL, USA) were used per sample. The beads were equilibrated and the strong 
binding sites were blocked with D-Biotin (Pierce, Rockford, IL, USA) according to the 
manufacturer’s recommendations. Briefly this involved washing the beads 2 x with PBS 
and then incubating the beads for 30 mins in a solution of 2 mM D-Biotin in PBS. The 
beads were subsequently washed 3 x with PBS. The tryptic digest was supplemented with 
1 mM PMSF to inactivate the trypsin. The beads were then added to the tryptic digest and 
incubated for 1 h at 4 ºC. The suspension was subsequently transferred into a disposable 
column (Pierce, Rockford, IL, USA) and the beads were washed with 20 mL PBS and 10 
mL water. Biotin-labelled peptides were eluted for direct mass spectrometry (MS) 
analysis in 100 µL fractions with 80 % acetonitrile containing 5 % formic acid. 
 
2.10 Sample preparation for SDS-PAGE analysis of CD4 complexes 
The two or three elution fractions containing the majority of CD4 were combined and 
100 µL of Strataclean resin (Stratagene, La Jolla, CA, USA) were added. Proteins were 
allowed to bind to the resin for 2 h at 4 ºC. The resin was then pelleted and proteins were 
eluted with 2 x 30 µL SDS-PAGE sample buffer containing 25 mM TCEP (Pierce, 
Rockford, IL, USA) at 95 ºC. TCEP was omitted when indicated. 
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2.11 Immunoprecipitations of CD4 and CD71  
Cell lysate (0.5 – 1 mL) was precipitated by incubation at 4ºC for 1 h with 2.5 µg of the 
respective antibody and 20 µL Protein G Sepharose (Amersham-Pharmacia, Uppsala, 
Sweden). The beads were washed exhaustively with HBS, pH 7.5, containing 10 mM 
CaCl2 and 0.1 % (v/v) Triton X-100. Bound protein was eluted into sample buffer by 
incubation for 5 min at 95 ºC. TCEP was omitted from the sample buffer when indicated. 
 
2.12 SDS-PAGE, Western and Dot blotting and Coomassie Brilliant Blue staining 
Immunoprecipitation- or affinity chromatography-derived samples were separated by 
polyacrylamide gel electrophoresis on an 8-16 % gradient gel (Gradipore, Frenchs Forest, 
NSW) using a Mino-PROTEAN II electrophoresis system (BioRad, Regents Park, NSW, 
Australia). Protein gels for mass spectrometry analysis were stained in Coomassie 
Brilliant Blue staining solution for 4 h or over night and destained in 40 % (v/v) 
methanol, 10 % (v/v) acetic acid. Protein gels for western blotting experiments were 
subjected to electrophoretic transfer of the proteins to nitrocellulose membranes using a 
Mini Trans-Blot Transfer Cell (BioRad, Regents Park, NSW, Australia). After blocking 
with 5 % (w/v) Diploma skim milk powder in wash buffer, the membranes were 
incubated for 1 h with primary antibody and then 1 h with horseradish peroxidase-
conjugated secondary antibody. Antibody incubations were carried out in 1 % (w/v) 
Diploma skim milk powder in wash buffer. Blots were developed, using the western 
lightening detection kit (Perkin Elmer, Boston, MA, USA). For Dot Blots, 1 µL of the 
respective sample was spotted onto the dry Nitrocellulose membrane and allowed to dry. 
The membrane was then incubated in 5 % milk in TBS, pH 8.0, containing 0.1 % (v/v) 
Triton X-100 and proteins were detected as for western blots. 
 
2.13 In-gel digest and peptide extraction 
Gel-slices were excised from the Coomassie-stained gels and dehydrated with methanol 
for 5 min and rehydrated with 30 % methanol for 5 min. Slices were washed twice with 
water and then three times for 10 min each with 100 mM ammoniumbicarbonate, 30 % 
(v/v) acetonitrile. Gel slices were then crushed into fragments, washed with 30 % (v/v) 
acetonitrile and dehydrated for 5 min with 100 % ethanol. Fragments were dried for 1 h 
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in vacuum, 50 – 80 µL of trypsin solution (5 ng/µL sequencing grade modified trypsin in 
25 mM ammoniumbicarbonate solution) was added and enzymatic digestion was carried 
out at 37 ºC over night. The supernatant was aspirated and proteins were extracted three 
times by addition of 50 µL extraction solution (50 % acetonitrile, 5 % formic acid) for 30 
min. In between extractions, gel-slices were rehydrated by addition of 30 µL water and 
20 min incubation. The aspirated extraction solutions and water supernatants were 
combined with the aspirated trypsin solution. The samples were then concentrated and 
acetonitrile was evaporated using a “Speed-Vac”™ vacuum centrifuge with moderate 
heating. The resulting peptides were purified for MS analysis using “ZipTips” (Millipore, 
Bedford, MD, USA). The “Zip-Tip” resin was first wetted with 10 µL 50 % Acetonitrile 
and washed twice with 10 µL 5 % (v/v) formic acid. The peptide sample was acidified by 
adding 15 µL 5 % (v/v) formic acid and applied to the resin twice. The resin was then 
washed 5 x with 10 µL 5 % (v/v) formic acid and peptides were eluted into 10 µL 50 % 
(v/v) acetontrile containing 5 % (v/v) formic acid. All solutions used for experiments 
described in this section had been made using HPLC grade water. 
 
2.14 Introduction to mass spectrometry 
Mass spectrometry (MS) involves the measurement of mass an intrinsic property of all 
molecules. A mass spectrometer is made up of three major parts: an ionisation source, a 
mass analyser and a detector. The source generally both vaporises and ionises the 
molecules of the sample by a range of techniques. The generated ions are then 
accelerated in an electrical field and enter one of a range of different devices where they 
are analysed or separated according to their mass (or more accurately mass-to-charge 
ratio). A detector detects the separated ions, and via a digital interface collects data, 
which is transferred to a computer for analysis. 
The major technological advances that lead to the use of mass spectrometry for 
the analysis of large biomolecules were the introduction of ionisation techniques that 
enabled transfer of the biomolecules to the gas phase without degradation. The two main 
techniques used now are matrix assisted laser desorption ionisation (MALDI) and 
electrospray ionisation (ESI). In MALDI-MS, the analyte is crystallised on an analytical 
target together with a matrix, which is generally an aromatic organic acid, that absorbs 
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UV light. To ionise the analyte, a nitrogen laser beam targeted onto the crystallised 
matrix/analyte spot transfers energy rapidly to the matrix leading to vaporisation of both 
matrix and analyte molecules. The molecules are ionised via proton transfer reactions in 
the matrix (Karas et al. 2000; Spengler 2001).  
ESI-MS is a fundamentally different ionisation technique, which is based on 
direct injection of the analyte dissolved in an aqueous/organic solvent under the influence 
of an electric field. The solution evaporates in source with the assistance of heat or a 
nebulising gas leading to the formation of small droplets from which solvent and analyte 
molecules are formed. The precise mechanism by which ions are formed is not fully 
understood but two models exist describing the formation of ions. The charge residue 
model suggests that repeated droplet fission occurs until there is only one analyte ion left 
in the droplet. Evaporation of the remaining solvent then releases the ion into the gas 
phase. The ion evaporation model suggests that during the process of droplet shrinking 
owing to evaporation, the Coulombic forces become so strong that individual analyte ions 
are ejected from the droplet (Smith, R. D. et al. 1990). Nanoelectrospray-MS (nanoESI-
MS) is a variant of ESI-MS where the analyte solvent is not pumped into the source but 
introduced into a metal-coated glass capillary. Capillary forces and the influence of the 
electric field lead to the formation of a steady spray out of the tip of the capillary from 
which analyte molecules vaporise again into the source. Charges are acquired by the ions 
in a mechanism(s) similar to ESI-MS except that droplets are smaller and ion transfer is 
more efficient. The advantage of nanoESI-MS is the requirement of only a small volume 
of analyte (at similar or lower concentrations) so in comparison to ESI-MS much less 
sample is required. Figure 2.1 shows a diagram of a typical nano-ESI source. 
 
Figure 2.1 
Diagram of a nanoESI Source 
showing analyte in a coated glass 
capillary spraying towards the 
source of the MS that directs the 
ions to the mass analyser 
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The main two mass analysers, which are employed for biomolecular MS, are the 
quadrupole mass filter (Q) and the time-of-flight (TOF) mass analyser. In the Q mass 
filter, the ions are filtered by the application of both direct current (DC) and an 
alternating current (AC) radio frequency (RF) electric fields. The quadrupole filters are 
comprised of four parallel rods and selectively transmit ions of a given mass-to-charge 
(m/z) window as the voltage applied to the rods is scanned, thereby generating a 
spectrum of ion abundance as a function of m/z. A TOF mass analyser takes advantage of 
the different velocities that ions have according to their mass-to-charge ratio when 
subjected to acceleration in an applied electric field. The velocity of the ions depends on 
their m/z ratio so ions with a lower m/z reach the detector faster than molecules with a 
higher m/z do when passed through the field free region of the flight tube in a TOF 
analyser. 
A tandem mass spectrometer is essentially a source followed by two mass 
analysers separated by a collision cell or region and then the detector. The advantage of 
such an instrument is that in the first mass analyser (usually a quadrupole), ions can be 
mass-selected. Fragment or product ions are produced in the collision cell via collisions 
with an intert gas such as argon in a process known as collision-induced dissociation or 
decomposition (CID). The resulting ions are analysed in the second mass analyser which 
might be either a quadrupole or TOF analyser*. Structural data from the selected ion can 
therefore be obtained from the tandem or MS/MS spectra. See general literature or the 
reviews from (Corthals et al. ; Yates 2000; Aebersold 2003) for more information. Figure 
2.2 shows a diagram of the Quadrupole time-of-flight (Q-tof) instrument used throughout 
this study. It consists of a nanoESI source followed by a quadrupole and a time-of-flight 
mass analyser. A hexapole collision cell is located between the two mass analysers to 
allow for fragmentation of selected ions. 
 
* Other forms of tandem mass spectrometry used for biomolecules involve quadrupole ion traps, Fourier 
transform ion cyclotron resonance and most recently TOF/TOF analysers, but a discussion of these 
analysers is beyond the scope of this thesis 
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2.15 Introduction to peptide analysis via mass spectrometry 
One of the most powerful applications of MS in protein research is the analysis of peptide 
mixtures. The strength of MS lies not only in its ability to determine the mass of the 
individual peptides in mixtures, but it is especially able to determine a part or the full 
amino acid sequence of a peptide. This is often sufficient to determine the protein from 
which the peptide is derived in combination with information available in protein 
databases. Thus MS has become an invaluable tool in protein identification. 
A peptide is any molecule consisting of two or more amino acids joined by a 
peptide bond but usually peptides with the length of at least 6 amino acids up to about 30 
amino acids can be analysed by tandem MS to obtain sequence information. The 
molecular masses of much larger peptides and proteins can be determined by ESI-MS or 
MALDI-MS but sequencing by MS is usually confined to those peptides generated 
through proteolytic digest of the protein. The most common protease used for generating 
peptides for MS is trypsin, which cleaves proteins after lysine or arginine except if a 
proline follows the basic amino acid. 
ESI-MS analyses of peptides yield ions of one or more of its mass-to-charge ratio 
and or charge state. When using low resolution mass analysers such as quadrupole mass 
filters, the charge must be determined by solving two simultaneous equations and hence 
requires the presence of two ions for each peptide. In the case of the Q-Tof instrument 
used in this work (and also quadrupole ion traps and FT-MS instruments) it is possible to 
Figure 2.2: 
Diagram of the 
Quadrupole-time-of-
flight mass 
spectrometer (Q-
TOF) used in all the 
studies conducted in 
this thesis.  
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determine the charge on the ion from the spacing between adjacent isotopic peaks. Each 
peptide (or other molecule species) gives more than one ion in an MS spectrum owing to 
the occurrence of heavier isotopes of the elements that are naturally incorporated into the 
peptide. The peak with the lowest mass is usually the “monoisotopic” peak and the 
molecule from which the peak is derived consists completely of atoms of the most 
abundant (=lightest) isotope of each element. The molecule to which the second peak can 
be assigned contains exactly one atom of a heavier isotope like deuterium or 13C. The rule 
continues for the other peaks, with the relative intensity of each peak is depending only 
on relative probability of isotopic combination. The spacing between peaks differing in 
mass by 1 yields the charge. That is doubly charged ions are separated by 0.5 m/z, triply 
by 0.33 m/z etc. The total mass of the peptide can be calculated by multiplying the mass 
to charge ratio with the charge-state and subtracting one mass unit for each charge state 
since for positive ions the charge arises from addition of a proton. 
Tandem MS has the ability to select an individual peptide ion and subject it to 
collision-induced dissociation (CID). Under normal CID conditions, peptides fragmentate 
at the peptide bond. Figure 2.3 shows the typical fragmentation of a peptide and the 
nomenclature of the ions that are produced. Sequence information can be obtained by 
analysing the mass differences between the ions in each series which are characteristic of 
the individual amino acids. For tryptic peptides the most abundant precursor ions are 
usually doubly or triply charged since each tryptic peptide has at least two basic sites for 
protonation. These ions usually produce abundant y ion series. See general literature of 
the reviews from (Corthals et al. ; Yates 2000; Aebersold 2003) for a more detailed 
description of tandem MS. 
 
 
 
Figure 2.3: 
Diagram of the typical 
fragmentation of a peptide 
in MS/MS. Fragmentation 
occurs at the peptide 
bonds. 
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2.16 Mass spectrometry analysis 
Electrospray mass spectrometry (ESI-MS) analyses were carried out using a Q-Tof2 
(Micromass, Manchester, UK) in nanoelectrospray mode. Typically 5 µL sample was 
loaded into a coated glass capillary (Protana, Odense, Denmark). The ESI parameters 
were as follows: Capillary voltage, 800 – 1000 V; Cone voltage, 30-40 V; desolvation 
temperature, 40 ºC; desolvation gas flow rate, 50 - 100 L/h. Peptides were detected by 
acquisition of the m/z range from 50 – 2000 using a 2.4 s integration time and a 0.1 s 
delay. Precursor ions were selected for fragmentation within a mass window of 4 m/z. 
MS/MS spectra were collected using collision cell voltages from 25 V to 45 V with argon 
as the collision gas. The instrument was calibrated with a solution of 100 fM [Glu1]-
fibrinopeptide B in 40 % acetonitrile, 2.5 % formic acid. To reduce the intensity of 
detergent-derived singly charged species, the voltage on the MCP detector was reduced 
to 2000 V during MS acquisitions whilst kept at 2300 V during MS/MS acquisitions (Loo 
and Ogorzalek-Loo, 1995). Typically, all multiply charged ions that could be easily 
distinguished from the background were subjected for fragmentation. Exceptions were 
made for ions that were known to be peptides derived from certain proteins, which were 
sometimes omitted when the protein had already been identified. Also a targeted ion 
approach was sometimes used when a multiply charged ion that could not be clearly 
distinguished from the background was subjected to fragmentation because the presence 
of a peptide ion at the m/z was expected. 
 
2.17 Protein identification 
Amino acid sequence tags (a series of consecutive amino acids representing a part of the 
peptide sequence that were indentified from the fragmentation spectra via their residue 
mass) obtained from the MS/MS spectra were used for database searches with the PepSea 
software (Protana, Odense, Denmark, http://195.41.108.38/PepSeaIntro.html) or the 
ScanProsite software (SWISS-PROT database, Swiss Institute of Bioinformatics (SIB), 
Geneva, Switzerland, http://au.expasy.org/tools/scanprosite/). Proteins containing the 
sequence tag were subjected to a theoretical digest with trypsin and the resulting peptides 
searched for the peptide that contained the sequence-tag. To be identified as the sequence 
of a fragmented ion, the total mass of the peptide including the additional masses of 
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amino acid modifications (biotin tag: 326.1 Da, Met oxidation: 16 Da, 
carboxamidomethylcysteine: 71 Da, N-terminal acetylation: 42 Da) needed to be 
equivalent to the precursor ion mass. Additionally, a series of product ions from the 
MS/MS spectrum had to match the predicted y and b ions of the sequence. The full 
peptide sequence was again entered into the ScanProsite search engine and the protein 
was considered to be identified conclusively in the affinity chromatography-derived 
sample if it was the only human protein producing this peptide after a tryptic digest.  
 Alternatively, fragmentation specta were matched using MASCOT 
(http://www.matrixscience.com/cgi/index.pl?page=/search_form_select.html). Obtained 
matches were generally confirmed via manual sequencing. 
 
2.18 Immunoprecipitations and Co-immunoprecipitations of DC-SIGN complexes 
Unless otherwise indicated, 0.5 mL lysate were precipitated with either 2.5 µg anti DC-
SIGN antibody or 10 µL anti gp120 serum bound to 20 µL Protein G beads for 1 h at RT. 
For co-immunoprecipitations, 2.5 µg gp120 was incubated with the lysate for 1 h at RT 
prior to addition to the antibody bound to the beads. For precipitations with mannan 
beads, the beads were washed with HBS, pH 7.5, 10 mM CaCl2 and 0.1 % (v/v) Triton X-
100 and then incubated with the lysate. 
After binding, the beads were washed 5 x with HBS, pH 7.5, 10 mM CaCl2 and 
0.1 % (v/v) Triton X-100 and resuspended in 1 x SDS sample buffer. If indicated, DTT 
was added to a concentration of 50 mM for reduction of the disulfide bonds. Proteins 
were analysed via western blotting and detected with a polyclonal anti DC-SIGN 
antibody. 
 
2.19 Cross-linking of cell surface molecules and cell lysate preparation 
Cells were washed twice with cross-link buffer (CLB) and then resuspended in CLB at 5 
× 106 cells/mL. DSP or DSS in dimethylsulfoxide was added to the cell suspension (2 mL 
of 25 mM per 100 mL suspension unless otherwise indicated). Cross-linking was carried 
out for 30 min at room temperature. Unreacted cross-linker was quenched by adding 
TBS, pH 7.5, and resuspending the cells in TBS, followed by a 15 min incubation at 
room temperature. Cells were then pelleted and lysed in lysis buffer 2 at a concentration 
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of 107 cells/mL. After 60 min at 4ºC, insoluble debris was pelleted and the supernatant 
passed through a 0.22 µm syringe-driven filter unit (Millipore, Bedford, MD, USA). The 
lysate was then supplemented with 10 mM CaCl2. For preparation of mock-cross-linked 
cell lysates, dimethylsulfoxide was added without dissolved cross-linker. 
 
2.20 Generation of affinity chromatography medium   
Antibodies were purified from hybridoma supernatant using HiTrap Protein G HP 
columns (Amersham Pharmacia , Uppsala, Sweden). After application of the antibody, 
the column was washed exhaustively with PBS and eluted with 0.2 M Glycine, pH 2.5-
2.8. Purified antibody was then dialysed into a buffer suitable for the next preparation 
using dialysis tubing (Life Technologies, Gaithersburg, MD, USA). For generation of 
affinity beads antibody was dialysed into coupling buffer and the concentration was 
determined spectrophotometrically by measuring protein absorption at 280 nm. The 
concentration was calculated according to equation 1 with the denominator 1.3 derived 
from the extinction coefficient for IgG molecules: 
 
concentration[µg/ml] = A(280) / 1.3    Equation (1) 
 
The antibody was then coupled to Cyanogen-bromide activated sepharose (Sigma, St. 
Louis, MO, USA). Sepharose (0.4 g will produce about 1 mL gel) was swelled in 1mM 
HCl and washed with 100 mL 1 mM HCl per 1 g sepharose used. Beads were then 
washed twice with water and once with coupling buffer followed by addition of the 
antibody solution. The reaction was performed for 2 h at RT followed by an incubation at 
4 ºC over night. The beads were then washed with coupling buffer and unreacted sites 
were blocked by resuspending in coupling buffer containing 1 M ethanolamine for 2 h. 
The resin was then washed alternately with coupling buffer and acetate buffer for five 
times and resupended in HBS containing 1 % (v/v) Triton X-100, 1 % (v/v) NP-40, 10 
mM EDTA and 0.1 % (w/v) NaN3. Coupling efficiency was determined by Dot Blot and 
was generally above 90 %. For coupling of commercially obtained antibody, the antibody 
was buffer exchanged into coupling buffer at a smaller scale using Amicon Ultra 
Centrifugal filter devices (Millipore, Bedford, MD, USA). The obtained antibody was 
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added to 1 mL coupling buffer and the solution transferred into a filter device. The 
antibody solution was concentrated by centrifuging at 7000 x g until 100 µL remained. 
Another 1 mL aliquot of coupling buffer was added and the concentration/dilution 
repeated for a total of four times. The concentration of the antibody was again determined 
spectrophotometrically (as above) and coupling of the antibody was performed similar to 
antibody derived from hybridoma supernatant but usually at a smaller scale. 
 
2.21 Labelling of antibodies with fluorophores 
Antibodies were labelled with either 6-(fluorescein-5-carboxamido)hexanoic acid, 
succinimidyl ester (Molecular Probes, Eugene, OR, USA) or Cy3 (Amersham-Pharmacia, 
Uppsala, Sweden). Antibodies were buffer exchanged into Cy3 labelling buffer or 
fluorescein labelling buffer as described in 2.20. For labelling with fluorescein, per 50 µg 
antibody, 1 µL of a solution of 0.05 mg  6-(fluorescein-5-carboxamido)hexanoic acid, 
succinimidyl ester in 50 µL DMSO was added. For labelling with Cy3, one aliquot Cy3 
NHS ester supplied by the manufacturer was suitable for labelling 1 mg antibody. For 
smaller quantities the Cy3 NHS ester was dissolved in DMSO and the respective part was 
added to the protein solution. The reaction was allowed to proceed for 30 min at RT in 
the dark and labelled antibodies were separated from unconjugated dyes using 
gelfiltration on Sephadex G-25 (Amersham-Pharmacia, Uppsala, Sweden) and PBS. For 
spectrophotometric determination of the concentration and the degree of labelling, the 
absorption was determined at 280 nm and 494 nm for fluorescein conjugates and 280 nm 
and 552 nm for Cy3 conjugates. The concentration was determined using equation 2 and 
3 respectively: 
 
For fluorescein: conc (µg/mL) = (A280 – 0.2 * A494) / 1.3   Equation (2) 
For Cy3:  conc (µg/mL) = (A280 – 0.08 * A552) / 1.3 Equation (3) 
 
The degree of labelling (DOL) was determined using equation 4 and 5 respectively: 
 
For fluorescein: DOL = A494 * 2.2 / conc (µg/mL)   Equation (4) 
For Cy3:  DOL = A552 * 1.13 / conc (µg/mL)  Equation (5) 
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2.22 Flow cytometry measurements 
For each flow cytometry sample, 5 x 105 cells were washed 2 x with FACS buffer. Cells 
were resuspended in 35 µL heat-inactivated fetal calf serum (CSL, Parkville, Vic.) and 
incubated for 15 min at 4 ºC. Cells were then labelled with the antibodies. Usually 0.5 µg 
antibody was used per antibody per sample and the labelling was carried out at 4ºC for 30 
min. Cells were then washed 2 x with FACS buffer and resuspended in 300 µL FACS 
buffer. Flow cytometry measurements were carried out using a FACScalibur (Becton-
Dickenson, San Diego, CA, USA) using a 488 nm laser for excitation. Fluorescein 
fluorescence was measured at 530 nm. Cy3 fluorescence was measured at 585 nm. Life 
cells were gated to exclude debris and dead cells and no compensation was used. Data 
were collected in “List” mode and mean fluorescence intensities were used for 
evaluation. 
 
2.23 FRET 
Fluorescence Resonance Energy Transfer (FRET) technology has become a versatile tool 
for the study of protein-protein interactions especially because it can be used for 
membrane protein interactions on the surface of living cells. FRET is a physical 
phenomenon that involves energy transfer from an excited donor molecule (e.g. 
fluorescein) to a suitable acceptor molecule (e.g. Cy3 or rhodamine). The transfer 
efficiency is highly dependent on distance and does not take place if donor and acceptor 
are separated by more than 5 to 10 nm thus acting as a molecular ruler to investigate 
proximity between cell surface proteins. FRET is measured as energy transfer efficiency 
(E), which is the percentage of excited donor molecules that transfer their energy to an 
acceptor molecule. An E value of more than 5 to 7 % indicates a protein interaction 
(Matyus et al. 1995; Dornan et al. 2002). Here we measured FRET using flow cytometry 
and fluorescein and Cy3 labeled monoclonal antibodies using either donor quenching for 
heteroassociations or acceptor sensitizing for homoassociations (Szollosi et al. 1984; 
Tron et al. 1984; Guo, C. et al. 1995a; Kenworthy et al. 2000; Szollosi et al. 2002). 
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2.24 FRET measurements on protein homoassociations 
Cells were labelled similarly as for flow cytometry analysis. Cells were labelled with 
either unconjugated antibody, with fluorescein (donor) or with Cy-3 (acceptor) 
conjugated antibody for determining the control values. For FRET measurements, cells 
were labelled with a mixture of fluorescein and Cy-3 conjugated antibody employing 
various Ab-fluorescein/Ab-Cy3 ratios. Flow cytometry measurement was carried out 
using a FACSVantage SE DiVa from Becton-Dickinson (San Diego, CA, USA). Three 
fluorescence intensities were collected, two with excitation at 488 nm and detection at 
530 nm (I1) and 585 nm (I2). The third fluorescence intensity was collected with 
excitation at 514 nm and detection at 585 nm (I3). No compensation was used. Cells were 
gated to exclude debris and dead cells and both mean and median fluorescence intensities 
were used for analysis. To eliminate the influence of cellular autofluorescence, test values 
were obtained using equation 6:  
 
(test value) = (mean fluorescence intensity obtained with conjugated antibody) – 
(mean fluorescence obtained with unconjugated antibody).  Equation (6) 
 
Values I530 and I585 (see below) were derived from two samples labelled to saturation 
with either WM82-fluorescein or WM82-Cy3. I530 was detected at 530 nm with the 
WM82-flurescein sample and excitation at 488  nm whereas I585 was detected at 585 nm 
with the WM82-Cy3 sample and excitation at 488 nm. Energy transfer efficiencies were 
calculated from the test values using equations 7-9 (Szollosi et al. 1984; Tron et al. 
1984): 
 
 a = I585 * DOL (WM82-Fluorescein)    x  2.15   Equation (7)  
  I515*DOL (WM82-Cy3)   
 
       I2 – S2xI3  
 A =        1 – S3xS2     - S1         Equation (8) 
   S1 
 
 E = A/(a + A)        Equation (9) 
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     The values for S1 to S3 were obtained as follows: S1 = I2/I1 for cells labelled only 
with the donor, S2 = I2/I3 for cells labelled only with the acceptor and S3 = I3/I1 for cells 
labelled only with the donor. E values were excluded when the value obtained from the 
median fluorescence intensities differed from the value obtained from the mean 
fluorescence intensities by more than 50 %. The FACSVantage DiVa was operated by 
Tara McDonald (Centennial Institute, Camperdown, NSW, Australia) at the Centennial 
Institute. 
 
2.25 FRET measurements on protein heteroassociations 
For FRET measurements on associations between different proteins, cells were labelled 
similarly as for flow cytometry analysis. The less abundant molecule was hereby used as 
donor and the higher abundant molecule as acceptor. Four samples were prepared for 
each measurement. Cells were stained with unconjugated donor and acceptor antibody 
(blank sample), with unconjugated acceptor antibody and fluorescein conjugated donor 
antibody (donor sample), with Cy3 conjugated acceptor antibody and unconjugated donor 
antibody (acceptor sample) and Cy3 conjugated acceptor antibody and fluorescein 
conjugated donor antibody (FRET sample). Flow cytometry analysis was carried out 
using a FACScalibur (Becton Dickinson, San Diego, CA, USA) with a 488 nm laser. 
Cells were gated to exclude debris and dead cells and mean fluorescence intensities were 
used for analysis. Two fluorescence intensities were collected, FL1 at 530 nm and FL2 at 
585 nm. All samples were stored on ice until analyzed. Cells were subsequently 
incubated at 37 ºC for a given time and then analyzed again. For study of the influence of 
PMA on the association, 100 ng/mL PMA was added to each sample before the 
incubation period. Nothing was added to mock treated samples. Energy transfer 
efficiencies were determined as donor fluorescence quenching and calculated using 
equation 10: 
 
E = [{FL1 (Donor) – FL1 (FRET)} / {FL1 (Donor) – FL1 (blank)}] × 100 %. 
          Equation (10) 
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2.26 Purification of DC-SIGN complexes 
The monoclonal anti DC-SIGN antibody was coupled to cyanogen bromide-activated 
sepharose as described in 2.20. Lysate from about 9 x 107 MDDCs that had been treated 
with DSS as described in 2.19 was first passed over ~ 100 µL of an irrelevant antibody 
coupled to sepharose to absorb non-specifically binding proteins and subsequently passed 
over ~ 100 µL anti DC-SIGN beads (containing approximately 100 – 150 µg 
immobilized antibody). The beads were then washed with TBS, pH 8.0, containing 0.1 % 
(v/v) Triton X-100. Complexes were eluted by boiling the beads for 5 min in 1 x SDS 
sample buffer. 
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CHAPTER THREE: 
 
SEARCH FOR PROTEINS CO-PURIFYING 
WITH THE CD4 RECEPTOR COMPLEX USING 
MASS SPECTROMETRY 
 
EVALUATION OF AFFINITY-TAG MEDIATED PURIFICATION 
OF TRYPTIC PEPTIDES TO IDENTIFY PROTEINS PURIFIED 
WITH Q425 AFFINITY CHROMATOGRAPHY 
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3.1 Aims 
The work described in this chapter aimed to: 
(i) Develop a method to identify the proteins present in an affinity chromatography-
derived purification of the CD4 complex using affinity tag-mediated purification 
of tryptic peptides; 
(ii) Evaluate the strategy with respect to both the capacity to identify protein-protein 
interactions and the extent to which the possible proteins in each sample are 
detected; 
(iii) Confirm (or otherwise) the possible interactions between CD4 and the detected 
proteins using control experiments. 
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3.2 Introduction 
The CD4 protein as described in chapter 1 is an integral membrane protein of 55 kDa 
consisting of four extracellular domains, a transmembrane domain and a cytoplasmic tail 
(Maddon et al. 1987). CD4 functions as a coreceptor in the activation of CD4+ T-cells 
(Gay et al. 1987), as a chemotactic receptor for IL-16 in various cells (Cruikshank, W. W. 
et al. 1994) and together with CCR-5 and CXCR-4 as the receptor for the entry of HIV-1 
into its target cells (Lapham et al. 1996; Wu, L. et al. 1996). CD4 cannot transmit signals 
into the interior of the cell by itself nor on its own allow entry of HIV-1 (reviewed in 
chapter one). The correct function of the CD4 molecule is mediated by its associating 
molecules. Thus, to function correctly as a co-receptor in MHC class II recognition, CD4 
associates with the tyrosine kinase lck via its cytoplasmic tail and with the tyrosine 
phosphatase CD45 via a lateral interaction in the membrane. For entry of HIV-1 into a T 
cell, as reviewed in chapter 1, the virus first interacts with CD4 which is not sufficient for 
entry. Only recruitment of a co-receptor, CCR5 or CXCR4 and subsequent membrane 
fusion allows for infection of the cell. Pre-assembled complexes of CD4 with those co-
receptors have been suggested but little data is available on such an interaction (see 
section 1.2.3.2). Furthermore studies at our centre have suggested host cell-derived 
effects on HIV replication that could be derived from CD4-associated proteins (Naif et al. 
1999). The mechanism by which IL-16 mediates chemotaxis is poorly understood and 
little is known about the CD4-associating molecules in non-lymphoid cells that area also 
susceptible to IL-16, though some evidence for the presence of associating proteins has 
been reported (Graziani-Bowering et al. 2002). Several molecules have been described 
associating with CD4 in T-lymphocytes that could be involved in CD4 function namely, 
ACP33 (Zeitlmann et al. 2001), LAT-1 (Bosselut et al. 1999), raf-related polypeptide 
(Prasad and Rudd, 1992) and the T-cell receptor (Vignali and Vignali, 1999). However, 
those reports have yet to be confirmed so apart from its extracellular ligands IL-16, MHC 
class II and HIV-gp120, only the interactions with p56lck and CD45 are generally 
accepted. Most of the proteins listed above, such as p56lck or ACP33 that were reported 
to associate with CD4 could be detected using co-immunoprecipitation techniques 
followed by western detection. Thus affinity purification of CD4 from a detergent 
solubilized lysate, which is technically identical to co-immunoprecipitation at a larger 
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scale, should purify any associating proteins along CD4. CD4 affinity purification had 
been established in our laboratory (Lynch et al. 1999) so this study aimed to identify the 
proteins present in the affinity purified sample to detect any associating molecules that 
could play a role in CD4 function. For this purpose a method is required that detects all 
proteins present via determining the amino acid sequence of the molecules present in a 
mixture of proteins.  
Recent years have seen the introduction of powerful techniques to obtain rapid 
information on protein identity, relative protein expression or protein interactions owing 
to the demand of rapid information of protein function. Aebersold and co-workers 
demonstrated quantitative analysis of changes in protein expression after changes in 
growth conditions using isotope-coded affinity tags (ICAT) (Gygi et al. 1999). This 
method has also been used successfully to determine alterations in membrane protein 
expression (Han et al. 2001) and a similar approach was employed to identify proteins 
released from permeabilized mitochondria (Spahr et al. 2000). Membrane proteins are 
generally very difficult to study and often the low abundance of important receptor 
molecules requires additional strategies for their detection. Simpson and co-workers have 
used a "targeted" ion approach to identify "predicted" peptides from a low-abundance 
protein in a digested membrane fraction. They demonstrated that even when low 
abundance proteins are known to be present, the resulting peptide ions are normally not 
detected in the presence of ions from more abundant proteins (Simpson et al. 2000). To 
overcome the problem of low abundance, trace enrichment procedures are commonly 
used to purify low copy proteins together with associating molecules. MS analysis of the 
purified complex, usually done using 1-D PAGE followed by in-gel digest and MS, 
yields very valuable data on protein interactions as demonstrated in the publication of the 
yeast interaction map (Ho, Y. et al. 2002). 
In this study, a method is developed for the identification of proteins present in an 
affinity-purified CD4 sample to investigate CD4-associating molecules. To identify the 
proteins present in the purification of the CD4 receptor complex, a tryptic digest of the 
whole protein mixture was employed to circumvent the 1-D PAGE step generally used in 
similar studies. The resulting complex peptide mixture, however, requires separation of 
peptides to facilitate detection. Common approaches to achieve this are multidimensional 
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chromatography, usually ion-exchange chromatography followed by reverse phase (RP)-
chromatography (Spahr et al. 2000). To avoid the use of a multidimensional 
chromatography a variation of the cysteinyl affinity capture method of Spahr et al. (2000) 
was used to generate a representative subset of cysteine-containing peptides for 
subsequent MS analysis without prior RP-separation of peptides. 
This method is shown as a rapid alternative to 1D-PAGE-MS for the study of 
protein interactions involving membrane proteins. The proteins present in the CD4-
affinity purification were identified and information on whether they specifically interact 
with CD4 was obtained. The reduction of sample complexity using this strategy has been 
evaluated and also some potential limitations of this approach are delineated. 
 
3.3 Results and Discussion 
 
3.3.1 Mass spectrometry analysis of affinity purified tryptic peptides. 
To identify the proteins associated with the purified CD4 receptor complex, 109 CemT4 
cells were lysed (see 2.6) and purified (see 2.7) using a CD4-specific affinity column (see 
2.20 for column generation). The eluted proteins were labelled with BIAM at cysteine 
residues and digested with trypsin (see 2.8). The cysteine-containing peptides carrying 
the biotin tag were purified by affinity chromatography using monomeric avidin gel (see 
2.9) and the eluted fractions subsequently analysed by ESI MS (see 2.16). Figure 3.1 
shows the MS screen of the affinity-purified peptide mixture with one enlarged region 
showing isotopic resolution of peptide ions. 
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Figure 3.1: Mass spectrometry identification of peptides derived from the purification of CD4 associating 
proteins. ESI-mass spectrum of a purified mixture of cysteine-containing peptides derived from the CD4 
receptor complex is shown together with the ion at m/z 961 enlarged. 
 
The spectrum shows strong peaks from contaminating singly charged species in 
the m/z range up to 700. The distance of 44 Da between the peaks strongly points to a 
polyethyleneglycol (PEG)-based contamination. As both Triton X-100 and NP-40 are 
PEG-based polymers and were used for efficient solubilization of CD4, it is obvious that 
those detergents were not completely eliminated during the purification process. The 
carry over of the detergents through the purification is undesirable because it interferes 
with MS analysis owing to strong singly charged ions derived from the polymeric 
molecules. For washing away the detergents, similar studies used additional separation 
steps like cation exchange chromatography (Han et al. 2001), which were not desired in 
this study. Alternatively, SDS has been employed for protein solubilization (Han et al. 
2001), however, SDS could not be used here as it might have destroyed the protein 
interactions we aimed to investigate in high concentrations. 
Despite the singly-charged background, numerous ions attributed to peptides can 
be distinguished in the spectrum. The inset shows the region around m/z 961 where the 
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individual isotopic peaks are clearly resolved and the difference in m/z of 0.25 between 
the peaks shows the ions are quadruply charged yielding a parent ion mass of 3841 Da. A 
comparison of the detected parent ions with the masses of trypsin autolysis fragments 
(2211Da, 1045 Da and 842 Da) showed that none of those commonly-seen contaminating 
trypsin peptides were present, demonstrating the ability of the method to eliminate those 
species. Many other ions that could be assigned to peptides were detected, enabling a 
total of 18 to be identified and the protein of origin determined as described below (see 
also  2.17 for a description of methods used for protein identification). 
 
3.3.2 Identification of the proteins present in the affinity-purification of CD4. 
Table 3.1 shows all peptides that were identified in the affinity-chromatography purified 
sample and Figure 3.2 shows a representative MS/MS spectrum used for identification of 
a tryptic peptide from CD4. With the exception of avidin-derived peptides, all identified 
peptides contained a cysteine carrying the biotin tag (C*) and no peptide resulted from a 
tryptic miscleavage. In the spectrum shown in figure 3.2 the precursor ion at m/z 1176.3 
was shown to be triply charged yielding a mass of 3526 Da. The spectrum showed a 
series of singly charged, C-terminal sequence ions from y1+ through to y8+. This identifies 
the C-terminal portion of the sequence as V[LI][LI]ESN[LI]K (notation according to the 
ScanProsite software tool from the SwissProt database). Note that a mass difference of 
113 can be equally derived from a leucine or an isoleucine residue so the software used 
for database searching requires that both residues are entered at the position representing 
a mass difference of 113. Here this is done by putting into square brackets both residues 
permitted at the respective position. It is also not possible to distinguish between lysine 
(K) and glutamine (Q) on the basis of mass; however, in this case lysine can be placed at 
the C-terminus because it is a tryptic peptide. Entering the above pattern into the 
ScanProsite software searching all human entries in the SwissProt database identifies 
CD4 as the only match out of 14,353 entries. Searching the CD4 sequence for the peptide 
containing the tag identifies the peptide at position 357-385 to contain the sequence at the 
C-terminus. Its mass of 3200.6 Da together with the mass of the biotin tag of 326.1 yields 
3526.7 Da matching the detected mass of the precursor ion. Inspection of the predicted 
fragmentation of the peptide shows that many other ions detected in the MS/MS spectrum 
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can be assigned to predicted product ions of the peptide. Figure 3.2 also shows evidence 
of a b-ion series representing fragments containing the N-terminal part of the peptide as 
well as doubly charged ions from fragments with a higher mass that can also be assigned 
to the peptide leading to its unambigous identification. 
Analogous MS/MS spectra were obtained from the peptides listed in Table 3.1 
allowing their unambiguous identification by the same type of strategy. Fifteen cysteine-
containing tryptic peptides were identified by MS/MS analysis in three subsequent 
experiments (Table 3.1). Of the 15 peptides identified, two were from CD4 and one from 
the binding partner p56lck. This demonstrates that the strategy under investigation in this 
study is a suitable method for rapid identification of proteins present in a mixture derived 
from affinity chromatography using a single chromatographic step. The detection of both 
CD4 and p56lck highlights the ability of the method to detect protein complexes. Since 
CD4 and p56lck are known to interact in T-lymphocytes (Veillette et al. 1988) and the 
identification of both proteins serves as a proof-of-principle for the versatility of this 
approach. The detection of avidin-derived peptides has a different origin. Avidin is 
present in the peptide sample owing to tryptic hydrolysis of the avidin beads during 
incubation of the tryptic peptide mixture with the beads. PMSF, a trypsin inhibitor was 
added to the digest in order to inactivate trypsin, however, traces of the avidin-derived 
peptides were always present. For the remaining peptides identified additional 
experiments were conducted to assess the specificity of binding to CD4 as outlined 
below. 
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Table 3.1. Peptides and proteins identified by ESI-MS/MS 
mass Peptide sequence    Protein matched    Acc. Number 
          SWISS-PROT 
3189.5 Ac-ASVSELAC*IYSALILHDDEVTVTEDKa) 60 S Acidic ribosomal protein P1 P05386 
4078.0 ALANVNIGSLIC*NVGAGGPAPAAGAAPAGG- 60 S Acidic ribosomal protein P1 P05386 
PAPSTAAAPAEEK  
2928.3 YGWSADESGQIFIC*SQEESIKPK  HSPC029    Q9Y6D1 
1899.9 ALTNLPHTDFTLC*K   HSPC029    Q9Y6D1 
2619.1 NAFAC*FDEEATGTIQEDYLR  Myosin regulatory light chain  P19105 
3398.5 MTEEEVEMLVAGHEDSNGC*INYEAFVR Myosin essential light chain  P16475 
2977.5 LTTPTYGDLNHLVSATMSGVTTC*LR Tubulin β-5 chain   P04350 
3256.6 ITSAVWGPLGEC*IIAGHESGELNQYSAK eIF-3 β    Q13347 
3259.6 LSRPC*QTQKPQKPWWEDEWEVPR  p56lck    P06239 
3526.7 AVWVLNPEAGMWQC*LLSDSGQVLLESNIK  CD4    P01730 
3005.5 TLSVSQLELQDSGTWTC*TVLQNQK  CD4    P01730 
1330.7 LGEWVGLC*K    40 S ribosomal protein S12  P25398 
2545.2 HLYTLDGGDIINALC*FSPNR  Guanine nucleotide binding protein P25388 
2251.0 YTVQDESHSEWVSC*VR   Guanine nucleotide binding protein P25388 
3012.4 TNHIGHTGYLNTVTVSPDGSLC*ASGGK Guanine nucleotide binding protein P25388 
919.5 VGINIFTR    Chicken avidin   P02701 
3264.7 TMWLLRSSVNDIGDDWKATRVGINIFTR Chicken avidinb   P02701 
3219.7 SSVNDIGDDWKATRVGINIFTRLRTQKE Chicken avidinb, c   P02701 
a) C* represents cysteine carrying the biotin tag 
b) two avidin-derived peptides contain miscleavages 
c) comprises of the C-terminal part of avidin 
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Figure 3.2: Identification of CD4 via tandem mass spectrometry. The MS/MS spectrum of the ion at m/z 
1176 (3+, precursor mass 3526 Da) is shown. The full peptide sequence is 
AVWVLNPEAGMQCLLSDSGQVLLESNIK. Singly and doubly charged product ions are labelled. 
 
3.3.3 Specificity of the interaction with CD4 
To determine whether the other proteins identified in the affinity purification of the CD4 
receptor complex were molecules that specifically interact with CD4, two different 
control experiments were performed. These included the analysis of an affinity 
purification of a CD4 negative cell line (A2.01) and an affinity purification using 
immobilised IgG1 to identify the proteins that bind non-specifically to the column. Figure 
3.3 shows representative portions of the ESI mass spectra for 3 peptides. These show the 
presence or absence of ions in the purified sample derived from the CD4 affinity 
chromatography and the control sample. Table 3.2 summarises the data for all proteins 
and indicates whether peptides derived from their tryptic digest were detected in the 
control experiments. It can be seen that only CD4 and p56lck are uniquely present in the 
purification of the CD4 receptor complex demonstrating the versatility of this approach to 
distinguish specific components of a receptor complex from non-specific interactors. 
Though present in the control sample, cytoskeletal proteins are often found to be 
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associated with membrane receptors through intermediate adaptor proteins and an 
association between CD4/p56lck and the cytoskeleton has been reported (Kinch et al. 
1994; Thuillier et al. 1994). Thus we cannot exclude the possibility that in addition to the 
non-specific binding to the resin, cytoskeletal components are also associated with CD4 
and p56lck via intermediate linker proteins. The results indicate that the affinity 
purification procedure probably results in a loss of specific binding partners as none of 
the other described interacting molecules such as ACP33 or LAT (section 1.1.4.2) are 
observed. Further, the method also promotes non-specific protein interactions, therefore 
more refinement was needed to promote the preservation of specific interactions without 
promoting nonspecific binding. 
       
Figure 3.3: Comparison of regions of ESI mass spectra of representative peptides showing ions at m/z 651 
(p56lck), m/z 1176 (CD4) and m/z 961 (60 S acidic ribosomal protein P1). Shown are the same regions 
from (A) CD4 negative control; (B) the IgG1 affinity chromatography control; and (C) the sample of the 
CD4 receptor complex. Scales with the ion abundances are indicated at the right of each section. 
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Table 3.2. Proteins detected by ESI-MS and ESI-MS/MS analysis of the CD4 preparation 
and control experiments 
Protein     CD4   IgG1 control CD4-negative 
     Purification   control 
60 S Acidic ribosomal protein P1  MS/MSa) MS/MS  MSb) 
40 S Ribosomal protein S12  MS  MS/MS 
Chicken avidin    MS/MS  MS/MS  MS 
Myosin regulatory light chain  MS/MS  MS/MS 
Myosin essential light chain  MS/MS  MS  MS/MS 
Tubulin β-5 chain   MS/MS  MS/MS 
eIF-3 β     MS/MS  MS 
Guanine nucleotide binding protein MS/MS  MS/MS 
HSPC029    MS/MS  MS 
p56lck     MS/MS 
CD4     MS/MS 
a) indicates that identity was confirmed by MS/MS analysis 
b) indicates that the peptide was detected by MS analysis 
 
3.3.4 Evaluation of the reduction of sample complexity 
Using tandem mass spectrometry, the determination of the amino acid sequence of a 
single tryptic peptide is usually sufficient to identify unambiguously the protein from 
which this peptide originated (Mangasarian and Trono, 1997). When studying the digest 
of an unseparated protein mixture, it is therefore desirable to have only a few peptides per 
protein (ideally one unique peptide allowing the identification of the protein) in order to 
reduce the complexity of the peptide sample used for protein identification. Therefore a 
modification of the cysteinyl affinity capture method of Spahr and co-workers  (Spahr et 
al. 2000) was employed here to purify only cysteine-containing peptides. Cysteine is a 
relatively rare amino acid and a protein usually produces only a few tryptic peptides, 
which contain a cysteine residue, but 96.7 % of the human protein entries in the 
SwissProt database do contain at least one cysteine residue. Hence, apart from the 
information on the remaining 3.3 % of proteins, which would not be accessible with this 
method, it was investigated how far the reduction of sample complexity reaches and 
whether it is likely that information on additional proteins is not obtained with this 
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method. To do this the number of peptides that were detected in the MS analysis were 
compared with the number of cysteine-containing peptides and the total number of tryptic 
peptides derived from the proteins that were identified. As a minimum of about 7 amino 
acids is required for a peptide to obtain sufficient sequence information based on a single 
protein for identification and to have a high enough mass to be seen in the MS (relatively 
free from singly charged background ions), only those peptides were considered.  To 
ensure that no peptides from the detected proteins were missed, all spectra from the CD4 
affinity purification were screened for the expected range of multiply charged ions from 
tryptic peptides that contain one or more cysteine assuming charge states between +2 and 
+5 depending on peptide size. This search identified only one ion that could have been an 
additional peptide from the guanine nucleotide binding protein. The original MS/MS 
analysis of this ion did not yield fragment ions in high enough abundance to be sufficient 
for peptide identification. This shows that almost all peptides that could be detected from 
those proteins were indeed identified. Table 3.3 summarises the data from this approach 
and shows that from a total of 148 tryptic peptides, 15 had been identified in the sample 
leading to a reduction of sample complexity of about 90 %. This is a very desirable value 
as a mixture of 15 peptides is much easier to analyse than a mixture of 150 peptides. 
However, the 15 identified peptides represent only ~ 30 % of a total of 47 peptides, 
which contain a cysteine residue. A similar result was reported by Gygi et al. (1999), 
where 15 out of 44 cysteine-containing tryptic peptides derived from a model protein 
mixture were identified (Gygi et al. 1999). It also correlates with the results from Spahr et 
al. (2000) who report identification of 22 out of 68 cysteine-containing peptides from a 
model protein mixture consisting of 17 proteins (Spahr et al. 2000). In that study, the 
authors used a different method for biotin labelling and avidin affinity chromatography. 
They employed a thiol exchange reaction for the labelling of reduced cysteine-containing 
peptides and used DTT to elute bound peptides from the immobilised avidin by cleaving 
the disulfide bond in the linker region of the affinity tag. Despite the difference in the 
methodology, the loss of a large portion of cysteine-containing peptides tends to be a 
characteristic of this procedure. Additionally, it can be seen that, in this study, 
predominantly relatively large peptides were identified (about half of the detected 
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peptides have a mass of > 3 kDa) and no peptides having two cysteine residues (of 6 
possible ones) were detected. 
 
Table 3.3. Summary of proportion of peptides detected for each protein. 
Protein    number of number of tryptic peptides number of 
    cysteinesa) tryptic peptidesb) with cysteinec) detected peptides 
60 S Acidic ribosomal protein P1  2  4  2  2 
40 S Ribosomal protein S12  6  7  3  1 
Myosin regulatory light chain  1  9  1  1 
Myosin essential light chain  3  10  3  1 
Tubulin β-5 chain   8  22  6  1 
eIF-3 β     7  6  6  1 
HSPC029    5  13  5  2 
Guanine nucleotide binding protein 8  20  8  3 
p56lck     9  25  5  1 
CD4     11  18  8  2 
Total     60  148  47  15 
a) number of cysteine residues in the whole protein 
b) number of all tryptic peptides that are at least 7 amino acids long 
c) number of tryptic peptides of 7 amino acids or longer which contain one or more cysteine residues 
 
The reasons for the loss of so many peptides remain elusive. First, the possibility 
was considered that it arises from the unsuccessful reduction of some disulfide bridges. 
The two peptides originating from CD4 contain one cysteine involved in the domain D4 
disulfide-bridge and one cysteine involved in the domain D2 disulfide-bridge (Maddon et 
al. 1987), but the peptides containing the other cysteines involved in those disulfide 
bridges were not detected despite one of them having a convenient size of about 1760 Da. 
It is thus more likely that the absence of a large portion of cysteine-containing peptides is 
a consequence of the affinity tag-mediated purification. It is possible that smaller 
peptides, and peptides containing multiple cysteine residues, bind more tightly to the 
avidin resin and cannot be eluted as easily as the larger peptides that contain only one 
affinity tag. Further it would be unrealistic to expect that all peptides carrying a cysteine 
could be detected in the MS analysis, some peptides are just too small or too large to be 
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detected or to yield useful MS/MS data. Additionally, for example, the peptide spanning 
the transmembrane domain of CD4 also contains a cysteine and such a hydrophobic 
peptide is unlikely to be readily purified and/or detected in the MS analysis. However, 
coverage of only one third of cysteine-containing peptides suggests that more protein 
information is lost than originally expected. It is possible that other proteins are present in 
the sample but were not identified. According to Spahr and co-workers, they identified 
only 9 out of 13 cysteine containing proteins (out of 17 total proteins) by analysing the 
peptides that bound to the avidin resin (Spahr et al. 2000). To detect proteins that are 
present in the affinity chromatography-derived sample but missed with this strategy, the 
flow-through fraction of the avidin affinity column could be subjected to MS analysis. 
However this was not performed owing to the presence of detergents in the flow-through 
fraction which would have required additional purification steps. To put this in context, 
however, no method of protein identification using MS will identify all proteins. It is 
known that 2D-PAGE-MS analysis lacks coverage of small, acidic and hydrophobic 
proteins (Moseley 2001). As with so many analytical techniques, it is best to have several 
complementary techniques available to achieve the best possible coverage. According to 
the results presented in this study, this method adds to the repertoire of protein 
identification techniques and demonstrates its usefulness for studying interactions of 
membrane proteins. The advantage of this method lies in the simplicity of the analysis. It 
does not require PAGE separation of proteins, staining of the gel and the dissection of the 
gel into slices. It also does not employ multidimensional chromatography. Instead of 
analysing several gel slices or several chromatography fractions independently, this 
method allows the identification of a proportion of the proteins of interest in one single 
mass spectrometry experiment.  
 
3.4 Conclusion 
The results described in this chapter demonstrate the versatility of a modified ICAT 
strategy to determine the components of a protein mixture and investigates its limitations. 
An affinity chromatography purification of the CD4 receptor complex was studied and 
the proteins present in the sample were identified. A relatively low coverage of cysteine-
containing peptides was observed making it possible that some proteins are not identified. 
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This shows the need of additional strategies to achieve a higher coverage of the 
components of the CD4 receptor complex. The strategy proved to be successful for the 
study of CD4 and its associating molecules as both CD4 and p56lck, which is known to 
be associated with CD4, were identified. However, the majority of the proteins found in 
the affinity chromatography derived sample were probably present because of non-
specific binding to the matrix during the affinity chromatography step. The results 
described in subsequent chapters will therefore investigate approaches to reduce non-
specific binding as well as preserving labile and/or transient protein interactions. Besides, 
a different technological approach (1D-PAGE) has been evaluated for its ability to detect 
proteins that may have missed detection using the approach outlined in this chapter. 
 
3.5 Summary 
The study of protein interactions using mass spectrometry (MS) for identification of the 
components of purified protein complexes is leading to the description of increasingly 
valuable data on protein function. Commonly proteins in a given complex are identified 
via MS analysis of in-gel digests of gel-electrophoretically separated proteins. In this 
study, the use of an approach employing the digest of the whole protein complex to 
identify directly the proteins present in a purification of the CD4 receptor complex is 
evaluated. A cysteinyl affinity capture method was used to reduce the complexity of the 
peptide mixture that was obtained from the tryptic digest of the whole protein complex to 
the rather limited mixture of only cysteine-containing peptides. 
Here the use of this approach with mass spectrometry is described for 
identification of the CD4 receptor complex components CD4 and p56lck, along with 
several other proteins present in the detergent-solubilized fractions from the purification. 
These proteins were identified using peptide sequence data obtained from cysteine-
containing peptides. With appropriate control experiments, the specific nature of the 
CD4-p56lck interaction was demonstrated. In contrast, the other proteins identified are 
shown to arise from non-specific interactions during the affinity chromatography 
purification suggesting a possible loss of specific interactions during the chromatography 
procedure. The complexity of the mixture was reduced such that only 10% of the 
peptides derived from tryptic digest of the identified proteins were detected. This 
represents only one third of the cysteine-containing peptides, however, suggesting that 
this approach does not enable detection of all individual proteins.  
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CHAPTER FOUR: 
 
SEARCH FOR PROTEINS CO-PURIFYING 
WITH THE CD4 RECEPTOR COMPLEX USING 
MASS SPECTROMETRY 
 
EVALUATION OF ONE-DIMENSIONAL POLYACRYLAMIDE 
GEL ELECTROPHORESIS FOLLOWED BY IN-GEL DIGEST TO 
IDENTIFY PROTEINS PURIFIED WITH Q425 
CHROMATOGRAPHY. 
 
EVALUATION OF DIFFERENT SOLUBILISATION METHODS. 
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4.1 Aims 
The work outlined in this chapter aimed to achieve the following: 
(i) To evaluate the use of one-dimensional polyacrylamide gel electrophoresis (1D-
PAGE) followed by in-gel digest and mass spectrometry analysis for identifying 
the proteins present in an affinity chromatography-derived purification of the CD4 
receptor complex; 
(ii) To discuss that strategy with respect to its ability to identify the proteins present 
and compare the strategy to the method described in chapter 3; 
(iii) To investigate the use of a different detergent system containing SDS for the 
solubilisation of the CD4 receptor complex and determine its effect on 
(non-)specific binding; and 
(iv) To evaluate all detected proteins in terms of an interaction with CD4; finally a 
summary of the data from results in chapters 3 and 4 is provided and the potential 
of the approach of the methods in chapters 3 and 4 for identifying novel CD4 
binding proteins is discussed. 
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4.2 Introduction: 
Most proteins, including CD4, carry out their function in association with other proteins 
with which they interact either transiently or permanently as reviewed in chapter 1. Often 
the proteins that are involved in a specific task such as ligand binding (followed by 
transmission of signals) preassemble in large complexes. Identification of the individual 
subunits of such a complex often provides valuable data on the function of individual 
components. The increasing demand for rapid information on protein function has 
therefore seen an increase in studies aiming to define the components of protein 
complexes. Complexes are normally affinity-purifed and the mixture of proteins that is 
obtained is then analysed using one of several different approaches that are now 
available. When purifying protein complexes for MS analysis, several factors need to be 
considered. The purification strategy needs to preserve the protein interactions that hold 
the complex together without introducing non-specific binding of abundant cellular 
proteins. This can be a problem when the use of detergents is required for solubilizing 
membrane proteins as it has been suggested that different detergents can influence the 
protein interactions ultimately detected (Beyers et al. 1992). Furthermore, cross-linking 
of protein interactions may be helpful for preserving and identifying specific protein 
interactions (Wine et al. 2002). 
 After purification of the complex, the protein mixture needs to be digested with 
trypsin and the tryptic peptides analysed by MS. As noted earlier, because tryptic 
cleavage of only a few proteins already produces a large number of peptides, the mixture 
of which is often difficult to analyse, usually at least one more separation step is required 
prior to MS analysis. This separation can be achieved via SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) of the protein mixture followed by analysis of the 
individual slices (Wine et al. 2002) or by liquid chromatography-MS (LC-MS) analysis 
of the tryptic peptides derived from all proteins (Link et al. 1999). A 2D-PAGE 
separation of the purified complex, albeit possible, is not normally employed. This is 
because a purified complex is a mixture of a rather limited number of proteins that can be 
sufficiently separated by 1D-PAGE whereas 2D-PAGE is able to resolve large numbers 
of proteins. It was also not undertaken here because hydrophobic proteins such as 
membrane proteins generally separate poorly during the isoelectric focussing step. In 
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chapter 3 a strategy was evaluated using affinity tags introduced at cysteine residues and 
purification of peptides containing the affinity tag to create a representative subset of 
only few tryptic peptides per original protein thereby increasing the numbers of proteins 
that can be detected in one MS experiment (Bernhard et al. 2003). These results showed 
the identification of the components of the CD4 receptor complex CD4 and lck, a 
tyrosine kinase that has been reported to associate with CD4 (Veillette et al. 1988) 
functioning in T cell activation. In addition, to those two proteins several unrelated 
proteins were identified, which were shown using different control experiments to result 
from non-specific binding. It was assumed that non-specific binding was promoted by the 
use of the non-ionic detergents Triton X-100 and NP-40. Specific protein–protein 
interactions may have been obscured because of the background from the detergents or 
ions derived from non-specifically binding proteins. Proteins that did not contain a 
cysteine residue or where the peptides containing cysteine residues were not detectable 
with mass spectrometry would also not be identified with that method (Bernhard et al. 
2003). 
 In this chapter, the use of one-dimensional gel electrophoresis followed by mass 
spectrometry analysis of in-gel digested protein bands was investigated as an alternative 
strategy to identify proteins present in the detergent solubilized sample. It describes the 
identification of many different copurifying proteins and provides a comparison between 
the SDS-PAGE-based method and the method described in chapter 3 based on the 
experience obtained in this study. In order to reduce non-specific binding, the use of a 
detergent combination of NP-40, sodium deoxycholate (DOC) and SDS was evaluated 
for cell lysis. This combination was chosen because it has been shown previously that 
interactions persist in this detergent combination (Sheng et al. 1994) when different 
subunits of the N-methyl-D-aspartate (NMDA) complex could be co-
immunoprecipitated. The presence of SDS, which is a potent detergent for disrupting 
non-covalent protein interactions suggests that weak protein interactions such as non-
specific binding will be reduced. It was therefore chosen to compare the extent of non-
specific binding when using this lysis buffer with the non-specific binding detected when 
Triton/NP-40 was used for cell lysis. 
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4.3 Results 
 
4.3.1 Proteins detected visually in the coomassie stained gels 
To identify proteins purifying together with CD4, the affinity-purified (section 2.6 & 2.7) 
complexes from ~1 x 109 cells were concentrated (section 2.10) and separated on an 
8-16 % gradient polyacrylamide gel and the gel was stained with Coomassie Brillant 
Blue (section 2.12). Figure 4.1 shows a representative example for all experiments of a 
Coomassie stained gel containing the proteins of a CD4 affinity purification using the 
SDS containing lysis buffer. The visible pattern is very weak and apart from major bands 
at 60, 50 and 37 kDa, several minor bands of different strengths (but all very weak) can 
be seen. 
 
                         
 
4.3.2 Proteins identified in the sample prepared with Triton X-100/NP-40 lysis 
buffer 
Two experiments were carried out to determine proteins present in an affinity purification 
of CD4 employing the Triton X-100/NP-40 based lysis buffer. Whereas in the first 
experiment, only visible protein bands were excised and analysed (sections 2.13, 2.16 & 
2.17), in the second series of experiments, the entire lane of the gel was dissected into 
slices from the very top of the gel down to the area representing the molecular weight of 
15 kDa. A total of 23 proteins were identified in the two different experiments using the 
1D-PAGE-MS strategy. Table 4.1 lists all identified proteins. In all, 8 proteins were 
identified in the first experiment, 6 of them were identified again in the second 
Figure 4.1: Visualisation of 
proteins present in the 
affinity-purification of the 
CD4 receptor complex. CD4 
and associating proteins 
from approximately 109
cells were separated on an 
SDS-Polyacrylamide gel 
and stained with Coomassie 
Brilliant Blue. 
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experiment along with 15 other proteins. Proteins were mainly derived from the 
transcription/translation machinery, besides, some cytoskeletal proteins were identified 
along with chaperones such as heat shock proteins. 
 
4.3.3 Proteins identified in the sample prepared with NP-40/DOC/SDS lysis buffer 
To investigate whether the use of a more stringent detergent combination has a positive 
effect on reducing non-specific binding, three experiments were carried out employing a 
different detergent combination including SDS in the lysis buffer. CD4 complexes were 
purified (section 2.6 & 2.7) as described above and it was determined that CD4 binding 
to the antibody is not abrogated in the presence of SDS (shown in a different context in 
5.4.1). Figure 4.2 shows a representative mass spectrometry analysis of the purified 
peptide mixture obtained from a tryptic digest of an excised band containing only a 
barely visible amount of protein. The inset shows the expansion of a part of the spectrum 
allowing the identification of doubly charged ions at m/z 802.6 and 803.6. Figure 4.3 
shows a MS/MS spectrum of the ion at m/z 802.6 leading to the unambiguous 
identification of elongation factor 1-beta. Sixteen peptide ions were identified in this gel 
slice as indicated with the labels resulting in the identification of 9 different proteins 
(excluding trypsin). Table 4.2 lists all peptides and proteins that were identified in this gel 
slice. A total of 54 proteins were identified in three independent experiments using 1D-
PAGE MS analysis of purified CD4 derived from cells lysed with NP-40/DOC/SDS 
buffer. Table 4.1 lists all proteins that were identified in these experiments. It can be seen 
that again, most proteins are part of the transcription/translation machinery along with 
cytoskeletal proteins and chaperones. However, in this study other proteins were 
identified such as importins, ion channel subunits or the leucine-rich protein which have 
different functions than the usually seen non-specifically binding proteins. 
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Figure 4.2: Mass spectrometry identification of peptides derived from the tryptic digest of an excised gel 
slice. The ESI-mass spectrum of the tryptic peptides derived from the proteins in a gel slice of about 30 
kDa is shown together with the ions at m/z 802.6 and 803.6 enlarged. 
 
 
 
Figure 4.3: Identification of proteins via tandem mass spectrometry. The MS/MS spectrum of the ion at 
m/z 802.6 (2+, precursor mass 1604.2 Da) is shown. Singly charged product ions are labelled. The peptide 
sequence SPAGLQVLNDYLADK identified it as derived from the Elongation factor 1-beta. 
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Table 4.1: Proteins identified by ESI-MS/MS in all experiments 
   
Protein Name   Sprot#a MW number Peptides identified in experiment 
     kDa of Cys [Biotin]b 1Ac 1B 2A 2B 2C 
 ====================================================================================== 
Leucine-rich protein   P42704 145 21 . . . 8 . . 
Eukaryotic translation initiation  factor 3 Q99613 105 12 . . 2 . . . 
subunit 8       . . . . . . 
Importin beta-2 subunit  Q92973 101 26 . . . 1 . . 
Importin beta-1 subunit  Q14974 97  23 . . . 3 . . 
Eukaryotic translation initiation factor 3 P55884 92  7 . . 1 . . . 
subunit 9       . . . . . . 
Heat-shock protein HSP 90-alpha P07900 85  7 . . . 3 . . 
Neprilysin   P08473 85  12 . . . . 1 . 
Heat-shock protein HSP 90-beta P08238 83  6 . . . 8 . . 
Structure-specific recognition protein 1 Q08945 81  6 . 2 4 . . 4 
Annexin A6   P08133 76  6 . . . . 9 11 
Nucleolin    P19338 76  1 . . 5 . . 5 
DEAD-box protein 3  O00571 73  7 . . 1 . . . 
Heat shock cognate 71 kDa protein P11142 71  4 . 4 2 3 . . 
Probable RNA-dependent helicase p68 P17844 69  9 . . 2 . . . 
Phenylalanyl-tRNA synthetase beta chain Q9NSD9 66  11 . . 1 . . . 
Eukaryotic translation initiation factor 3 O15371 64  11 . . 4 . . . 
subunit 7       . . . . . . 
60 kDa Heat shock protein  P10809 58  3 . . . 4 . . 
P56lck    P06239 58  9 1 2 2 9 16 2d 
ATP synthase alpha chain, mitochondrial  P25705 55  2 . . . 3 . . 
CD4    P01730 55  11 2 3 1 3 7 5d 
Vimentin    P08670 54  1 . . . 1 . . 
Eukaryotic translation initiation factor 3 Q64252 52  7 . 2 6 . . . 
subunit 6       . . . . . . 
Tubulin alpha-1 chain  P05209 50  12 . . 1 . . . 
Tubulin beta-1 chain   P07437 50  9 . 2e 1 . . . 
Tubulin beta-5 chain   P04350 50  8 1 . 1 . . . 
Heterogeneous nuclear   P31943 49  5 . . 1 . . . 
ribonucleoprotein H      . . . . . . 
Alpha enolase   P06733 47  6 . . . 8 . . 
Eukaryotic initiation factor 4A-II Q14240 46  4 . . . 1 . . 
GA17 protein   O60735 43  8 . 1 . . . . 
Actin, cytoplasmic I   P02570 42  6 . . . 2 . . 
Guanine nucleotide-binding protein G(i), P04899 40  10 . . . . . 1 
alpha-2 subunit      . . . . . . 
Annexin A1   P04083 39  4 . . . . 2 2 
Heterogeneous nuclear   P09651 39  2 . . 1 1 . . 
ribonucleoprotein A1     . . . . . . 
Annexin A2   P07355 38  4 . . . . 8 7 
Heterogeneous nuclear   Q14103 38  3 . . 1 . . . 
Ribonucleoprotein D0     . . . . . . 
Voltage-dependent anion-selective P45880 38  10 . . . 1 . . 
channel protein 2      . . . . . . 
Heterogeneous nuclear ribonucleoproteins P22626 37  1 . . 1 . . . 
A2/B1       . . . . . . 
Eukaryotic translation initiation factor 3 Q13347 37  7 1 1 . . . . 
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subunit 2       . . . . . . 
Glyceraldehyde 3-phosphate   P04406 36  3 . . . 6 2 . 
dehydrogenase      . . . . . . 
Nuclease sensitive element binding P16991 36  0 . . . . . 2 
protein 1       . . . . . . 
Guanine nucleotide binding protein P25388 35 8 3 . . . . . 
60 S acidic ribosomal protein P0 P05388 34  3 . . 2 . . 1 
40 S ribosomal protein SA  P08865 33  2 . . 4 . . . 
Nucleophosmin   P06748 33  3 . . 1 . . . 
Voltage-dependent anion-selective P21796 31  2 . . . 1 . . 
channel protein 1      . . . . . . 
40 S ribosomal protein S3A  P49241 30  4 . . 1 1 . . 
60 S ribosomal protein L7A  P11518 30  3 . . . . . 1 
Voltage-dependent anion-selective  Q9Y277 30  6 . . . 1 . . 
channel protein 3      . . . . . . 
Prohibitin    P35232 30  1 . . . 2 . . 
40 S ribosomal protein S4  P12750 29  4 . . . . . 1 
60 S ribosomal protein L7  P18124 29  1 . . . . . 1 
Dehydrogenase/reductase SDR   Q13268 27  6 . . . 2 . . 
family member 2      . . . . . . 
Elongation factor 1-beta  P24534 25  3 . . . 2 . . 
HSPC029    Q9Y6D1 25 5 2 . . . . . 
40 S ribosomal protein S8  P09058 24  5 . . . . . 1 
GTP-binding nuclear protein RAN P17080 24  3 . . . 1 1 . 
40 S ribosomal protein S7  P23821 22  0 . . . . . 1 
40 S ribosomal protein S9  P46781 22  1 . . . . . 1 
60 S ribosomal protein L18  Q07020 22  2 . . . . . 1 
60 S ribosomal protein L11  P39026 20  4 . . . . . 1 
Myosin regulatory light chain  P19105 20 1 1 . . . . . 
40 S ribosomal protein S10  P46783 19  0 . . . . . 1 
40 S ribosomal protein S18  P25232 18  0 . . . . . 4 
40 S ribosomal protein S13  Q02546 17  0 . . . . . 1 
Myosin essential light chain  P16475 17 3 1 . . . . . 
40 S ribosomal protein S19  P39019 16  0 . . . . . 1 
40 S ribosomal protein S24  P16632 15  0 . . . . . 1 
60 S ribosomal protein L22  P35268 15  1 . . . . . 1 
40 S ribosomal protein S12  P25398 14 6 1 . . . . . 
Histone 2B   P02278f 14  0 . . . . . 2 
60 S Acidic Ribosomal Protein P1 P05386 12 2 2 . . . . . 
Ubiquitin    P02248 8.5 0 . . . . . 1 
Total: 66 proteins (not including [Biotin])     8 23 26 8 26 
a Swiss-Prot accession number 
b detected in the study described in chapter 3 (Bernhard et al. 2003) 
c + indicates in which of five experiments the protein was detected. Experiment labels 1/2 refer to the respective lysis buffer Triton X-
100/NP-40 or NP-40/DOC/SDS and A/B/C refer to one of two or three independent experiments. 
dSeveral ions typical of CD4- or lck-derived peptides were detected but not subjected to fragmentation 
ethe detected peptide matched two or more tubulin beta chains 
fthe detected peptide matched various alleles of the same protein, one allele is listed representative for all matches. 
 
 
 
 115
Table 4.2: Peptides and proteins identified in an excised gel-slice of ~ 30 kDa 
Precursor Peptide Sequencec   MASCOT Protein     Swiss MW 
m/za massb    Score Name     Prot# kDa 
===============================================================================================
473.4 944.6 LVPVGYGIK  12 Elongation factor 1-beta   P24534 24.6  
501.4 1001.5 LITEDVQGK  25 40 S ribosomal protein S3A   P49241 29.8 
508.9 1015.6 LTLSALVDGK  34 Voltage-dependent anion-selective  P45880 38.1 
      channel protein 2 
575.4 1029.6 LTLSALIDGK  33 Voltage-dependent anion-selective  Q9Y277 30.7 
      channel protein 3 
593.4 1184.7 DLQNVNITLR  26 Prohibitin     P35232 29.8 
607.5 1212.7 VLPSITTEILK  34 Prohibitin     P35232 29.8 
618.0 1233.7 IEVIEIM*TDR  29 Heterogeneous nuclear ribonucleoprotein A1  P09651 38.7 
687.5 1373.7 WTEYGLTFTEK  7 Voltage-dependent anion-selective  P21796 30.6 
      channel protein 1 
706.5 1410.8 GALQNIIPASTGAAK 32 Glyceraldehyde 3-phosphate dehydrogenase P04406 35.9 
737.8 2210.1 LGEHNIDVLEGNEQFIN 47 Trypsin     P00761 23.5 
  AAK 
749.2 2244.1 VIISAPSADAPM*FVM* 13 Glyceraldehyde 3-phosphate dehydrogenase P04406 35.9 
  GVNHEK 
802,6 1602.8 SPAGLQVLNDYLADK 57 Elongation factor 1-beta   P24534 24.6 
803.6 1604.9 VAVVTGSTSGIGFAIAR 17 Dehydrogenase/reductase SDR family  Q13268 27.3 
      member 2 
807.6 1612.9 LVINGNPITIFQER  46 Glyceraldehyde 3-phosphate dehydrogenase P04406 35.9 
882.6 1762.8 LISWYDNEFGYSNR 42 Glyceraldehyde 3-phosphate dehydrogenase P04406 35.9 
931.1 1860.0 SPALLLSQLLPYM*ENR 45 Dehydrogenase/reductase SDR family  Q13268 27.3 
      member 2 
a given is the experimentally determined m/z value 
b given is the theoretical uncharged monoisotopic peptide mass 
c M* indicates oxidized methionine 
 
4.4 Discussion 
 
4.4.1 Identification of peptides and proteins 
Proteins usually carry out their function in complexes and the knowledge of the 
interacting partners is crucial to determine the function of a given protein. CD4 has 
multiple functions in T cell activation (Gay et al. 1987), as an interleukin-16 receptor 
(Cruikshank, W. W. et al. 1994) and in HIV-1 entry (Lapham et al. 1996; Wu, L. et al. 
1996). In chapter 3 proteins which copurify with CD4 were sought in a search for novel 
binding partners that could could contribute to the function of this receptor (Bernhard et 
al. 2003). In that study proteins were identified using affinity tag-mediated purification of 
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tryptic peptides which carried a biotin tag at cysteine residues. However, only the 
CD4/lck complex was identified along with several non-specifically binding proteins. It 
was therefore suggested that proteins present in the affinity chromatography-derived 
sample could have escaped detection because they did not contain a cysteine residue 
required for biotin labelling or the labelled peptide was not detectable via ESI-MS 
analysis (Bernhard et al. 2003). To investigate the possibility that potential protein 
partners were missed, in this study the use of SDS-PAGE followed by in-gel digest and 
mass spectrometry analysis was evaluated as an alternative method to the affinity tag-
mediated purification of biotin labelled peptides reported in chapter 3 (Bernhard et al. 
2003). SDS-PAGE has the advantage that the protein pattern can be visualised with 
staining and that individual bands can be excised and the approximate molecular weight 
assists in their later identification. As figure 4.1 shows, in all the experiments, only a very 
faint pattern of proteins was visible after the gel was stained showing that affinity 
purification of CD4 from lymphoid cells produces only a small amount of protein, 
roughly estimated as less than 1 µg from the intensity of the band. Still, the employed 
strategy led to the identification of many CD4-derived peptides for which clean and easy-
to-interpret MS/MS spectra were obtained. The same applies to the tyrosine kinase lck. 
Most of the CD4 is associated with lck in lymphoid cells (Veillette et al. 1988), so the 
purification strategy led to the isolation of a similar amount of lck so that this protein was 
identified as easily as CD4. 
 Besides a band at ~55 kDa, that could represent either or both CD4 (55 kDa) and 
lck (58 kDa), several other (barely visible) bands were present in the gel. Analysis of gel 
slices containing those proteins was still able to unambiguously identify the proteins that 
were contained in the slices. Even regions of the gel that did not contain any visible 
protein band yielded protein data upon mass spectrometry analysis demonstrating the 
ability of the strategy to detect proteins in sub Coomassie-stainable amounts (i.e. < 
pmols). In one instance, up to nine different proteins along with trypsin could be 
identified in one mass spectrometry analysis of a single gel slice that contained only a 
barely detectable amount of protein (Figures 4.2 and 4.3, Table 4.2). 
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4.4.2 Comparison of this method with the method described in chapter 3 
A total of 23 different proteins were identified in two different experiments in the affinity 
purification of CD4 employing similar purification methods as in described in chapter 3 
(Bernhard et al. 2003). However, in that study, only a total of 10 proteins were detected 
in three different experiments indicating that the SDS-PAGE based method is a more 
powerful approach for identifying most of the proteins present. CD4 and lck were 
detected in all experiments, but only two other proteins were identified by both 
technological approaches. Significant run-to-run differences in the intensity of non-
specific binding to CD4 probably account for much of these differences but the 
differential abilities of the two methods to identify proteins is also a factor. Whereas the 
SDS-PAGE based method can identify a protein based on any of its tryptic peptides, the 
affinity tag-based method specifically detects only peptides containing a cysteine. As not 
all proteins contain a cysteine residue and not all peptides containing a cysteine residue 
can be observed in a mass spectrometry experiment (Bernhard et al. 2003), the SDS-
PAGE based method has the potential to identify more of the proteins present in the 
sample. Of the 66 proteins we identified in this study, 9 do not contain a cysteine residue 
and therefore would have been missed using the affinity tag-mediated purification. In 
contrast, non-PAGE based methods have the advantage of identifying proteins which 
migrate poorly in gels (Moseley 2001) and the detection of the small acidic myosin and 
ribosomal proteins in the affinity tag-based method could be because this method does 
not involve such a separation. Therefore the observed difference in the identified proteins 
is likely to be a not only a result of the differential protein binding in different 
experiments. Also the different sensitivities of the methods but also the lower overall 
sensitivity of the affinity tag-based method because of the interference by the detergents 
contribute to the differences between the two studies.  
When choosing the appropriate method for an investigation, several other factors 
must be taken into account concerning the speed with which the experiments and the 
protein identification can be carried out. Protein identification fundamentally relies on 
how efficiently tandem mass spectra can be matched to tryptic peptides of proteins. The 
affinity tag-based method led to detection of mainly peptides of high molecular weight 
(Bernhard et al. 2003), which produced complicated fragmentation spectra containing 
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multiply charged peptides that complicated manual analysis. In contrary the gel-based 
method mainly detected peptides in the mass range of 1000 to 2000 Da the spectra of 
which mostly showed a predominant y ion series comprising of most of the peptide 
sequence facilitating fast manual identification of the peptide. Also the samples were less 
contaminated with singly charged species as the SDS-PAGE separation eliminated the 
non-ionic detergents that caused a significant background in the affinity tag-based 
method (Bernhard et al. 2003). The time for sample preparation is another factor. The 
affinity tag-based method has the advantage that representative peptides obtained from all 
proteins are present in a single fraction, which is relatively easy to investigate. Moreover 
the SDS-PAGE based method leads to a high degree of redundant protein identification. 
For example more than 15 peptides have been observed for lck in one experiment (Table 
4.1). Also each gel slice needs to be analysed separately leading to a much more time-
consuming analysis when using this method. Nevertheless the investigation of slices, 
provides the analyst with the approximate molecular weight of the protein (as noted 
above), which can be an advantage when doing a database search for protein 
identification. Clearly, this study demonstrates that no one method is capable of 
identifying all proteins present in such a complex mixture. Each method has its particular 
advantages. However for our aims the SDS-PAGE based method seemed more efficient 
because more proteins were detected and the spectra obtained were generally cleaner. 
When choosing the appropriate method for an investigation, those factors need to be 
taken into account. To achieve detection of as many proteins as possible, the use of both 
strategies may be necessary. 
 
4.4.3 Evaluation of a different lysis buffer 
Because of the high degree of non-specific binding to CD4 detected in chapter 3, a 
different purification strategy was evaluated that reduces the non-specific binding to 
CD4. Also, some CD4 has been reported to participate in detergent-insoluble 
microdomains (Percherancier et al. 2003). This compartment together with any possible 
associating molecules, is likely to escape detection in a method employing cell lysis in 
cold Triton X-100. To reduce contamination with abundant proteins from the 
transcription/translation machinery and to generally increase solubility of membrane 
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proteins a detergent combination was used for cell lysis that had been reported to 
efficiently solubilize proteins from the NMDA receptor complex (Tingley et al. 1993). 
Co-immunoprecipitation studies on the NMDA receptor complex have demonstrated that 
interactions between different subunits of the complex persist even in the presence of up 
to 0.2 % SDS (Tingley et al. 1993; Sheng et al. 1994). However, SDS is a potent 
detergent for inhibiting noncovalent protein-protein interactions and its incorporation 
should reduce non-specific protein interactions. Table 4.1 lists all proteins identified in 
three independent experiments, in which a total of 49 proteins were identified together 
with CD4 and lck. Only these two were identified in all experiments. Otherwise the 
pattern of copurifying proteins is different between the individual experiments and also 
different from the experiments employing the Triton X-100/NP-40 lysis buffer. However, 
there was no obvious reduction in non-specific binding and any conclusions on the nature 
of binding proteins in relation to the employed lysis buffer cannot be drawn because of 
the variability between the experiments. Based on these data, it cannot be stated whether 
employing the NP-40/DOC/SDS lysis buffer has any beneficial influence on non-specific 
protein binding. It could be that it does decrease non-specific binding but also induces 
partial unfolding of CD4 and/or lck-domains that are then accessible to non-specific 
binding, counteracting such benefits. Thus the choice of lysis buffer in this experiment 
apparently has no significant influence on purification of both the CD4 receptor complex 
and on non-specific binding.  
Whereas this strategy aimed to reduce non-specific binding by using SDS as a 
detergent for cell lysis, tandem affinity purification (TAP) would be an alternative way of 
reducing the presence of non-specifically binding proteins when purifying complexes for 
mass spectrometry analysis. It is normally performed by expressing the recombinant 
protein of interest with two different affinity tags and then perform two different affinity 
purifications. The sequential purification leads to a high purity of the complex, increasing 
the chance that detected proteins are specific interactors. It has been successfully used for 
several proteomic studies, including the human Smad proteins for example (Knuesel et al. 
2003). Those strategies are especially efficient when complexes that contain large 
numbers of subunits are purified where non-specific binding might be expected. In this 
study it could have been performed using two different monoclonal antibodies for 
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affinity-purification of CD4, even using two columns with the same antibody would have 
been an option. Alternatively, CD4 could have been expressed as a recombinant tagged 
protein such as (His)6-tagged in a CD4-negative cell line like A2.01 and TAP carried out 
via Ni-NTA and Q425 affinity chromatography. However, some preliminary studies have 
shown difficulties when eluting CD4 from columns made of other immobilised CD4 
antibodies such as OKT4 (data not shown). Recombinantly expressing tagged CD4 is 
also rather laborious so tandem-affinity purification was only considered to be a method 
of choice if the results obtained in this study had shown evidence that a large complex 
were present. As no evidence of a large CD4-containing complex could be found, this 
option was not further evaluated. 
 
4.4.4 Evaluation of the proteins regarding an association with CD4 
Eight proteins were found to copurify with CD4 in chapter 3 (Bernhard et al. 2003) but 
none of them was functionally related to CD4 and using control experiments, it was 
shown that all of them are non-specifically binding proteins. In this study, a further 62 
proteins were detected. As none of the detected proteins showed consistent signals in all 
experiments as observed for p56lck, the detected proteins were unlikely to be 
functionally related to CD4, similarly to the proteins detected in chapter 3 (Bernhard et 
al. 2003). Therefore no experiments were conducted to test the specificity of the 
interaction. This could have been done using independent technologies or by conducting 
control experiments with non-specifically absorbing beads it was done in chapter 3 
(Bernhard et al. 2003) and by others (Ranish et al. 2003). Along with the vast majority of 
the detected proteins, which are derived from the abundant protein synthesis, 
transcription or RNA processing machinery, several proteins from the cytoskeleton 
(actin, tubulin, and vimentin) were detected. As it was previously stated, a connection 
between CD4 and the cytoskeleton has been reported and the detection of components of 
the cytoskeleton could be a result thereof (Kinch et al. 1994; Thuillier et al. 1994) (and 
reviewed in chapter 1.1.4.1). However, more investigation is required to further clarify 
the mechanism of an association between CD4 and the cytoskeleton. Also because of the 
possibility that weak protein interactions might not be detected in every experiment, it 
could be possible that one of the detected proteins does specifically interact with CD4 via 
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a weak protein-protein interaction. However, this was not followed, because there 
appeared to be no direct functional connection between CD4 and the proteins identified 
here. Given the large number of non-specifically binding proteins and the different 
protein families they belong to, however this data also shows the importance of 
reproducibility and control experiments to validate protein interactions detected in such 
settings. 
 
4.4.5 General discussion of the method to determine novel CD4 binding proteins 
Taken together with chapter 3 (Bernhard et al. 2003), a total of about 70 proteins were 
identified co-purifying with the CD4 receptor complex the majority of which are likely to 
be non-specifically binding proteins. Different methods of protein identification were 
used and different lysis buffer systems were evaluated. Altogether this suggests that no 
specific CD4 binding proteins will be detected using this approach. This is probably due 
to such interactions being weak and/or transient in nature so that they will be lost during 
cell lysis or affinity purification. The next chapter therefore evaluates the use of chemical 
cross-linking prior to cell lysis to preserve such interactions. Besides, interactions can be 
cell type- and state- dependent and it may well be that in the resting lymphoid cells that 
were used in this study there are no strong protein interactions involving CD4 except for 
lck. Protein interactions could be induced by ligand binding and/or cell activation. Thus, 
investigation of CD4 interactions in activated cells or different cells is also a potential 
future study. 
 
4.5 Summary 
Mass spectrometry-based identification of the components of affinity purified protein 
complexes after polyacrylamide gel electrophoresis (PAGE) and in-gel digest has become 
very popular for the detection of novel protein interactions. As an alternative, the entire 
protein complex can be subjected to proteolytic cleavage followed by chromatographic 
separation of the peptides. Based on a method using affinity tag-mediated purification of 
cysteine-containing peptides to analyse proteins present in an affinity purification of the 
CD4/lck receptor complex described in chapter 3, here the use of one-dimensional 
polyacrylamide gel electrophoresis for analysis of the same receptor complex purification 
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is evaluated. Using electrospray and tandem mass spectrometry analyses of tryptic 
peptides from in-gel digested proteins the components of the CD4 receptor complex were 
identified along with 23 other proteins that were all likely to be non-specifically binding 
proteins and mainly different from the proteins detected in our previous study.  This 
strategy is compared with the affinity tag-based method that was described in chapter 3. 
It is shown that the PAGE-based method enables more proteins to be identified. Also the 
use of a more stringent lysis buffer for the CD4 purification is evaluated to minimise non-
specific binding and 52 proteins along with CD4 were identified in three independent 
experiments suggesting that the choice of lysis buffer had no significant effect on the 
extent of non-specific binding. Non-specific binding was inconsistent and involved 
various types of proteins underlining the importance of reproducibility and control 
experiments in proteomic studies especially given the discrepancies in the identitiy of 
non-specifically binding proteins detected in identical experiments. 
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CHAPTER FIVE: 
 
LATERAL MEMBRANE PROTEIN ASSOCIATIONS 
OF CD4 IN LYMPHOID CELLS DETECTED BY  
CROSS-LINKING AND MASS SPECTROMETRY 
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5.1 Aims 
The work outlined in this chapter was conducted with the following aims: 
(i) To develop a method based on cross-linking of cell surface molecules followed by 
affinity purification and mass spectrometry to define lateral protein associations of 
CD4; and 
(ii) To use Fluorescence Resonance Energy Transfer (FRET) measurements to 
independently confirm new protein interactions. 
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5.2 Introduction: 
Studies involving the large scale identification of protein interactions via identifying the 
components of purified protein complexes using mass spectrometry, as evaluated for 
CD4 in chapters 3 and 4 have become very popular in the biosciences community (Mann 
et al. 2001). Complexes can be either purified directly with immuno affinity 
chromatography such as performed in chapters 3 and 4 or after introduction of a tagged 
bait protein into the cells followed by affinity-tag mediated purification (Walsh et al. 
2002). Alternatively, the bait protein is expressed recombinantly and binding partners are 
pulled down from cell lysates (Carrascal et al. 2002). Different methods are available for 
identifying the proteins in the purified complexes with mass spectrometry as thoroughly 
discussed in chapters 3 and 4. Successful studies employing such strategies have included 
the yeast interaction map (Ho, Y. et al. 2002) and characterisation of the brain N-methyl-
D-aspartate receptor complex (Husi and Grant, 2000). However, to be detected in such a 
strategy, a protein interaction needs to be sufficiently strong to withstand dissociation 
during the cell lysis and/or affinity purification steps. Strong protein interactions that 
occur, for example, between antibodies and their antigens, are characterized by 
dissociation constants in the low nM to pM range. For CD4 and the monoclonal antibody 
IOT4a KD values between 38 nM (Velge-Roussel et al. 1995) and 0.5 nM (Idziorek et al. 
1992) have been measured. Weaker (but not less important) protein interactions have KD 
values much less than this. For example the interaction of CD4 and the adaptor protein 
AP-2, which mediates its endocytosis has a KD value of only 90 µM (Pitcher et al. 1999). 
Such weak protein complexes are likely to dissociate during the cell lysis and/or affinity-
purification steps and may not be detected. Detection of similar weak interactions 
between membrane proteins could provide important information on the function of those 
proteins (Szollosi et al. 2002). 
Known protein interactions of CD4 are with the kinase lck (Veillette et al. 1988) 
and the membrane phosphatase CD45 (Dornan et al. 2002). In chapters 3 and 4 different 
approaches aiming at the identification of CD4-associated proteins in T-lymphoblastoid 
cells were described using affinity-purification of CD4 complexes (Bernhard et al. 2003) 
(Bernhard et al. 2004a). The versatility of the methods was shown by identifying CD4 
along with its associated kinase lck. However, a large number of functionally unrelated 
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proteins were also detected in the studies, which were attributed to the promotion of 
nonspecific binding and the dissociation of weak protein associations in the presence of 
detergents, which probably accounted for the inability to detect the transmembrane 
phosphatase CD45. 
Chemical cross-linking has become a useful tool for the study of protein 
complexes including, for example, determination of the oligomerization state of proteins 
(Young et al. 2000). More sophisticated approaches combined with mass spectrometry 
are aimed at the determination of the individual cross-linked peptides to draw conclusions 
about spatial arrangements in a protein complex (Wallon et al. 2000). To determine 
whether a peptide connected to a cross-linker has arisen from cross-linking of the protein 
with itself or with another protein, an approach was delineated to distinguish peptides 
derived from inter and intramolecular cross-linking of proteins using differentially 
isotope labeled proteins (Taverner et al. 2002). Cross-linking in conjunction with mass 
spectrometry has also been used to detect novel protein interactions of a given protein. It 
has been used to cross-link the components of complexes bound to affinity-beads. After 
cleavage of the cross-linker, proteins that were cross-linked to the protein of interest can 
be identified by PAGE and MS analysis (Wine et al. 2002). Another strategy used cross-
linking to connect associated proteins in purified endosomes. The protein under 
investigation, apolipoprotein B, was then purified along with the proteins that were cross-
linked to it. Using SDS-PAGE and liquid-chromatography-mass spectrometry (LC/MS), 
Rashid and co-workers identified an impressive number of proteins that are possibly 
linked to the function of apolipoprotein B (Rashid et al. 2002). 
The work outlined in this chapter involves the use of cross-linking followed by 
affinity-purification and mass spectrometry analysis for the identification of proteins that 
associate with the CD4 receptor in the cell membrane. Figure 5.1 shows schematic the 
strategy for identifying associating proteins. After purifying cross-linked complexes, the 
three transmembrane proteins CD45, CD71 and CD98 were identified along with CD4 
indicating that those proteins are close to CD4 on the cell surface. Using co-
immunoprecipitation and fluorescence resonance energy transfer (FRET), evidence that 
at least some CD4 associates with (clusters of) CD71 was found and that this association 
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increases upon treatment of the cells with phorbol 12-myristate 13-acetate (PMA). An 
explanation for this based on the endocytic properties of the molecules is provided. 
            
 
5.3 Results 
 
5.3.1 Cross-linking of cell surface molecules and purification of cross-linked CD4 
complexes. 
Dithobis[succinimidylpropionate] (DSP), a cleavable, amine-reactive homobifunctional 
and membrane-permeable cross-linker with a 12Å linker was used to cross-link cell-
surface molecules that are closely associated (Section 2.19). To investigate whether 
cross-linked complexes that include CD4 could be affinity purified with the Q425 
antibody, small-scale immunoprecipitations were conducted and presence of CD4 was 
detected using Poly T4-5 antiserum (described in sections 2.6, 2.11 & 2.12). Figure 5.2 
shows a western-blot of affinity-purified CD4 from cells that had or had not been cross-
linked with DSP. The purified CD4 complexes were either left non-reduced or reduced so 
that cross-linked proteins were released as monomers. The data indicate that a significant 
part of the CD4 that purifies with Q425 is incorporated in complexes of high molecular 
weight if cell surface molecules had been cross-linked. Without cross-linking, the large 
majority of CD4 is present in the monomeric form. The complexes are observed to 
Figure 5.1: A 
strategy to identify 
proteins that come 
in close contact 
with CD4 on the 
cell surface. See 
experimental 
procedures sections 
2.19, 2.7, 2.10, 
2.12, 2.13, 2.16 
and 2.17 for details
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disappear upon reduction. CD4 dimers and higher oligomers as detected in the non-
reduced DSP- lane have been described previously (Lynch et al. 1999) and are disulfide 
bridged dimers and oligomers with undetermined physiological function. 
 
 
 
5.3.2 Mass spectrometry identification of the proteins cross-linked to CD4. 
The purification results suggested that part of CD4 is indeed cross-linked into complexes 
with a sufficiently high molecular weight so that the complexes only just migrate into the 
very top section of the gel. To investigate other molecules that were present in those 
complexes, they were affinity purified from 109 cells and separated by SDS-PAGE 
followed by Coomassie Brillant Blue staining (2.7, 2.10 & 2.12). A very faint band at the 
very top section of the gel was observed (data not shown). Because the employed MS 
strategy can detect proteins even in sub-Coomassie stainable amounts (Chapter 4) 
(Bernhard et al. 2004a) the region above 150 kDa was dissected into slices and subjected 
the protein identification strategy  (2.13, 2.16 & 2.17). Three transmembrane proteins 
CD45, CD71 (transferrin receptor) and CD98 (4F2 lymphocyte antigen) were identified 
along with the CD4 receptor complex CD4 and lck. To test for reproducibility, a total of 
three independent experiments were carried out. Whereas in the first experiments, the 
complexes were left in their high MW form, experiments 2 and 3 used TCEP to cleave 
the cross-linked complexes into their monomeric constituents so that individual proteins 
migrated according to their molecular weight. In the latter two experiments, the gel was 
Figure 5.2. Western Blot showing CD4 
purification with the Q425 antibody with or 
without preceding cross-linking of cell-
surface proteins. CD4 was purified from 
CemT4 lysates with the Q425 antibody after 
the cells were cross-linked with DSP (+) or 
not (-). CD4 was detected with Poly T4-5 
antibody and high MW complexes are 
indicated with an arrow. Reduction of the 
complexes before SDS-PAGE, where 
indicated, produces monomeric CD4 owing 
to the cleavage of the cross-linker. The 
difference in the intensity of the CD4 bands 
detected with or without cross-linking is 
arising from inactivation of antibody 
binding epitopes on CD4 by the cross-linker.
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dissected into individual slices from the very top to about 15 kDa. To determine any 
effect of the temperature on the composition of the cross-linked complexes, experiment 3 
involved cross-linking carried out at 4 ºC. Table 5.1 lists the proteins that were identified 
in the cross-linked complexes in the three experiments. See also section 8.3 for more 
details. It also shows how many peptides were identified by MS/MS in each individual 
experiment. Peptides from CD71 and CD45 were identified in each experiment, whereas 
the peptide derived from CD98 was observed only weakly in experiments 2 and 3. The 
second experiment had less abundant peptide ions. Figure 5.3 shows a MS/MS spectrum 
of a tryptic peptide from CD45 representative for MS/MS spectra leading to the 
identification of the constituents of the CD4 receptor complex, CD4 and lck along with 
the three transmembrane proteins CD45, CD71 and CD98. The strategy for manual 
interpretation of MS/MS spectra and protein identification was the same as outlined in 
section 2.17 and 3.4.2. Two peptides derived from annexin II were identified in the third 
experiment. None of the recorded MS/MS spectra showed evidence that it was derived 
from a DSP-linked peptide providing information on the epitope of the protein 
interaction. 
 
Figure 5.3: Identification of proteins that were cross-linked to CD4 via tandem MS spectrometry: A 
representative tandem MS spectrum from peptide with a precursor m/z of 641.0 (2+, peptide mass 1280.9) 
is shown. The full sequence is TLIDVPPGVEK and identified it as derived from CD45. Similar spectra 
were obtained from the other proteins (see 5.6.1). 
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Table 5.1: Peptides and proteins identified via MS/MS in the cross-linked sample. 
 
Protein Name  MW  SwissProt# Number of Peptides detected via 
   (kDa)   MS/MS in Experiment number 
      1  2  3  total 
CD45   144 P08575 3  1  2  3 
CD71 (TFR)  84 P02786 14  2  15  17 
CD98 (4F2 antigen) 60 P08195 1  (1)a  (1)  1 
p56lck   58 P06239 (1)  0  8  8 
CD4 receptor  55 P01730 9  1  4b  10 
Annexin II  38 P07355 0  0  2  2 
apeptides in brackets were only detected in low abundance using a targeted ion approach 
bseveral ions corresponding to typical CD4-derived peptides were present but not subjected to MS/MS 
 
5.3.3 A fraction of CD4 copurifies with CD71 only after cell surface molecules were 
cross-linked. 
Small-scale immunoprecipitations were conducted to investigate the specificity of the 
detection of CD71 along with CD4. Figure 5.4 shows detection of CD4 by Western blot 
after immunoprecipitation with WM82 antibody specific for CD71, Q425 antibody 
specific for CD4 or IgG2b isotype control. CD4 was detected co-purifying with CD71 
only after the cell-surface molecules had been cross-linked. The CD4-specific band was 
persistently observed in three independent experiments. No CD4 could be detected when 
the IgG2b isotype control experiment was carried out. No CD4 could be detected in 
similar experiments using anti CD98 and anti CD45 antibodies (data not shown). The 
reverse blot shows detection of CD71 after precipitation with the anti CD71 antibody 
WM82. No CD71 could be detected in the precipitation with Q425 presumably owing to 
the sensitivity of the polyclonal anti CD71 antibody which does not recognise its antigen 
as well as the highly sensitive Poly T4-5 antibody. 
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5.3.4 Cell surface expression of CD4, CD71, CD45 and CD98 does not correlate with 
the cross-linking efficiency. 
To evaluate a possible correlation between the degree of cell surface expression of the 
CD45, CD71 and CD98 molecules with the efficiency of cross-linking, the cell surface 
expression of those molecules was determined using standard flow cytometry procedures 
(2.22). Figure 5.5 shows that of the three molecules cross-linked to CD4, CD98 is the 
most abundant on the surface of CemT4 cells followed by CD71 and CD45. CD4 is the 
least abundant. A protein that is cross-linked more effectively to CD4 will be present in 
the gel to a higher amount. Even though protein abundance in the gel and peptide 
abundance as detected with mass spectrometry cannot be correlated quantitatively, it is 
obvious that CD98, which was only represented by one low abundant peptide throughout 
the study is less abundant in the gel than CD71, of which 17 peptides had been detected 
in sometimes very high abundance. Consequently, the efficiency with which those 
proteins were cross-linked to CD4 is not correlated with the cell surface expression of 
Figure 5.4: Western Blot 
detection of CD4 and CD71 
purified with antibodies for CD71 
(WM82), for CD4 (Q425) or with 
IgG2b (isotype control) with or 
without cross-linking. CemT4 
cells were either subjected to cell-
surface cross-linking with DSP 
(+) or not (-). Complexes were 
precipitated with either WM82 
antibody against CD71, Q425 
against CD4 or with an isotype 
control (IgG2b) for the WM82 
antibody. The cross-linker was 
reductively cleaved and proteins 
were separated by SDS-PAGE. 
A, CD4 was detected with 
PolyT4-5 antibody. The arrow 
indicates a small amount of CD4 
that co-purifies with CD71 only 
after cell-surface molecules had 
been cross-linked. B, reverse Blot 
against CD71 with a rabbit 
polyclonal antibody. 
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those proteins: CD98 was the most abundant protein on the cell surface but only one 
CD98-derived peptide was detected per experiment. 
 
 
 
5.3.5 FRET experiments detect clusters of CD71 molecules on CemT4 cells. 
To investigate if CD71 forms clusters on CemT4 cells, as has been reported on other cell 
types (Matyus et al. 1995), FRET measurements were conducted using the CD71 specific 
WM82 antibody labeled with either fluorescein or Cy3 (described in 2.24 & 2.25).  
Figure 5.6 shows energy transfer efficiencies measured on CemT4 cells that were labeled 
with mixtures of fluorescein and Cy3 labeled WM82 antibodies employing different 
donor/acceptor ratios.  Significant E values could be detected that vary with the 
donor/acceptor ratio. Experiments using WM82 as acceptor in combination with anti 
CD4 antibodies as donor molecules yielded FRET efficiencies of below 5 % (see below) 
showing that the energy transfer efficiencies observed between CD71 molecules are not a 
result of the high acceptor surface concentration. This behaviour is characteristic for 
FRET determination of receptor clustering (Kenworthy et al. 2000). However it indicates 
no strong association between CD4 and CD71 suggesting only a small fraction of CD4 
associates with CD71. 
 
 
 
Figure 5.5: Cell surface expression 
of the identified proteins on CemT4 
cells. Shown are the mean 
fluorescence intensities of 3-4 flow 
cytometry experiments using the 
fluorescein labeled antibodies Q4120 
(CD4), WM82 (CD71), anti-CD45 
and anti-CD98. FITC labeled IgG1 
and IgG2a were used as isotype 
controls. The degree of labelling for 
the fluorescein conjugated antibodies 
was similar allowing for direct 
comparison using the mean 
fluorescence intensities. 
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5.3.6 PMA treatment of cells induces an association between CD4 and CD71. 
The cell activator PMA is known to induce CD4 endocytosis in lymphoid cells (Pelchen-
Matthews et al. 1993). To investigate further whether the association between CD4 and 
CD71 is mediated through their endocytic properties, cell surface expressions of CD4 and 
CD71 were investigated as well as energy transfer efficiencies between CD4 and CD71 
before and after treatment with PMA or a mock treatment (section 2.25). Figure 5.7 
shows expression of CD4 and CD71, before and after activation, showing a reduction of 
CD4 detection in both samples with the reduction being slightly stronger when cells were 
treated with PMA. The expression of CD71 is similarly reduced after PMA and mock 
treatment. Figure 5.8 shows the energy transfer efficiency between CD4 and CD71 before 
and after activation and it can clearly be seen that only after PMA treatment, can 
significant association between CD4 and CD71 was detected.  
 
 
Figure 5.7: Cell surface expression of 
CD4 and CD71 before and after 8 min 
treatment with PMA (shaded bars) or 
mock treatment (filled bars) was 
measured using the fluorescein 
conjugated Q4120 antibody and 
detection at 530 nm and the Cy3 
conjugated WM82 antibody and 
detection at 585 nm. Shown are the mean 
fluorescence intensities of three 
independent experiments. 
 
Figure 5.6: FRET detection of 
clustering of the CD71 molecule. 
Energy transfer efficiencies were 
measured on CemT4 cells that were 
labeled with different ratios of 
fluorescein and Cy3 labeled WM82 
antibodies. Energy transfer efficiencies 
are shown for different ratios of 
donor:acceptor labeled antibodies. 
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5.4 Discussion 
 
Membrane proteins have very important functions, for example in cell signalling, growth 
inhibition and as virus receptors. However, membrane proteins are intrinsically difficult 
to study because, for example, detergents are required for solubilisation of the proteins 
which, in turn can interfere with their interactions. Further, their function is more subtely 
controlled by the membrane environment in which they reside. Participation in, or 
exclusion from, lipid rafts has an influence on protein function (Simons and Toomre, 
2000) as does the conformation and other proteins that permanently or transiently 
associate with the membrane (Szollosi et al. 2002). Detecting proteins that reside in close 
proximity to a protein of interest can provide crucial information on how the function of a 
protein is influenced by those proteins. Standard methods such as immunoprecipitation 
are not always suited for detecting such associating proteins as they rely on membrane 
solubilisation, which is likely to interfere with weak lateral protein associations. 
Chemical cross-linking is a tool that can maintain protein associations because the 
proteins become covalently linked. In conjunction with immunoprecipitation, cross-
linking can be used to detect proteins that are associated in the cell membrane. Here a 
strategy was developed based on this method that allows de-novo identification of 
proteins that can be cross-linked to the cell-surface receptor CD4. Lateral associations of 
CD4 are especially important because of its function in the immune system and as a 
receptor for HIV-1. There is still controversy about its function as a receptor for IL-16 as 
researchers have postulated that the real IL-16 receptor is a different molecule in close 
Figure 5.8: Energy transfer between 
CD4 and CD71 before and after 8 min 
treatment with PMA (shaded bars) or 
mock treatment (filled bars) was 
measured using fluorescein conjugated 
Q4120 and Cy3 conjugated WM82 
antibody. Shown are the mean energy 
transfer efficiencies of three independent 
experiments. 
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proximity to CD4 (Mathy et al. 2000). Differences in susceptibility to different HIV-1 
strains that cannot be explained by differences in tropism (Naif et al. 1999) could also be 
connected to different CD4 associating proteins in the membrane. 
 To cross-link adjoining proteins on the cell membrane, a protocol was used 
employing DSP that has previously been used to determine the oligomerization state of 
CD45 (Takeda et al. 1992). DSP is a cross-linker with a short range of only 12Å, which 
minimizes non-specific cross-linking. To maximize solubilisation of cross-linked 
complexes, a detergent combination containing SDS was employed because it had been 
shown to efficiently solubilise membrane proteins (Husi et al. 2001). Then it was 
investigated whether CD4 is still bound by the Q425 antibody after cross-linking, as this 
is a prerequisite for a purification of CD4-containing complexes generated by cross-
linking. Using small-scale immunoprecipitations with Q425 followed by detection of 
CD4 by polyT4-5 a significant reduction in the amount of CD4 that was precipitated with 
Q425 was found. Such a reduction is likely to originate from the modification of lysine 
residues by the cross-linking reaction that leads to a decreased recognition of CD4 both 
by the Q425 antibody as well as by the polyT4-5 antibody. Still it can be seen that a large 
fraction of CD4 becomes part of high molecular weight complexes that are present when 
surface molecules had been cross-linked. Reduction cleaves the cross-linker and yields 
monomeric CD4. Without cross-linking, the majority of CD4 remains in its monomeric 
form. The above result suggested that part of CD4 is indeed cross-linked into complexes 
with a sufficiently high molecular weight such, that the complexes only just migrate into 
the very top section of the gel. Following purification of CD4-containing complexes out 
of a large number of cells, three transmembrane proteins CD45, CD71 (transferrin 
receptor) CD98 (4F2 lymphocyte antigen) were identified along CD4, lck and in one of 
three experiments annexin II. 
 The detection of CD71 and CD45 together with CD4 is very unlikely to arise from 
non-specific cross-linking with CD4 on the cell surface. If this were the case, the level of 
cell-surface expression of those molecules should have correlated with the efficiency 
with which those proteins were cross-linked to CD4. Obviously a highly abundant protein 
is more likely to be cross-linked to CD4 after non-specific lateral diffusion than less 
abundant molecules. However, this is not the case here as CD98 was the most abundant 
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molecule of those three on the surface of CemT4 cells in comparison with CD71 and 
CD45 but only one, low abundant peptide from CD98 was detected by MS/MS. This 
shows that the method is not artificially favoring the abundant molecules. CD71, 
however, is much less prominent on the cell surface but is cross-linked extremely 
efficiently to CD4 as shown by the detection of 17, CD71-derived peptides in the three 
experiments. Furthermore, given the large number of cell surface molecules, if non-
specific cross-linking were significant, one would then expect a broad band of many 
molecules in low amounts co-purifying with CD4. Such a very high background level of 
tryptic peptides derived from many non-specifically cross-linked proteins would make 
any MS/MS analysis extremely difficult. This was not the case, however, as peptides 
from CD45 and CD71 were easily distinguishable from the background and MS/MS 
spectra obtained were of a very good quality. Furthermore, cross-linking at 4ºC should 
result in a reduction in lateral mobility of cell-surface molecules and therefore should 
produce a decrease in cross-linking of proteins that have no affinity for each other. 
Because cross-linking at 4 ºC may subject the membrane to a phase change, detected 
interactions would less likely resemble the true state on the native cell and data obtained 
from such a setting needs to be interpreted more carefully. However, little reduction was 
observed for CD71 and CD45, supporting the notion that specific cross-linking was 
observed. CD71 or CD45 did not non-specifically bind to the resin. Chapter 3 and 4 
reported extensive studies searching for molecules that co-purify with CD4 without 
cross-linking under similar conditions but CD45, CD71 or CD98 were never identified in 
any of those experiments (Bernhard et al. 2003) (Bernhard et al. 2004a). Annexin-II, 
however, was identified without cross-linking (Chapter 4) (Bernhard et al. 2004a), and, 
given its described ability to bind calcium ions, it is most likely to bind non-specifically 
to the Q425 antibody via a calcium bridge. CD98, which is the most abundant molecule 
on the cell surface of the three, was only once detected in high abundance and then only 
one peptide was detected so that non-specific cross-linking for this protein cannot be 
excluded. 
 These results suggest that there is an association of CD4 with both CD45 and 
CD71 on the cell surface. The interaction or association between CD4 and CD45 has 
been reported previously using techniques such as co-capping (Leitenberg et al. 1996), 
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co-immunoprecipitation (Bonnard et al. 1997) and FRET measurements (Dornan et al. 
2002). CD45 is thought to play a role in controlling the kinase activity of lck via its 
function as a tyrosine phosphatase. Whether the CD4-CD45 interaction involves a direct 
or indirect binding has been controversial and it has been suggested that the T cell 
receptor and an associated protein mediates the interaction between CD4 and CD45 
(Veillette et al. 1999). Were this the case, one would have expected that the proteins 
would have been cross-linked to CD4 and identified in this study. These results therefore 
suggest that the CD4-CD45 interaction is either direct or that the bridging molecule is the 
transferrin receptor CD71 forming a cluster with CD4 and CD45. 
 The human transferrin receptor CD71 is a ubiquitous type II transmembrane 
glycoprotein. The number of CD71 molecules on the cell surface depends on cell type 
and activation state (Cerny et al. 1996). The receptor plays a role in iron metabolism and 
regulates the cellular uptake of iron, which is thought to control the proliferation of T 
cells (Cano et al. 1990). Whereas our studies suggest a direct CD4-CD71 interaction, 
previous studies have suggested an indirect interaction in large non-covalent complexes 
of CD71 with CD4, CD3, CD45 and a range of other molecules on lymphocytes (Cerny 
et al. 1996). The transferrin receptor has been shown to form clusters on a number of cell 
types that incorporate various other molecules such as HLA-A, -B and -C (Matyus et al. 
1995). The large number of peptides that were identified from CD71 and the good quality 
of the MS/MS spectra suggest that a significant amount of CD71 was cross-linked to 
CD4. It was also shown that a part of CD4 can be cross-linked to CD71 and that CD71 
forms clusters on the investigated cells. 
 Because of the differences in function between CD4 and CD71, the reason for 
their association remains elusive, like the described association between CD71 and HLA 
molecules (Matyus et al. 1995). However, Matyus and co-workers, who reported the 
association between CD71 and the HLA molecules, suggested an explanation based on 
the endocytic properties of the molecules. Both HLA and CD71 molecules are 
internalized via coated pits and coated vesicles on the cells where an association between 
them had been shown indicating that the interaction results from clustering of the 
molecules during the endocytic process (Matyus et al. 1995). On T lymphocytes and T 
cell lines, CD4 is actively endocytosed owing to a dileucine motif on its cytoplasmic tail. 
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However, only a very small fraction of CD4 is endocytosed at any time owing to the 
interaction with p56lck, which prevents targeting of CD4 to coated pits (Pitcher et al. 
1999). CD71 carries a different endocytic signal on its cytoplasmic tail but both signals 
target proteins to similar endocytic compartments (Marks et al. 1996). To investigate 
whether the observed association of a fraction of CD4 with clusters of CD71 is because 
of their endocytic properties, the association between CD4 and CD71 was investigated 
after treatment with PMA. PMA is a cell activator that strongly enhances endocytosis of 
CD4 in lymphoid cells (Pelchen-Matthews et al. 1993). Thus, if the association of CD4 
and CD71 was because of their combined endocytosis, an increased association should be 
detectable after PMA stimulation and hence an increased participation of CD4 in the 
endocytosis process. Using FRET measurements, a significant increase in energy transfer 
between CD4 and CD71 after PMA treatment was observed demonstrating that an 
association of those molecules can be induced via stimulating CD4 endocytosis. The 
observed energy transfer was not a result of a PMA induced reduction in CD4 expression 
because the energy transfer was dependent on the difference in fluorescence signal 
between the donor and the FRET sample, both of which were treated with PMA. CD4 
levels decreased only slightly in the PMA and in the mock treated sample with the 
decrease being slightly more intense in the PMA treated sample where an increased CD4 
endocytosis was expected. The similarity between the mock and PMA treated samples 
relates to the labeling of CD4 prior to PMA induced endocytosis and/or CD4 still present 
in open endocytic pits. CD71 expression was monitored to check that the energy transfer 
efficiency was not a result of a change in CD71 levels. However, despite a significantly 
decreased detection of CD71 after the (mock) activation, no difference was observed 
between the PMA the mock treated samples. These results suggest that in unstimulated 
cells only CD71 is subject to bulk endocytosis and that a small fraction of CD4 is being 
endocytosed at the time resulting in the detected cross-linking with CD71 clusters. These 
clusters are also targeted for endocytosis in the same coated pits. Treatment of cells with 
PMA then leads to a large portion of CD4 being targeted for endocytosis and a significant 
association can be detected with FRET. Figure 5.9 shows a schematic diagram of the cell-
surface arrangement of the three molecules CD4, CD45 and CD71 without activation 
according the interpretation proposed from these data. Whereas the majority of CD4 is 
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not associated with other cell surface molecules, a fraction of it is associated with the 
tyrosine phosphatase CD45. CD71 forms clusters on the cell surface and probably 
becomes associated with CD4 during endocytosis via coated pits. 
Several other cell surface molecules have been described associated with CD4, 
most importantly the T cell receptor (Veillette et al. 1999; Vignali and Vignali, 1999) and 
the HIV coreceptor CCR5 (Xiao et al. 1999). However, no peptides derived from these 
proteins could be detected probably because either such associations are with cytoplasmic 
domains or cross-linking of their external domains with CD4 is difficult. The association 
with AP-2 that mediates CD4 endocytosis (Pitcher et al. 1999) was not detected because 
it is characterised by a very weak affinity and the cross-linking occurred mainly 
extracellularly. The expression and associations of cell surface molecules may be altered 
on malignant cell lines (Elghetany 1998) compared to those on resting native T cells. 
Further studies will therefore concentrate on primary or activated cells to address these 
questions. 
 
 
 In summary, a novel method was used to investigate association of CD4 with 
external domains of membrane proteins and the previously reported association with 
CD45 was confirmed and identified a new association, with CD71 within clathrin coated 
pits on forming endocytic vacuoles was identified. These results contribute to the task of 
defining the complex and changing quaternary associations of cell surface molecules and 
demonstrate the general utility of combining cross-linking with mass spectrometry. 
Figure 5.9: Hypothetical arrangement of 
the cell-surface molecules CD4, CD45 
and CD71 according to our interpretation 
of the reported data: Whereas the 
majority of CD4 is not associated with 
other cell-surface molecules, a fraction 
of it associates with the phosphatase 
CD45. When undergoing endocytosis, 
CD4 is targeted to coated pits (indicated 
by a developing pit at the front) where it 
becomes associated with clusters of 
CD71 molecules that are also targeted 
for endocytosis into the same pit. The 
sizes of the molecules are not to scale. 
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 Further studies will investigate CD4 associations in different cell lines or primary 
cells or will address lateral protein interactions of other HIV receptors. 
 
5.5 Summary: 
Interactions of membrane proteins are important in various aspects of cell function. 
However, weak membrane protein-protein interactions are difficult to study using 
techniques like co-immunoprecipitations.  CD4 is a cell surface protein involved in T cell 
activation and the binding of the human immunodeficiency virus to HIV target cells. 
Here the use of cross-linking followed by affinity-purification of CD4 in combination 
with mass spectrometry is reported for identification of proteins that are in close 
proximity to CD4. Besides the components of the CD4 receptor complex, CD4 and lck, 
by tandem mass spectrometry seventeen tryptic peptides from the transferrin receptor 
CD71 were identified as well as three peptides from the protein phosphatase CD45 and 
one peptide from the 4F2 lymphocyte activation antigen CD98. The efficiency of the 
cross-linking did not correlate with the cell surface expression of the detected molecules, 
excluding a possible bias of the cross-linking towards the most abundant cell-surface 
molecules. Whereas the association of CD4 with CD45 has been reported, the 
associations with CD71 and CD98 have not been previously described. Small-scale 
immunoprecipitation after cross-linking in combination with fluorescence resonance 
energy transfer (FRET) measurements were used to investigate the association between 
CD4 and CD71. The data show that CD71 self associates on the cell-surface, that a small 
fraction of CD4 can be detected co-purifying with CD71 after cross-linking and that the 
association between CD4 and CD71 significantly increases after phorbol 12-myristate 13-
acetate-induced endocytosis of CD4. This suggests that a small fraction of CD4 
associates with clusters of CD71. As both molecules undergo endocytic recycling, the 
association and cross-linking, results from their clustering in the same pit/vesicle. The 
association CD4-CD98 is probably resulting from non-specific cross-linking. 
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CHAPTER 6 
 
DC-SIGN FORMS TETRAMERS ON MONOCYTE-DERIVED 
DENDRITIC CELLS WHICH INCREASES ITS AFFINITY FOR 
MANNAN AND HIV GP120 
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6.1 Aims 
The work outlined in this chapter had the following aims: 
(i) To apply the proteomic method of cross-linking followed by mass spectrometry 
described in chapter 5 to the DC-SIGN molecule to determine whether it is 
engaged in lateral protein interactions on the surface of human monocyte-derived 
dendritic cells; 
(ii) To determine the protein composition and stochiometry of the detected 
complexes; and 
(iii) To investigate whether detected protein interactions play a role in binding of the 
natural ligands of DC-SIGN, mannan and HIV gp120. 
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6.2 Introduction 
Dendritic cells (DCs) are potent antigen presenting cells (APCs) functioning at the 
interface between adaptive and innate immune system (Banchereau and Steinman, 1998). 
A variety of different subsets exist in different types of peripheral tissue where they act as 
sentinels searching for pathogens (Turville et al. 2002). Once a pathogen or foreign 
antigen is encountered it is internalised and processed for MHC (class I or II)- mediated 
presentation to T lymphocytes. During this process, dendritic cells mature, migrate 
through underlying tissues and to lymph nodes where they encounter T cells. Increased 
expression of co-stimulatory molecules during maturation enhances T cell activation with 
pathogen-derived peptides presented on MHC class I or II molecules (Banchereau and 
Steinman, 1998); reviewed in sections 1.1.5.1 and 1.2.3.2. 
 To internalise pathogens, DCs express a series of pathogen recognition receptors 
such as toll-like receptors that recognise lipoproteins, lipopolysaccharide or bacterial 
DNA commonly found on various bacteria. Also expressed are C-type lectin receptors 
(CLRs) that bind to conserved oligosaccharides that are commonly found on the surface 
glycoproteins of viruses. CLRs expressed by DCs include the mannose receptor (CD206), 
DEC-205 (CD205), Langerin (CD207) and DC specific intercellular adhesion molecule 
3-grabbing non-integrin (DC-SIGN; CD209) (Figdor et al. 2002). Those receptors differ 
not only in their expression on various subsets of DCs and other tissues but they also 
recognise different oligosaccharides thus discriminating between different ligands 
(Figdor et al. 2002; Frison et al. 2003). 
 DC-SIGN is a 44 kDa type II transmembrane protein that consists of a 
carbohydrate recognition domain, a neck domain involved in oligomerisation, a 
transmembrane domain and a cytoplasmic tail mediating interactions with the 
endocytosis machinery important for ligand internalisation (Geijtenbeek et al. 2000; 
Mitchell et al. 2001; Figdor et al. 2002; Frison et al. 2003). DC-SIGN binds and 
internalises several viruses such as HIV, Ebola virus, CMV, Dengue virus and hepatitis C 
virus (Alvarez et al. 2002; Halary et al. 2002; Navarro-Sanchez et al. 2003; Pohlmann et 
al. 2003) though other receptors are also involved (Turville et al. 2002). Other non-viral 
pathogens can also interact with DC-SIGN (van Kooyk and Geijtenbeek, 2003). Many of 
these viruses, however, have evolved a mechanism leading to their escape from 
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lysosomal degradation and allowing them to either infect DCs or to hide inside the cells 
followed by transfer to and infection of T cells when these cells are being activated by the 
mature DC. In mature monocyte-derived DCs (MDDCs) it has been shown that HIV 
binding to DC-SIGN and subsequent internalisation into the DC does not lead to the 
complete degradation and part of it is protected and subsequently infects T cells (Moris et 
al. 2003; Turville et al. 2003). The mechanism of this protection is poorly understood 
(Kwon et al. 2002; van Kooyk and Geijtenbeek, 2003) but it was suggested that it is an 
HIV-induced change in endocytic routing (Turville et al. 2003; van Kooyk and 
Geijtenbeek, 2003). A detailed knowledge of the DC-SIGN interaction with HIV 
glycoproteins is thus crucial for the understanding of DC-SIGN-induced routing of 
internalised ligands and involves both the selectivity for individual sugar structures as 
well as the stoichiometry of the DC-SIGN-ligand complex. 
 In contrary to CD4, which binds gp120 via a protein-protein interaction, DC-
SIGN recognises the sugar moieties via a carbohydrate recognition domain. Crystal 
structural data have revealed that DC-SIGN binds to internal tri-mannose glycosylation 
structures present in N-linked high-mannose oligosaccharides. The receptor makes 
contact with the three adjacent mannose residues at an internal branched structure but 
fails to bind to the core trimannose motif in complex oligosaccharides owing to steric 
interference resulting from different anomeric linkages (Feinberg et al. 2001). This 
explained the preference of DC-SIGN for high-mannose carbohydrate structures and is in 
contrast to binding characteristics of other CLRs such as the mannose receptor, which 
was suggested to bind to single terminal mannose residues (van Kooyk and Geijtenbeek, 
2003). Based on the oligomerisation on its extracellular domain, it was suggested that 
DC-SIGN forms tetramers and that this oligomerisation enhances the affinity for 
neoglycoproteins (Mitchell et al. 2001) It is therefore proposed that the interaction 
between DC-SIGN and glycoproteins involves several molecules of DC-SIGN binding to 
differential sugar moieties on the glycoprotein spaced at appropriate distances determined 
by the DC-SIGN oligomerisation (Mitchell et al. 2001). However, there is no direct 
evidence that DC-SIGN forms oligomers in the membrane environment present on 
immature DCs. Furthermore, it is still unclear whether any DC-SIGN associated proteins 
are involved in the carbohydrate recognition and how oligomerisation influences binding 
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affinity to the natural ligands of DC-SIGN such as HIV-1 gp120. The latter is important 
as the mechanisms of infection of DCs by HIV suggests a possible association between 
CD4 and DC-SIGN in the plasma membrane which has been shown by colocalization 
(Lee, B. et al. 2001). 
 Here the techniques described in chapter 5 based on mass spectrometry (MS) are 
used to investigate lateral protein associations of native DC-SIGN on MDDCs. Chapter 5 
described the versatility of those tools in determining lateral membrane protein 
associations on lymphoid cells (Bernhard et al. 2004b). In this chapter, cross-linking, 
immunopurification and western blotting are used to show that DC-SIGN assembles into 
oligomers of very high apparent molecular weight on the cell-surface of MDDCs. Mass 
spectrometry analysis of the purified complexes identified them as homo-oligomers of 
DC-SIGN and cross-linking at different concentrations of the cross-linker suggests that 
they are tetramers. Fluorescence resonance energy transfer (FRET) measurements did not 
detect any association between DC-SIGN and CD4. The complexes were also shwon to 
bind with high affinity to immobilized mannan (a yeast-derived polysaccharide) as well 
as gp120 whereas DC-SIGN monomers are not bound. This confirms the formation of 
DC-SIGN tetramers on immature MDDCs, shows that they do not associate with other 
proteins and that the oligomerisation mediated by the lateral organisation in the 
membrane is required for high-affinity ligand binding. 
 
6.3 Results: 
 
6.3.1 Complexes of high molecular weight containing DC-SIGN can be detected 
after cross-linking 
Because DC-SIGN was reported to form tetramers based on the properties of the 
recombinantly expressed extracellular domain, it is investigated here, whether DC-SIGN 
is engaged in lateral protein interactions on the surface of immature MDDCs. Cells were 
treated with DSS or subjected to a mock treatment (see section 2.19) and DC-SIGN was 
visualised after PAGE separation and western blotting using a DC-SIGN specific 
polyclonal antibody (see sections 2.12 & 2.18). Figure 6.1 shows the detection of DC-
SIGN in lysates and immunoprecipiates from mock or DSS-treated cells. In a whole cell 
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lysate from mock treated MDDCs, DC-SIGN shows an apparent molecular weight of 
around 50 kDa, which is a good approximation to the theoretical molecular weight of 44 
kDa from PAGE results alone. DC-SIGN present in a clarified lysate from mock treated 
cells shows a similar molecular weight to that in untreated cells whereas DC-SIGN 
present in the lysate from cells treated with DSS has an apparent molecular weight of 
more than 300 kDa indicating that DC-SIGN was cross-linked into large complexes. 
Immunoprecipitation of DC-SIGN with a murine monoclonal antibody confirms that the 
detected species are monomers and large complexes of DC-SIGN. The band at ~250 kDa 
in the DSS-treated sample from precipitation with anti-DC-SIGN antibody (and similar 
bands in later figures) is the murine anti DC-SIGN antibody that is weakly recognized by 
the anti rabbit secondary antibody. 
 
 
 
6.3.2 The complexes are homo-oligomers of DC-SIGN 
To investigate whether the identified large complexes of DC-SIGN are homo-oligomers 
or associations with other molecules, complexes were affinity-purified from 
approximately 9 x 107 MDDCs after DSS treatment (see section 2.26), separated on a 
polyacrylamide gel and visualized with Coomassie Brilliant Blue (see section 2.12). 
Purification with an irrelevant antibody prior to the DC-SIGN purification was included 
as a control for non-specific binding. Figure 6.2 shows the visualised proteins from the 
DC-SIGN and the control purification. A band of high molecular weight can be seen in 
Figure 6.1: Detection of high MW oligomers of 
DC-SIGN after cross-linking of cell surface 
molecules. MDDCs were subjected to cross-
linking with DSS where indicated. Cells were 
either directly lysed in SDS sample buffer 
(whole cells) or a cleared lysate was prepared 
and supplemented with SDS sample buffer 
(cleared lysate). DC-SIGN was also precipitated 
out of cleared lysate using a murine antibody 
(DC-SIGN precipitation). DC-SIGN was 
detected with a rabbit polyclonal antibody. The 
band at ~250 kDa in the DSS- sample from 
precipitation with anti-DC-SIGN antibody (and 
similar bands in later figures) is the murine anti 
DC-SIGN antibody that is weakly recognized 
by the anti rabbit secondary antibody. 
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the lane containing the purified DC-SIGN complexes whereas a band of around 250 kDa 
can be seen in the control lane. 
 
 
 
Mass spectrometry analysis was carried out on the excised bands to determine 
their protein composition (see sections 2.13 - 2.17). Peptide identification was carried out 
as described in section 2.17 and chapter 3. Table 6.2 shows the peptides detected in the 
sample derived from the in-gel digest from the visible DC-SIGN complex. Using the 
sensitive nano-ESI-MS and nano-ESI-MS/MS-techniques, ten tryptic peptides from DC-
SIGN were detected whereas no other protein was identified showing that the complexes 
are most likely homo-oligomers of DC-SIGN (see section 8.4 for MS/MS data). Further, 
no ions that could represent cross-linked peptides were detected. The band in the control 
purification was identified as murine IgG1 (data not shown) suggesting that part of the 
antibody eluted from the beads during boiling of the sample. 
 
 
 
 
 
 
 
Figure 6.2: Purification of the DC-SIGN 
complexes from MDDCs. MDDCs were 
treated with DSS and lysate was applied to a 
control column followed by an anti DC-SIGN 
column. The eluted proteins were separated on 
a SDS-PAGE and stained with Coomassie 
Brilliant Blue. A band of high molecular 
weight can be seen in the DC-SIGN 
purification and a band with an apparent 
molecular weight of 250 kDa is visible in the 
control purification. 
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Table 6.1: DC-SIGN-derived peptides identified in the purified complexes: 
 
Precursor Peptide  Sequencec   Position  MASCOT 
m/za  massb         Score  
 
818.9  1635.8  SAEEQNFLQLQSSR 296-309 87 
784.9  1567.9  LQQLGLLEEEQLR 9-21  58 
760.9  1519.8  QQEIYQELTQLK  235-246 32 
753.4  1504.8  LQEIYQELTQLK  97-108 62 
663.8  1325.6  M*QEIYQELTR  166-175 70 
655.8  1309.6  MQEIYQELTR  166-175 18 
654.3  1306.7  QQEIYQELTR  189-198d 37 
646.3  1291.7  LQEIYQELTR  120-129 52 
609.3  1216.6  VPSSISQEQSR  63-73  53 
528.3  1054.6  EVGAQLVVIK  286-295 47 
457.3  912.5  AAVGELPEK  109-117d 60 
a given is the experimentally determined m/z value 
b given is the theoretical uncharged monoisotopic peptide mass 
c M* indicates oxidized methionine 
d the protein produces multiple peptides of the same sequence, the first position only is shown 
 
6.3.3 The high molecular weight complexes are tetramers 
In order to deduce the oligomerisation state of the complexes, MDDCs were subjected to 
cross-linking with different concentrations of DSS. Cells were then lysed and the cleared 
lysate separated on 8-16 % gradient gels as well as on 5 % gels in order to increase the 
resolution in the high molecular weight region of the gel. Figure 6.3 shows representative 
DC-SIGN oligomers detected in the cleared lysate after cells had been treated with 
increasing concentrations of DSS. It can be seen in Figure 6.3A that the amount of 
monomeric DC-SIGN gradually decreases and that bands of high apparent molecular 
weight appear with increasing concentration of the cross-linker. Figure 6.3B shows 
resolution of the high molecular weight bands into three individual bands indicating that 
they consist of DC-SIGN dimers, trimers and tetramers. Dimers are detected at an 
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apparent molecular weight of around 100 kDa slightly below a non-specifically 
recognised band. Trimer bands migrate at approximately 150 kDa whereas the tetramer 
bands are detected slightly below 250 kDa. Their migration is slightly above the 
predicted molecular weight, which is probably a consequence of some globularity being 
retained through the cross-linking that interferes with the normal migration of the 
proteins through the gel. A similar effect can be seen in Figure 6.2, where the antibody of 
a molecular weight of 150 kDa migrates at an apparent molecular weight of 250 kDa. 
This is probably due to the globularity of the antibody that is retained through the intact 
interchain disulfide bridges. 
 
 
Figure 6.3: Detection of DC-SIGN oligomers after cross-linking was performed with different 
concentrations of DSS. MDDCs were subjected to cross-linking DSS at different concentrations as 
indicated. Cleared lysates were prepared and directly separated on an 8-16 % gradient gel (6.3A) or a 5 % 
gel (6.3B). DC-SIGN complexes were detected after western transfer with a polyclonal antibody. Figures 
6.3A and 6.3B are derived from two independent experiments and the different onset of detection of 
multimers suggests some variability between experiments, however, the overall observed pattern is 
representative for more than three different experiments. 
 
6.3.4 The tetramers bind to mannan and HIV-1 gp120 
It has been proposed that DC-SIGN tetramerisation is required for high-affinity ligand 
binding. An increased affinity of the extracellular domain for mannosylated BSA was 
detected when the neck region required for oligomerisation was present (Mitchell et al. 
2001). Albeit an affinity constant of 1.4 nM has been determined beetween DC-SIGN 
and monomeric gp120 (Curtis et al. 1992), no data is available to determine the relative 
affinity of monomeric, dimeric or tetrameric DC-SIGN to gp120. To investigate directly 
whether HIV gp120 as well as yeast-derived mannan binds with higher affinity to DC-
SIGN tetramers than to monomers, we conducted co-immunoprecipitation experiments 
between the molecules (see section 2.18). Figure 6.4 shows the co-immunoprecipitation 
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of DC-SIGN tetramers (arrow) with HIV gp120 whereas DC-SIGN monomers, detected 
by precipitation with a murine anti-DC-SIGN antibody, were not detected. This shows 
that the interaction between the complexes and HIV gp120 is strong enough to allow for 
co-immunoprecipitation and is stronger than the interaction between gp120 and DC-
SIGN monomers. Bands derived from non-specific recognition of the anti gp120 
antibody can be seen at ~50 kDa in Figure 6.4A and at 150-250 kDa in Figure 6.4B 
owing to the large amount of antibody present in the sample. Figure 6.5 similarly shows 
precipitation of DC-SIGN complexes with mannan beads whereas no DC-SIGN 
monomers are precipitated. Complexes were not detected involving binding by Sepharose 
itself indicating that the binding occurs predominantly between mannan and DC-SIGN. 
 
 
Figure 6.4: Co-immunprecipitation of DC-SIGN complexes and HIV gp120. MDDCs were subjected to 
cross-linking with DSS or to mock cross-linking and DC-SIGN complexes were precipitated with an anti 
DC-SIGN or anti gp120 antibody. If indicated, DC-SIGN complexes were allowed to bind gp120 for 1h 
before precipitation. Samples were either subjected to reduction with DTT (A) or not (B) and DC-SIGN 
was detected with a rabbit polyclonal antibody. The two blots represent results obtained in two independent 
experiment and are not reduced/non reduced variants of the same experiment. 
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6.3.5 FRET measurements do not detect an association between CD4 and DC-SIGN 
Because it was suggested that there is an association between CD4 and DC-SIGN, but no 
peptides from other proteins were detected in the cross-linked complexes, FRET 
measurements between CD4 and DC-SIGN were conducted similarly as in chapter 5 
between CD4 and the transferrin receptor on CemT4 cells which was included as a 
positive control. Figure 6.6 shows energy transfer efficiency measured between CD4 and 
DC-SIGN using two different anti-CD4 antibodies as donor molecules. Energy transfer 
efficiencies between CD4 and the transferrin receptor with or without stimulation with 
PMA are also included as a positive control for a protein association. It shows that no 
significant energy transfer (above 5-7 % is considered significant (Bernhard et al. 
2004b)) could be detected between CD4 and DC-SIGN. This suggests that there is no 
interaction between the two molecules that involves a large proportion of both molecules 
as it is the case for CD4 and the transferrin receptor on CemT4 cells after PMA 
stimulation. However, it is well possible that only a fraction of either molecule is 
involved in an association as we have described for CD4 and the transferrin receptor on 
unstimulated CemT4 cells (Bernhard et al. 2004b). 
 
Figure 6.5: Precipitation of DC-SIGN complexes 
with mannan beads. MDDCs were subjected to 
cross-linking with DSS or mock cross-linking as 
indicated. DC-SIGN was precipitated out of cleared 
lysate using either sepharose, mannan beads or anti 
DC-SIGN antibody-Protein G beads. DC-SIGN 
complexes were detected by western blot using a 
rabbit polyclonal antibody. 
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6.4 Discussion 
Interactions between DCs and pathogens such as HIV are a key and probably the first 
step in the immune recognition of the pathogens and initiation of the subsequent cell-
mediated response to control them. Alternatively, HIV may use DCs to obtain access to 
its major cellular targets, CD4+ T lymphocytes. The complex formation between CLRs 
on dermal (or epidermal) DCs such as DC-SIGN and HIV-1 gp120 may be the first 
contact between the virus and its new host. A detailed understanding of this interaction is 
crucial for the development of any antiviral agents addressing this early stage of HIV 
infection. DC-SIGN is a CLR that recognises high-mannose oligosaccharides present on 
pathogen surfaces (Geijtenbeek et al. 2000; Kwon et al. 2002). DC-SIGN has been shown 
to function as the receptor for numerous viruses including HIV (van Kooyk and 
Geijtenbeek, 2003) and also to recognise self-proteins, a process that is thought to be 
involved in cell adhesion processes (Geijtenbeek et al. 2000). Apart from DC-SIGN, 
other receptors such as the mannose receptor or langerin may also contribute to HIV 
attachment (Turville et al. 2002). Normally binding is followed by endocytosis and 
degradation of the pathogen and presentation of pathogen-derived peptides to T cells via 
MHC molecules (Banchereau and Steinman, 1998). However, some viruses, especially 
HIV have developed the ability to escape the degradation normally following uptake and 
endocytosis, allowing infectious viruses to survive in DCs and subsequently infect T cells 
(Geijtenbeek et al. 2000; Moris et al. 2003; Turville et al. 2003). Alternatively, a minor 
proportion of HIV is transferred to the CD4/CCR5 infection pathway. To understand how 
Figure 6.6: FRET measurements between 
CD4 and DC-SIGN on MDDCs and 
between CD4 and CD71 on CemT4 cells. 
Energy tranfer efficiencies were measured 
between different fluorescein conjugated 
donor and cy3 conjugated acceptor 
antibodies before (dark bares) and after 15 
minutes incubation with or without a 
stimulus (shaded bars). Shown are the 
mean energy transfer efficiencies of ten 
independent experiments (OKT4/DC-
SIGN) or four independent experiments 
(all others). 
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virus binding results in a differential entry into these pathways it is crucial to obtain a 
detailed knowledge on all the interactions involved in the binding of the viral 
glycoprotein including the oligomerisation of the receptor and possible other protein 
interactions with the CLR. 
DC-SIGN has been reported to form tetramers based on the properties of 
recombinantly expressed extracellular parts of the receptor. However, the properties of 
extracellular fragments outside the natural membrane environment do not always 
correlate with the true cell surface arrangement of proteins. For example, CD4 was 
shown to crystallize as dimers interfacing in domain D4 (Wu, H. et al. 1997) whereas 
other studies suggested disulfide bridged dimers mediated by domain D2 (Matthias et al. 
2002). Chapter 5 described the use of cross-linking/mass spectrometry to efficiently 
determine lateral protein interactions of this transmembrane protein including interactions 
in which only a fraction of CD4 was involved (Bernhard et al. 2004b). Here it is shown 
that DC-SIGN assembles into complexes on the surface of immature MDDCs and that no 
other proteins were detected in those interactions, especially CD4. Furthermore, because 
DC-SIGN has been suggested to associate with CD4 to facilitate infection of DCs (Lee, 
B. et al. 2001), flourescence resonance energy transfer (FRET) measurements were also 
conducted between both molecules to investigate whether an association between the 
molecules could be detected. Although chapter 5 has shown an association between CD4 
and the transferrin receptor CD71 using FRET on lymphoid cells after stimulation 
(Bernhard et al. 2004b), here no significant interaction between CD4 and DC-SIGN could 
be detected, suggesting that such an association might involve only a small fraction of the 
receptors and/or depend on gp120 binding to DC-SIGN (Figure 6.6). 
Using cross-linking at various concentrations of DSS, evidence was obtained that 
the complexes are indeed tetramers as has been suggested previously from studies of 
recombinant fragments of the DC-SIGN extracellular domain (Mitchell et al. 2001). This 
provides confirmation of the mechanism of ligand recognition of DC-SIGN on cells as 
first described by Mitchell and co-workers (Mitchell et al. 2001) supporting their 
hypothesis that DC-SIGN assembles as tetramers on the surface of DCs mediated by the 
neck region of the molecule. The so defined arrangement of four carbohydrate 
recognition domains at a predetermined distance provides a platform for recognition of 
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ligands carrying appropriately spaced carbohydrate structures that are then recognised 
with high affinity. Unfortunately, studies on DC-SIGN-oligosaccharide interactions have 
mainly focused on defining ligands for DC-SIGN using synthetic oligosaccharides or 
purified glycopeptides (Feinberg et al. 2001; Mitchell et al. 2001; Frison et al. 2003). 
Little information is available on the influence of receptor oligomerisation on ligand 
binding, especially on binding of native ligands such as HIV gp120. Studies on full 
length extracellular DC-SIGN and extracellular DC-SIGN lacking the neck region that 
mediates oligomerisation have suggested that the constructs containing the neck domain 
bind ligands with higher affinity (Mitchell et al. 2001). This provided evidence that 
oligomerisation increases the affinity of DC-SIGN for its ligands. However, those studies 
were conducted using neoglycoproteins such as BSA containing up to 30 individual 
mannose residues (Mitchell et al. 2001). The sugar structure on those proteins is 
significantly different from the structure of high mannose oligosaccharides that are 
efficiently bound by DC-SIGN (Feinberg et al. 2001). Whereas mannosylated BSA 
contains individual mannose residues that are linked to the protein, DC-SIGN 
preferentially binds to three anomerically linked mannose residues present on the 
carbohydrate moiety of high mannose oligosaccharides (Feinberg et al. 2001). 
Here, using the more natural ligands of DC-SIGN, yeast-derived mannan and 
HIV-1 gp120, DC-SIGN tetramers were successfully co-immunoprecipitated with these 
ligands. The binding is conducted in a buffer system containing 0.1 % SDS, a potent 
detergent disrupting non-covalent protein interactions. It can thus be assumed that DC-
SIGN is present as a monomer after the cells have been solubilised, as the weak 
associations mediating tetramer formation are destroyed. Cross-linking, however, 
conserves the spatial arrangement of the tetrameric complexes which are now preserved 
in the presence of SDS. The cross-linked complexes retain their ability to bind mannan 
and gp120 with high affinity whereas the solubilised monomers fail to bind the 
glycoproteins with sufficient affinity to be co-immunoprecipitated in an amount 
detectable via western blot. This demonstrates that the assembly of DC-SIGN into 
tetramers in the membrane environment and, in these experiments conserved by cross-
linking, is required for high-affinity binding of pathogens by DC-SIGN. 
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This study thus provides evidence for a binding mechanism involving a DC-SIGN 
tetramer binding to glycoproteins carrying probably four individual high-mannose 
carbohydrate residues spaced at a defined distance. This mechanism is distinct from the 
mechanism by which other lectins such as the mannose-binding protein (MBP) bind their 
ligand as discussed by Mitchell et al (Mitchell et al. 2001). Each MBP binds to individual 
mannose residues on the surface of the glycoprotein whereas the assembly of MBP into 
trimers allows for recognition of broad mannose-containing structures with high affinity. 
In contrast, DC-SIGN requires a specific arrangement of carbohydrates on its ligands 
which explains its selectivity.  
Further studies will also attempt co-precipitation of HIV-1 gp120 with 
immobilized DC-SIGN tetramers and examine gp120 trimer and direct viral particle 
binding to DC-SIGN tetramers to assess whether X4 or R5; T-tropic or M-tropic viral 
strains are bound with different affinities by DC-SIGN. Mass spectrometry studies will 
be conducted to search for cross-linked peptides from interchain cross-links to provide 
spatial information on the residues that are involved in cross-linking. 
Thus this is the first demonstration of DC-SIGN tetramer formation on dendritic 
cells (or any cell type). As the formation of tetramers significantly influences the binding 
affinity for ligands like HIV, attempts to design molecules to block these interactions 
must take into account the oligomeric nature of this protein. These quaternary 
interactions may also provide a paradigm for high affinity gp120 binding to other C-type 
lectin receptors. 
 
6.5 Summary: 
DC-SIGN (dendritic cell specific intracellular adhesion molecule 3 grabbing non-
integrin) or CD209 is a type II transmembrane protein expressed by dendritic cell (DC) 
subsets which binds to high mannose glycoproteins promoting their endocytosis and 
potential degradation. It also mediates attachment of HIV to DCs along with other 
receptors. HIV binding to this receptor can subsequently lead to endocytosis or 
enhancement of CD4/CCR5 dependent infection. Endocytosis of HIV virions does not 
necessarily lead to their complete degradation. A proportion of the virions remain 
infective and can be later presented to T cells mediating their infection in trans. 
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Previously, the extracellular domain of recombinant DC-SIGN has been shown to 
assemble as tetramers and in this study a short-range covalent cross-linker is used to 
show that DC-SIGN exists as tetramers on the surface of human monocyte-derived 
dendritic cells (MDDCs). There was no evidence of direct binding between DC-SIGN 
and CD4 by either cross-linking and fluorescence resonance energy transfer 
measurements as an explanation for cis enhancement of infection. Importantly it is also 
shown that the tetrameric complexes, in contrast to DC-SIGN monomers, bind with high 
affinity to high-mannose glycoproteins such as mannan or HIV gp120 suggesting that 
such an assembly is required for high-affinity binding of glycoproteins to DC-SIGN. 
Thus these results provide the first direct evidence that DC-SIGN forms tetramers on 
immature MDDCs and is essential for high affinity interactions with pathogens like HIV. 
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Summary 
Interactions of HIV gp120 with surface receptors of HIV target cells are a key step for 
virus dissemination throughout the body, for virus entry and an important target for 
antiretroviral drugs. The understanding of the interactions of HIV with its receptors has 
increased dramatically during the last few years elucidating the mechanisms of how it 
infects cells and spreads throughout the body. The first cells to come into contact with 
HIV during infection are thought to be dendritic cells which express a series of C-type 
lectin receptors for recognition and internalisation of viruses that is normally followed by 
degradation and presentation of viral peptides via MHC molecules. HIV is bound via the 
interaction of C-type lectins such as DC-SIGN, which binds to a trimannose motif present 
in high-mannose carbohydrates on the HIV envelope glycoprotein gp120. HIV-induced 
alterations of endocytic routing is thought to allow the virus to remain infective in DCs 
for transfer of the virus to T cells which are subsequently infected. DCs can also be 
infected with HIV. HIV infects cells by binding to the cell surface glycoprotein CD4 
followed by structural changes in the envelope protein gp120. Newly exposed domains 
bind to a chemokine receptor, mostly CCR5 or CXCR4 which is followed by the 
membrane fusion process. CD4 plays a key role in HIV replication as it is the primary 
receptor for HIV and its structure and protein associations can influence virus binding 
and subsequent fusion with the host membrane. Furthermore IL-16, the natural ligand of 
CD4 has been shown to inhibit replication of HIV via a mechanism that is little 
understood. 
 This work aimed to develop “proteomics-based” analytic techniques based on 
protein identification with mass spectrometry to study proteins that associate with CD4 
and later to study interactions of DC-SIGN. Based on an affinity-purification of CD4 that 
had been developed previously in our laboratories, a method was established to identify 
the proteins present in the affinity chromatography-derived sample in order to search for 
novel CD4 binding proteins. The method employed a strategy to selectively purify 
cysteine-containing peptides to reduce the complexity of the sample analysed via mass 
spectrometry. The method was shown to be successful as both CD4 and lck, the CD4-
associated kinase, were identified. A series of other proteins were also detected, however, 
using control experiments, they were shown to be non-specifically binding during the 
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affinity-chromatography step. An evaluation of the reduction of sample complexity via 
the cysteine-capture method revealed that only a third of the cysteine-containing peptides 
theoretically present were actually detected. This suggested the possibility that proteins 
present could have escaped detection because either they did not contain a cysteine or 
because the cysteine-containing peptide was not detected during the mass spectrometry 
analysis. 
 To investigate whether proteins could have been missed using the method 
employing affinity purification of cysteine containing peptides, an alternative strategy 
was evaluated, employing 1D-PAGE separation of the proteins in the affinity purification 
of CD4. Proteins present in the sample were then identified using mass spectrometry 
analysis of peptides derived from in-gel digests of individual gel slices. A large number 
of proteins were identified that had no apparent functional connection and were 
considered to be non-specifically binding. With the aim to reduce non-specifically 
binding to the resin, a detergent combination was evaluated for cell lysis that did include 
the anionic detergent SDS. This detergent cocktail had been used by other groups for 
successful co-immunoprecipitations and here, in several experiments on the CD4 
purification, the components of the CD4 receptor complex, CD4 and lck were detected. 
However, again a large number of proteins were identified which were considered non-
specifically binding because they were not functionally related to CD4 and they were not 
consistently detected in the different experiments. A total of more than 60 non-
specifically binding proteins were identified, all with inconsistent binding characteristics 
suggesting a careful investigation of detected proteins is needed when interacting partners 
are sought in such studies. The 1D-PAGE-based method was also compared with the 
strategy employing affinity-tag mediated peptide purification and advantages and 
limitations of both methods were discussed. Whereas the affinity-tag based method was 
characterised by a more rapid sample preparation and an easier MS analysis as all 
peptides were present in one sample, the 1D-PAGE based method allowed for 
identification of more proteins and delivered cleaner spectra. Thus this method was 
chosen for the following studies. The absence of any proteins specifically interacting with 
CD4 in all experiments was interpreted as that the CD4 receptor complex in the 
 160
investigated cell type is a rigid unit that is only engaged in weak and/or transient protein 
interactions that cannot be detected in these types of experiments. 
 To identify proteins that weakly and/or transiently associate with CD4 in the 
membrane of CemT4 cells, a novel technology was developed employing covalent cross-
linking of cell surface molecules on the intact cells. Subsequently, CD4, together with 
proteins that were cross-linked to it, was affinity purified and proteins present in the 
purified sample were identified with mass spectrometry. The method successfully 
identified the three transmembrane proteins CD98, CD45 and CD71 along with the CD4 
receptor complex and annexin II. Whereas annexin II is likely to be non-specifically 
bound by the resin and CD98 is likely to be non-specifically cross-linked to CD4, the 
CD45-CD4 and CD71-CD4 interactions were shown to be specific. The CD4-CD45 
interaction is well described whereas the CD4-CD71 interaction is novel and was thought 
to be a result of the combined endocytosis of a fraction of CD4 with complexes of CD71. 
FRET measurements were developed and demonstrated both an aggregation of CD71 as 
it has been described for other cell types as well as a strong association of CD4 with 
CD71 after PMA-induced endocytosis of CD4. This demonstrated that both molecules 
are subject to a combined endocytosis, that in non-stimulating cells only a fraction of 
CD4 is endocytosed together with clusters of CD71 and that the mass spectrometry based 
method identifies this interaction in which only a fraction of CD4 is involved. 
 The techniques described for CD4 were then applied to DC-SIGN, a C-type lectin 
receptor on the surface of some types of dendritic cells that, in conjunction with other 
lectin receptors, mediates initial attachment of HIV. Because studies of the recombinant 
extracellular domain of DC-SIGN have suggested that it forms tetramers and 
colocalization studies suggested an interaction with CD4, it was aimed to elucidate 
protein interactions in which DC-SIGN is involved either with itself or with other 
molecules. Cross-linking studies showed that DC-SIGN forms large complexes on the 
surface of MDDCs. Mass spectrometry analysis of the complexes revealed them as 
homo-oligomers and studies with different concentrations of cross-linker suggested that 
they were indeed tetramers. This showed for the first time the quarternary structure of 
DC-SIGN on native MDDCs (or any cells) supporting a novel mechanism for 
carbohydrate recognition in which the assembly of four receptors contributes to high-
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affinity ligand recognition as previously described. Further supporting this hypothesis, 
co-immunoprecipitation studies revealed that the cross-linked complexes bound with 
high affinity to mannan and HIV gp120 whereas monomeric DC-SIGN was not bound. 
This showed for the first time that indeed the tetramerisation of DC-SIGN mediates high 
affinity binding of its natural ligands and has implications for the developments of 
antiretroviral agents blocking this step. Any such agents must address the oligomerisation 
state of DC-SIGN to ensure that the desired blocking is achieved by a high binding 
affinity. 
 
Future directions 
The work described in this thesis shows the successful development of novel “proteomic” 
tools to investigate interactions of membrane proteins and it also describes their 
application to CD4 and DC-SIGN revealing novel biological aspects of both molecules. 
The work described here can therefore be followed both technologically and biologically. 
 Technologically, the described methods can be applied to any other cell-surface 
molecule that fits the requirements for the study. Appropriate targets within HIV virology 
would be other HIV receptors, such as the mannose receptor, or studying the same 
receptor on different cells or activated cells. Certainly other cell surface markers 
important in various research fields such as cancer research could be investigated and 
their protein interactions revealed. FRET proved to be an excellent supportive tool to 
follow up protein interactions detected in such studies. It has the advantage of enabling 
real-time monitoring of the changes in protein associations, as demonstrated for the CD4-
CD71 interaction after PMA induced endocytosis. Therefore, it is highly suited to refine 
the mechanism of protein interactions detected by cross-linking/mass spectrometry. 
Lastly, the methods described can be developed further technically. A very useful way to 
improve the versatility of the method would be to establish LC-MS analysis of the 
purified cross-linked complexes. Not only could proteins be identified that are less 
abundant in the gel and were not detected using nanoESI-MS, but also identification of 
cross-linked peptides could provide much needed spatial information on the location of 
cross-linking. This could reveal the epitopes engaged in the protein interaction and assist 
in determining the quarternary structure of cell surface receptors. 
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 Biologically, novel interactions of CD4 were identified and the oligomerisation 
state of DC-SIGN was revealed on MDDCs. Whereas the interactions described for CD4 
have been thoroughly described, the oligomerisation of DC-SIGN provides a basis for 
several future studies. First, ligands can be designed that take into account the 
quarternary structure and they could serve as potential blocking agents for initial virus 
entry. Secondly, the complexes could be immobilised and binding affinities for different 
viral strains such as X4 or R5; T-tropic or M-tropic or trimeric gp120 compared. This 
could reveal preferential binding of individual strains, accounting for phenotypic 
differences in infecting DCss additionl to preference for CXCR-4 or CCR-5. Lastly, it 
will be very interesting to determine how ligand binding to quarternary DC-SIGN results 
in endocytosis of the complex and how binding of HIV alters the endocytic pathway to 
escape the lysosomal pathway, mediating transfer to T-lymphocytes and enabling the 
establishment of an infection in the peripheral lymph nodes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 163
 
CHAPTER EIGHT: 
 
APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 164
8.1 Appendix to chapter 3 
Figures 8.1 to 8.3 show key MS/MS spectra leading to the identification of p56lck, avidin 
and the guanine nucleotide binding protein. 
 
 
 
Figure 8.1: Identification of proteins via tandem MS spectrometry: A  tandem MS spectrum from a peptide 
with a precursor m/z of 652.4 (5+, peptide mass 3259.5) is shown with Figure 8.1A comprising of the m/z 
region up to 700 and Figure 8.1B representing the region from 700 to 1400. The full sequence is 
LSRPC*QTQKPQKPWWEDEWEVPR and identified it as derived from p56lck. 
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Figure 8.2: Identification of proteins via tandem MS spectrometry: A tandem MS spectrum from a peptide 
with a precursor m/z of 460.8 (2+, peptide mass 919.6). The full sequence is VGINIFTR and identified it as 
derived from avidin. 
 
 
Figure 8.3: Identification of proteins via tandem MS spectrometry: A  tandem MS spectrum from a peptide 
with a precursor m/z of 849.1 (3+, peptide mass 2545.2). The full sequence is 
HLYTLDGGDIINALC*FSPNR and identified it as derived from avidin. 
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8.2 Appendix to chapter 4 
Figures 8.4 to 8.6 show key MS/MS spectra leading to the identification of CD4, p56lck 
and the leucine-rich protein. 
 
 
Figure 8.4: Identification of proteins via tandem MS spectrometry: A  tandem MS spectrum from a peptide 
with a precursor m/z of 513.3 (2+, peptide mass 1025.5) is shown. The full sequence is FSPTDFLAK and 
identified it as derived from the leucine-rich protein. 
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Figure 8.5: Identification of proteins via tandem MS spectrometry: A  tandem MS spectrum from a peptide 
with a precursor m/z of 505.3 (2+, peptide mass 1009.5) is shown. The full sequence is SWITFDLK and 
identified it as derived from CD4. 
 
 
Figure 8.6: Identification of proteins via tandem MS spectrometry: A  tandem MS spectrum from a peptide 
with a precursor m/z of 612.3 (2+, peptide mass 1223.6) is shown. The full sequence is LIEDNEYTAR and 
identified it as derived from p56lck. 
 
 
 168
8.3 Appendix to chapter 5 
Figures 8.7 to 8.10 show key MS/MS spectra leading to the identification of CD4, 
p56lck, CD71 and CD98. Table 8.1 lists all proteins and peptides that were identified in 
the study and table 8.2 provides a list of all gel-slices analysed and the proteins identified 
therein. 
  
Figure 8.7: Identification of proteins that were cross-linked to CD4 via tandem MS spectrometry: A  
tandem MS spectrum from a peptide with a precursor m/z of 573.3 (2+, peptide mass 1145.6) is shown. 
The full sequence is IDIVVLAFQK and identified it as derived from CD4. 
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Figure 8.8: Identification of proteins that were cross-linked to CD4 via tandem MS spectrometry: A  
tandem MS spectrum from a peptide with a precursor m/z of 644.9 (2+, peptide mass 1288.8) is shown. 
The full sequence is DSAQNSVIIVDK and identified it as derived from CD71. 
 
Figure 8.9: Identification of proteins that were cross-linked to CD4 via tandem MS spectrometry: A  
tandem MS spectrum from a peptide with a precursor m/z of 602.5 (2+, peptide mass 1204.0) is shown. 
The full sequence is VILDLTPNYR and identified it as derived from CD98. 
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Figure 8.10: Identification of proteins that were cross-linked to CD4 via tandem MS spectrometry: A  
tandem MS spectrum from a peptide with a precursor m/z of 638.4 (2+, peptide mass 1275.8) is shown. 
The full sequence is ILEQSGEWWK and identified it as derived from lck. 
 
Table 8.1 Proteins and peptides that were identified in the study presented in chapter 5 
 
Mass (Da) Protein  Position  MASCOT Score Sequence 
1957.0  CD4  215-231 60  EGEQVEFSFPLAFTVEK 
1532.7  CD4  232-244 70  LTSGELWWAER 
1530.8  CD4  85-97  ND  SLWDGNFPLIIK 
1353.7  CD4  308-318 23  LHQEVNLVVM*R 
1352.6  CD4  34-46  ND  GDTVELTCTASQK 
1177.7  CD4  61-71  71  ILGNQGSFLTK 
1145.7  CD4  97-206  67  IDIVVLAFQK 
1009.5  CD4  250-257 31  SWITFDLK 
945.5  CD4  48-54  21  SIQFHWK 
720.4  CD4  338-343 16  LM*LSLK 
 
1203.7  CD98  203-212 42  VILDLTPNYR 
1672.8  CD71  395-409 65  GFVEPDHYVVVGAQR 
1616.8  CD71  601-613 36  LTHDVELNLDYER 
1561.7  CD71  40-53  55  LAVDEEENADNNTK 
1468.8  CD71  326-339 52  SSGLPNIPVQTISR 
1433.8  CD71  496-508 65  VSASPLLYTLIEK 
1314.7  CD71  429-439 50  LAQM*FSDM*VLK 
1298.7  CD71  429-439 59  LAQM*FSDMVLK 
1298.7  CD71  429-439 59  LAQMFSDM*VLK 
1288.7  CD71  194-205 64  DSAQNSVIIVDK 
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1227.6  CD71  135-145 41  LDSTDFTSTIK 
1226.7  CD71  614-623 43  YNSQLLSFVR 
1204.6  CD71  146-155 36  LLNENSYVPR 
1203.7  CD71  589-600 12  AAAEVAGQFVIK 
1095.5  CD71  656-665 40  LTTDFGNAEK 
1084.6  CD71  478-486 58  AFTYINLDK 
1016.7  CD71  386-394 32  ILNIFGVIK 
986.6  CD71  232-240 17  LVHANFGTK 
958.6  CD71  419-428 41  SGVGTALLLK 
936.5  CD71  487-495 56  AVLGTSNFK 
1244.6  Annexin II 135-144 44  TNQELQEINR 
1222.6  Annexin II 104-114 41  TPAQYDASELK 
1841.9  Lck  276-292 62  QGSM*SPDAFLAEANLM*K 
1464.7  Lck  118-129 50  ANSLEPEPWFFK 
1456.7  Lck  154-167 58  ESESTAGSFSLSVR 
1352.7  Lck  184-195 49  NLDNGGFYSPR 
1281.7  Lck  196-206 20  ITFPGLHELVR 
1275.6  Lck  89-98  58  ILEQSGEWWK 
1223.6  Lck  387-396 51  LIEDNEYTAR 
862.5  Lck  379-386 41  IADFGLAR 
 
1354.6  CD45  972-982 ND  NSNVIPYDYNR 
1320.7  CD45  651-660# 61  LFLAEFQSIPR 
1280.7  CD45  292-303 ND  TLILDVPPGVEK 
* indicates oxidises methionine 
 
# The detected peptide conflicts with the sequence of human CD45 from the SWISS-PROT database 
inasmuch as a leucine residue was detected at position 650 instead of a proline residue behind an arginine 
at position 649. The human CD45 sequence (NP_563579) from the NCBI database 
(http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query_old?) however shows a leucine residue in position 
650 as does the sequence of murine CD45. We concluded that either the sequence of the human CD45 is 
incorrectly held in the SWISS-PROT database or that there is a polymorphism, which in our cell line 
produces the detected peptide. The MASCOT score for this peptide represents the match with the rat CD45 
derived peptide. 
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Table 8.2 List of gel slices excised and proteins detected therein 
 
MW range (kDa) Experiment # Proteins detected 
 
> 300    1  CD4, CD71, CD45, lck 
200 – 300  1  CD4, CD71, CD45, CD98, lck 
150 – 200  1  CD4 
45 – 60   1  CD4 
 
> 250   2  CD71, CD45, CD98 
50 – 70   2#  CD4 
 
>150    3  CD45, CD71, CD4 
75 – 150  3  CD4, CD71, CD98 
40 – 75   3  CD4, lck 
15 – 40   3  Annexin II 
 
# Because of technical problems with the instrument the other excised gel-slices did not yield any and the 
successfully analysed gel-slices showed only low peptide abundance. 
 
 
8.4 Appendix to chapter 6 
 
Figures 8.11 and 8.12 show two representative MS/MS spectra leading to the 
identification of DC-SIGN. 
 
 
Figure 8.11: Identification of proteins via tandem MS spectrometry: A tandem MS spectrum from a 
peptide with a precursor m/z of 654.3 (2+, peptide mass 1307.6) is shown. The full sequence is 
QQEIYQELTR and identified it as derived from DC-SIGN. 
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Figure 8.12: Identification of proteins via tandem MS spectrometry: A  tandem MS spectrum from a 
peptide with a precursor m/z of 457.3 (2+, peptide mass 913.5) is shown. The full sequence is 
AAVGELPEK and identified it as derived from DC-SIGN. 
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